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The methodology for the perfusion of the lower limbs of
cadavers was improved to optimise yields. The most
satisfactory perfusion fluid employed was 5% dextrose -
0.1% Triton X-lOO - lOmM EDTA - lOu/ml Trasylol; this
was used at 37°C. Originally the initial perfusate was
rejected, but after protein and activity measurements it
ivas found that although the specific activity was lower
in these early perfusates, they contained the highest
activity levels and thus all the perfusate was collected
for purification. An average of 15,451 Ploug u/ml was
extracted per cadaver. However, it was found impossible
to predict ivhich cadavers, in terms of age, cause of
death and hours post mortem, would yield high levels of
activator. Alternative sources of the activator were
investigated but none proved as satisfactory as the
cadaver perfusion.
The initial purification procedure involved affinity
chromatography on lysine-Sepharose and protamine-Sepharose
followed by gel filtration on Sephadex G-200 in a buffer
containing 1.5M NaCl. Using this purification procedure
a value of 54,545 was found for the molecular weight of
the vascular plasminogen activator, 2.97nm for the Stokes
radius, 7.22 Ficks for the diffusion coefficient, 4.40
Svedbergs for the sedimentation coefficient and a value
of 1.18 for the frictional ratio.
V
PEG precipitation was investigated when it was realised
that the activator was obtained from the cadaver in a
high molecular weight complex that appeared to be more
stable than the free enzyme. Purification by effecting
a size change was investigated. The complexed activator
eluted at on Sepharose 6B but when re-run on Sephadex
G-200 in a buffer containing 1M lysine the activator
dissociated from the soluble fibrin carrier and eluted
away from the high molecular weight contaminating protein
which remained at Vq. This process often gave a very
pure product but was not reproducible.
Th e final purification procedure developed involved PEG
precipitation, followed by chromatography on hydroxyapatite,
Sepharose 6B and finally on either lysine-Sepharose or
fibrin-Sepharose.
Inhibition studies showed the vascular activator to be
inhibited by the synthetic inhibitor Val-Pro-Arg-CH^Cl,
DFP, PMSF and DTT and not inhibited by Trasylol or
iodoacetamide, whether tested on a fibrin plate or a
synthetic chromogenic substrate. EACA gave some measure
of inhibition on the fibrin plate but not with the synthetic
substrate. The vascular activator is thus a serine
protease that relies on bisulphide bonds to maintain its
tertiary structure for enzymic activity.
Urokinase differed in its inhibition profile from the
vascular activator in that iodoacetamide, which had no
effect on the vascular activator, inhibited urokinase,
and DTT which inhibited the vascular activator had no
effect on urokinase. A human melanoma activator showed
a similarity to the vascular activator in that it was not
inhibited by iodoacetamide„
The best synthetic chromogenic substrates for the vascular
activator were determined to be S-2322 and S-2444. However
it was noted that for meaningful assays, samples must be
free of all contaminating enzymic activity.
An apparent 8 electrophoretic mobility was determined
for the activator, but this xvas later attributed to the
soluble fibrin with which the activator was complexed.
Immunological and radiolabelling studies were unsatisfactor
mainly due to the insufficient amount of vascular activator
present in purified and semi-purified preparations.
Soluble fibrin polymers were prepared in vitro and some
of their properties investigated. A high affinity of
the vascular activator for soluble fibrin polymers as
well as insoluble fibrin was demonstrated; it was shown
that urokinase and the melanoma activator did not possess
this high affinity.
Finally poly-lysine xvas shown to accelerate the rate of
activation of plasminogen by the vascular activator and
human uterine tissue activator (both of which have high
vii
affinity for fibrin) whereas it had no effect with
urokinase and the melanoma activator (both of which have
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1 THE DEVELOPMENT OF KNOWLEDGE OF FIBRINOLYSIS
The fact that blood is able to clot must have been one
of the earliest physiological observations to be made:
that it can reliquefy took much longer to discover.
Hence the study of coagulation preceded the study of
fibrinolysis, and consequently coagulation has been shown
to be very complicated, but it would be wrong to assume
that fibrinolysis is as simple as present concepts depict
it to be. Indeed it is predictable that further research
will reveal factors, as yet unknown, which take part in
the fibrinolytic mechanism. Our present knowledge of
fibrinolysis is on a par with that which pertained to
coagulation at the beginning of this century. It is by
no means improbable that by the end of the century the
knowledge we now have of fibrinolysis will seem naive, and
that coagulation and fibrinolysis will be revealed as
ranking in complexity.
There are remarkable similarities between the txvo
mechanisms. Each involves an activating system which
converts a precursor into an active proteolytic enzyme-
thrombin in coagulation, plasmin in fibrinolysis - and
each shares a common substrate, fibrinogen-fibrin.
Fibrinolysis seems to be the physiological antithesis of
coagulation; and perhaps both mechanisms should be
regarded not as separate entities but as one whole
coagulation-fibrinolysis system concerned with the
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deposition and removal of fibrin.
The phenomenon of fibrinolysis was first observed over
200 years ago. Morgagni (1769) recorded an autopsy where
the blood was entirely fluid. He described the case of a
man he saw in 1725 who died shortly after being stabbed
through the heart, and suggested that the fluidity of the
blood was due to its dilution by the quantity of drink he
had taken prior to being stabbed. Hunter (1794) records
that in animals killed by lightning or electricity or in
animals 'who are run very hard, and killed in such a
state' the blood does not clot.
Fibrin stored in certain circumstances was noted to
dissolve spontaneously (Denis, 1838; Plosz, 1873) and
Green (1887) noted that when fibrin prepared from ox blood
had dissolved when incubated in saline, it could not be
clotted again by thrombin. Dastre (1893) observed that
fibrin left in contact with the blood of dogs which had
been subjected to the stress of repeated haemorrhage
would lyse spontaneously. The destruction of fibrin was
termed "fibrinolysis" by Dastre.
Gley and Le Bas (1897) published work showing that peptone
injections produce incoagulability of the blood in
hepatectomized dogs; Nolf (1904, 1905) reported that this
phenomenon is associated with a marked increase in
fibrinolytic activity that is due to irritation, by
peptone, of the vascular wall and the consequent release
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into the circulatory system of a substance that enhances
normal fibrinolysis. He conjectured that the agent res¬
ponsible for fibrinolysis is released from vessel walls,
a suggestion fully confirmed by more recent studies.
Whitehouse (1914), investigating the fluidity of menstrual
blood, showed that it was actively fibrinolytic and con¬
sidered that this activity was due to a tissue enzyme.
Fleisher and Loeb (1915) investigated the fibrinolytic
activity of a number of different tissues, and came to the
conclusion that this depended on a proteolytic enzyme in
the tissues concerned. However, Demuth and von Riesen
(1928) thought that the reaction was more complicated, and
suggested that the tissue enzyme activated a pro-enzyme
present in the blood, a suggestion that was supported by
the later observations of Fischer (1946) working with
tissue culture.
In 1933 Tillett and Garner showed for the first time that
broth cultures of beta haemolytic streptococci derived
from patients, as well as filtrates from these cultures,
are capable of rapidly liquefying normal human fibrin clots .
In 1941 Milstone reported that fibrin prepared from highly
purified fibrinogen was resistant to streptococcal fibrin¬
olysis, but that lysis occurred when a small quantity of
human globulin was incorporated in the test. A further
factor, Milstone's "lytic factor", was evidently necessary
for streptococcal fibrinolysis to take place. Christensen
and MacLeod (1945) made the breakthrough which revealed
the basis of the fibrinolytic mechanism and drew together
the hitherto unrelated observations on the behaviour of
serum and of fibrin made during the preceding hundred years.
These workers showed that plasma or serum contains an
inactive enzyme precursor, plasminogen, which is converted
to the active "proteolytic" enzyme plasmin, by an activator
or kinase produced by the streptococcus, which they called
streptokinase. Unless highly purified, fibrinogen prepar¬
ations always contain plasminogen, and this explains why
Milstone was unable to lyse purified fibrin unless the
"lytic factor", ie plasminogen, was added to the test.
However, Geiger (1952) reported that an additional factor
seemed to be required for the activation of certain animal
plasminogens by streptokinase. These species differences
If
were investigated further by Mullertz and Lassen (1953)
who found that,, although bovine plasminogen was not
activated by streptokinase alone, it reacted if a small
amount of normal human plasma globulin was added to the
mixture. The plasmin then produced was derived from the
bovine plasminogen, not the human globulin. It was there¬
fore suggested by these workers that there is a "proactivator
in human plasma which is converted to "activator" by
streptokinase and that plasminogen reacts with activator
and not directly with streptokinase. Bovine plasma was
considered to be deficient in proactivator, and is therefore
not responsive to streptokinase.
Macfarlane (1937) conjectured that the stress of surgical
operation causes fibrinolytic activity to appear in the blood
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Later with Biggs and Pilling (Biggs et al 1947) he showed
that clots made from the diluted plasmas of healthy people
who had undergone the stresses either of violent exercise
or of the injection of adrenaline would lyse if incubated
overnight; whereas clots made from the diluted plasmas of
unstressed subjects remained intact. These workers con¬
cluded that stress causes fibrinolytic activity to appear
in the blood, but that it is not normally present. How¬
ever, Fearnley and Tweed (1953) using a rigid low-temperature
technique between venepuncture and making dilute plasma
clots, investigated 60 healthy people in the resting state
and found fibrinolytic activity in nearly all of them.
The nature of the factor responsible for endogenous
fibrinolysis was unknown; it appeared to act as a plasmin¬
ogen activator, and Fearnley and Lackner (1955) christened
it "labile fibrinolytic component".
The fibrin plate method was originally described by Permin
(1947) and later improved by Astrup and Mullertz (1952).
Using this method, Albrechtsen (1957) demonstrated the
presence of activators of plasminogen in most of the
tissues of the body, the liver excepted. Fibrinolytic
activity has also been demonstrated in a variety of body
fluids, including milk, tears, saliva, various exudates,
ascitic fluid, amniotic fluid and cerebrospinal fluid
(Albrechtsen, Storm and Claassen, 1953).
From the fibrin plate method Todd (1959) developed the
fibrinolytic autograph technique, tvith which he was able
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to show that the endothelium and vasa vasorum of blood
vessels are rich in plasminogen activator.
Throughout the course of the observations and investigations
reviewed here, there have been many speculations, but few
experiments, on the function of the fibrinolytic mechanism.
It is postulated that the integrity of the endothelium
depends on a fibrin layer on its outer or inner surfaces,
thus excessive fibrinolysis causes haemorrhage, and
deficient lytic activity will lead to fibrin accumulations
and thus to thrombosis and atherosclerosis. During the
past 20 years the fibrinolytic system has emerged as a
mechanism active in its own right and the possible relation¬
ship of the fibrinolytic mechanism to other enzyme systems
in the plasma is a fascinating field of inquiry which
should be explored profitably now that many details of the
different mechanisms have been clarified.
COMPONENTS OF THE FIBRINOLYTIC SYSTEM
A PLASMINOGEN
a Structure and Properties
Plasminogen, a beta globulin (Robbins and Summaria, 1963)
is the inactive precursor of the enzyme plasmin (sea
Fig 1). The presence of plasminogen in various human
tissues was suggested by Kowalski et al (1958), and is
present in the blood and most body fluids (Sherry, 1966).
The source of plasminogen has not yet been fully elucidated,
although the liver and bone marrow eosinophils have been
claimed to be important (Miller and Bale, 1954). Barnhart
and Riddle (1963) suggested that plasminogen is transported
from the bone marrow and released to the circulation and
tissues when needed. More recent studies have suggested
that the kidney could be a significant source (Highsmith
and Kline, 1971). However, it is unlikely to be the only
source in man. as not all anephritic patients have low
plasma plasminogen levels.
Plasminogen can be extracted from Cohn fraction III with
strong mineral acid (Christensen and Smith, 1950; Kline,
1953) followed by a pH II denaturation of accompanying
impurities. The purified proenzyme proved to be insoluble
at neutral pH. The original technique was progressively









FIG 1 SCHEME OF THE FIBRINOLYTIC ENZYME SYSTEM
step, but the most considerable improvement in purificat¬
ion came with the use of affinity chromatography, developed
in 1970 by Deutsch and Mertz. They used lysine coupled
to Sepharose, thus avioding the acidic extraction step,
which probably produced several changes in the plasminogen
molecule including changes in molecular weight and sub¬
strate specificity (Slotta et al, 1962) . Plasminogen
obtained by these more gentle purification techniques
proved to be quite soluble at neutral pH, and considerable
structural studies have been done with this material.
Plasminogen is a single chain molecule consisting of 840
amino acid residues (Wallen, 1978). If measures are
taken to avoid proteolytic degradation during the prepar¬
ation isolated plasminogen has glutamic acid in the N-
terminal position (glu-plasminogen). If no such measures
are taken, plasminogen with N-terminal lysine (lys-
plasminogen) or valine (val-plasminogen) results. Incu¬
bation of glu-plasminogen with plasmin at 37°C for half
an hour gives val- or lys-plasminogen, consisting of a
single polypeptide chain with slower anodic mobility and
lower molecular weight than glu-plasminogen (Claeys et al,
1973). In all the above cases asparagine is the C-
terminal amino acid.
Physicochemical data indicate conformational differences
between the two plasminogen forms. Glu-plasminogen appears
to be larger in size than lys-plasminogen in SDS-acrylamide
gel electrophoresis. The amino acid compositions of glu-
plasminogen and lys-plasminogen, and their major isolated
isoelectric forms, are similar, but several amino acid
residues (glutamic acid, alanine, isoleucine, phenylalanine,
and lysine) have been found to be significantly higher in
glu-plasminogen.
The molecular weights of glu- and lys-plasminogen have been
variously quoted as
Glu-Plasminogen Lys-Plasminogen
93,000 - 1,000 89,100 ^ 1,400 (Claeys and Vermylen , 1974)
92,000 85,OOO (Wiman and Wallen, 1975a)
83,800 t 4,500 82,400 - 3,300 (Robbins et al, 1975)
The work on the primary structure of human plasminogen is
now practically finished, and it is therefore now possible
to calculate a molecular weight from the amino acid
composition. The molecular weights of glu-plasminogen and
lys-plasminogen would be 88,365 and 80,100 respectively,
if carbohydrates are not taken into account. Assuming a
carbohydrate content of about 1.5% (Wiman and Wallen, 1975c)
the values would be about 90,OOO and 81,500 respectively
(Wallen, 1978).
It has been shown that activation of lys-plasminogen occurs
through the cleavage of a single arginine-valine bond,
while activation of glu-plasminogen occurs in two steps,
involving the removal of the N-terminal part of the
molecule, as well as cleavage of the arginine-valine bond.
The release of peptide material from the N-terminal part
of plasminogen is followed by significant changes in
conformation that are reversible in the presence of an
?r
excess of the peptides (Sjoholm et al, 1973), indicating
a noncovalent interaction with another site in plasminogen
The dissociation of this interaction, which occurs in the
presence of certain omega amino acids is presumably res¬
ponsible for the differences in properties between glu-
!♦
^
and lys-plasminogen (Sjoholm et al, 1973; Wallen and
Winan, 1975b; Winan and Wallen, 1975a). One site responsibl
for this intramolecular interaction has been localized
45 46 47 43
to a heptapeptice sequence (-Ala -Phe -Gin -Tyr
His"' '-Ser^-Lys'^"'") situated in the N-terminal part of
giu-plasminogen (Wiman and Wallen, 1975a). It is reason¬
able to assume that the other site that participates in
the intramolecular interaction is the same as the site
responsible for the interaction between plasminogen and
lysine. This site, the lysine binding site (LBS), seems
to form a stoichiometric 1:1 complex with omega amino
acids resulting in marked conformational changes similar
to those observed on the release of N-terminal peptides.
Dissociation of the internal noncovalent interaction in
glu-plasminogen, either by proteolytic cleavage in the
N-terminal part of the molecule, or by the addition of
omega amino acids, causes a dramatic change in activation
kinetics (Claeys and Vermylen, 1974). Thus, using
urokinase as activator, lys-plasminogen is activated about
10 to 20 times faster than glu-plasminogen. While in vivo
the half-life is 0.8 days for lys-plasminogen and 2-2.5
days for glu-plasminogen (Collen et al, 1975b).
Activation results in a two-chain monomer, in which the
chains, heavy (A) and light (B), are connected by a single
disulphide bond. It is from the N-terminal portion of
plasminogen that the heavy (A) chain of plasmin derives
and the light (B) chain originates from the C-terminal
end of plasminogen.
Several groups have participated in work on the elucidation
of the primary structure of human plasminogen (Claeys et
al, 1976; Magnusson et al, 1976; Rickli et al, 1976;
Robbins et al, 1975; Wiman and Wallen, 1975a, 1975b., 1975c;
Wiman 1973, 1977), and a model, based on these studies,
is shown in Fig 2.
Many different molecular forms of plasminogen exist as
judged by electrophoretic criteria. Summaria et al (1972)
found 8 bands when a preparation of human plasminogen was
run in acrylamide gel electrophoresis at pH 8.4 in either
0.3M EACA or 8M urea. The S-carboxymethyl heavy (A) chain
derivative of plasmin did not show multiple molecular
forms whereas the derivatized light (B) chain did, but
only when run in 8M urea.
Wallen and Wiman (1972) stated that pure preparations of
plasminogen often contain up to 10 different forms, but
they considered that only 6 of these forms had electro-
FIG 2 A MODEL OF PLASMINOGEN
The disulphide arrangement and the sites
where proteolysis occurs on activation are
shoxvn by arrows (after Wallen, 1978).
phoretic properties identical to those in human plasma,
and that the remainder were probably proteolytically
degraded^ tohile Collen (1973) considered that human
plasminogen occurred in twelve main molecular forms in
the circulation.
Furthermore, Summaria et al (1976) described two affinity
forms of each zymogen when each were eluted from a L-
lysine-Sepharose affinity chromatography column using a
gradient of e-aminocaproic acid (EACA)„ The four zymogen
affinity chromatography forms glu-1-plasminogen; glu-2-
plasminogen; lys-1-plasminogen and lys-2-plasminogen show
distinct stepwise differences in their molecular size and
charge. Glu-1-plasminogen is the largest and most
acidic, while lys-2-plasminogen is the smallest and most
basic. The proteolytically altered lys-1 and lys-2 forms
appear to be specifically derived from the glu-1 and glu-2
forms respectively.
Although the sialic acid contents of the glu- and lys-
forms appear to be similar, the isolated affinity chroma¬
tography forms show distinct differences. Sialic acid
content of glu-1 and lys-1 are identical and substantially
higher than glu-2 and lys-2 which are also identical. The
charge differences of zymogen 1 and 2 forms may be related
to sialic acid content.
The plasmin-derived carboxymethyl light (B) chains, from
each of the four enzyme forms, appear to be identical,
whereas the carboxymethyl heavy (A) chains differ in
molecular size, in the same sequence as their parent
zvnogens. It thus appears that the region of the molecule
responsible for the differences in molecular size of the
four zymogens is the N-terminal portion of the molecule.
Plasminogen can be completely desialylated without loss
of proenzyme activity, suggesting that the sialic acid
does not play an essential role in the function of plas¬
minogen. However, Siefring and Castellino (1974) have
found that desialylated rabbit plasminogen has a markedly
shortened half-life.
Lovj molecular weight forms of plasminogen have been
described. Paoni and Castellino (1975) have isolated a
fully activatable plasminogen of molecular weight 50-55,030,
by treating sheep plasminogen with sheep plasmin. Yecies
and Kaplan (personal communication) have isolated a 42,000
molecular weight form of human plasminogen from fresh
plasma. Formation of low-molecular weight plasminogen was
diminished when DFP was incorporated into the purification
procedure indicating that plasma proteolytic enzymes can
degrade plasminogen without activating it.
As plasminogen is an inactive precursor, it has no active
site. Thus binding to L-lysine Sepharose must be at a
site or sites other than the active site; these are termed
lysine binding sites. It would appear that one such site
is found in the first triple disulphide loop (see Fig 2) in
the part of the molecule which corresponds to the heavy (A)
chain of plasmin (Rickli and Otavsky, 1975). A fragment
(6,000 daltons) containing the lysine binding site has been
isolated and characterized (Wiman and IVallen, 1975c). The
role of the lysine binding site in plasminogen is not
certain but presumably it is involved in the interaction
between plasminogen and fibrin. Holleman et al (1975)
described a p-aminobenzamidine binding site distinct from
the lysine binding site and on a different portion of the
molecule. The p-aminobenzamidine site, presumably an
arginine binding site in vivo, may also be involved in the
plasminogen-fibrin interaction.
b Activation of Plasminogen
i Urokinase
Activation of human plasminogen has been considered a
two-step process (Wiman and Wallen, 1973; Rickli and
Otavsky, 1973; Walther et al, 1974) (see Fig 3). The first
step of this process is cleavage of a peptide bond in the
N-terminal region of the molecule resulting in the release
of a peptide(s).
Wiman and Wallen (1973) activated glu-plasminogen (93,000)
by passage through a column containing immobilized
urokinase;, they collected the effluent in an excess of the






























































FIG 3 SCHEMATIC REPRESENTATION OF THE TWO-STEP
ACTIVATION MECHANISM OF HUMAN PLASMINOGEN
INDUCED BY UROKINASE
The arrows indicate the observed cleavage of
peptide bonds ( Riekli, 1975; Walther et al, 1974) .
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peptide material in the first step consisted of two
activation peptides. Wiman (1973) called these API and
APII, and showed that they occupied positions 1-63 and
64-68 respectively in intact glu-plasminogen. The two
bonds cleaved to produce the peptides are lysine-serine
(63-64) and arginine-methionine (68-69), and the result
is an intermediate form of plasminogen of molecular weight
86,000 and N-terminal methionine (Wiman and Wallen, 1973).
The second step of activation to plasmin involves cleavage
of an arginine-valine bond situated at about residue 600
(Robbins et al, 1967) resulting in a two-chain molecule
connected by disulphide bridges. Wiman and Wallen (1973)
found the intermediate plasminogen to yield plasmin with a
light chain of molecular weight 25,000 and N-terminal valine,
while the heavy chain was 63,000 and even though very
sensitive to proteolytic degradation in its N-terminal
region, evidence pointed to methionine as the true N-
terminal amino acid residue, although serine was sometimes
found in this position.
Wnen activation of glu-plasminogen by urokinase is carried
out in the presence of 0.01M TLCK, an 80,000 molecular
weight lys-plasminogen intermediate is formed and an 8,200
molecular weight pre-activat ion peptide originating from
the N-terminal of glu-plasminogen is released (Walther et
al, 1974). According to Walther et al (1974), this
intermediate then forms plasmin with a heavy chain of
55,000 and N-terminal of usually lysine, but sometimes valine,
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and a light chain of 26,000. The heavy chain is fairly
resistant to further proteolysis, but after prolonged
periods may break down to give a molecular weight of
50,OOO; whereas the light chain can be further degraded
to 18,OOO and 6,500 moieties, with concomitant loss of
plasmin activity.
A single-step activation mechanism has also been proposed.
Violand and Castellino (1976) found that when human glu-
plasminogen is activated by urokinase in the presence of
pancreatic trypsin inhibitor, the plasmin formed exclusively
contains a heavy chain derived intact from the original N-
terminus of glu-plasminogen. Sodetz et al (1974) working
with rabbit plasminogen found similar results. These
studies strongly indicate that the N-terminal peptide(s)
need not be released from glu-plasminogen prior to plasmin
formation.
However, the findings of Thorsen (1975) that native glu-
plasminogen is adsorbed to fibrin to a lesser degree than
proteolytically degraded plasminogen, has attributed a
physiological significance to the two-step activation
mechanism. The formation of the intermediate activation
product seems to be required to obtain plasminogen activation
in situ on the fibrin clot in an environment, which is
relatively free of plasmin inhibitors.
It can be questioned, however, whether the preactivation
peptide bond and the activation peptide bond are cleaved in
vivo by the same enzyme. According to the hypothesis
presented by Thorsen (1975), the preactivation bond should
be cleaved freely in the circulation, while the activation
peptide bond is essentially cleaved after adsorption of
the intermediate to the fibrin matrix. There is some in¬
direct evidence that the preactivation peptide bond is not
primarily a urokinase-sensitive bond.
Sodetz et al (1974) questioned whether urokinase was capabl
of cleaving this N-terminal peptide, as a three-fold
increase in the level of urokinase in the activation mix¬
ture in the presence of Trasylol, gave the same glutamic
acid N-terminal heavy chain. Sodetz et al implicate the
plasmin generated during the activation process as the
species responsible for removal of the peptide; as in the
absence of Trasylol the heavy chain of plasmin has an amino
terminal sequence which differs from the original native
plasminogen. Rickli (1975) also considers the variability
of the N-terminal residue of both the intermediate plasmin¬
ogen and the heavy chain of plasmin to be due to traces of
plasmin causing proteolysis.
Summaria et al (1975) also used Trasylol in an attempt to
distinguish between the action of urokinase and plasmin
during the activation of plasminogen. They criticised the
work of both Wiman and Wallen (1973) and Walther et al
(1974) on the basis that the inhibition of plasmin by the
methods employed was not instantaneous. Summaria et al
used an excess of Trasylol in the activation mixture, as
plasmin is immediately inhibited upon formation. Using
this system they found that urokinase does not cleave
peptide bonds in the N-terminal portion of human plasmin¬
ogen, and that the only bond that need be cleaved for the
generation of plasmin is the arginyl-valine bond. These
findings indicate that glu-plasmin does exist as an active
enzyme.
Comparing the primary structure preceeding the preactivation
bond (Arg-Lys-Ser-Ser-Ile-Arg Met) ( Wiman, 1972) and
the activation peptide bond (Lys-Lys-Cys-Pro-Gly-Arg
Val) (Sottrup-Jensen et al, 1975) no homology could be
found except for the arg residue in position 1, and the
lys residue in position 5. If both peptide bonds were
primarily cleaved by the same specific enzyme, a more pro¬
nounced homology would be expected.
Walther et al(1975) -found that the activation peptide
bond is cleaved 23 times faster by urokinase than the pre-
activation peptide bond, and Sodetz and Castellino (1975)
observed that urokinase could not split the preactivation
bond of rabbit plasminogen while it could hydrolyze the
activation peptide bond. Studies by Castellino and Violand
(1977) also .indicate that urokinase is not capable of
catalysis of the bond releasing peptide material from the
N-terminus of glu-plasminogen, glu-plasmin or the native
plasmin heavy chain (glu-H) isolated from glu-plasmin. On
the other hand, plasmin readily accomplishes cleavage of
this bond in all of the above molecules. The cleavage of
the arginine-valine bond, causing activation of plasminogen,
is catalyzed only by urokinase in this system.
These data indicate that the preactivation peptide bond is
not primarily a urokinase-sensitive bond, but that another
enzyme may be involved in cleavage of this bond in vivo.
The recent findings of Astrup and Fedderssen (1975) may be
relevant. These authors found that proteolytic enzymes,
probably belonging to the class of the cys-sensitive
cathepsins, may also catalyse the cleavage of the preactiv-
ation bond.
It has previously been accepted (Wiman and Wallen, 1973;
Rickli and Otavsky, 1973; Walther et al, 1974) that cleavage
of the preactivation peptide bond is the rate-limiting
step during activation of plasminogen by urokinase.
However, many authors (Rickli and Otavsky, 1973; Walther
et al, 1974) found that the intermediate accumulates in
the first phase of activation. This discrepancy can be
explained if it is accepted that cleavage of the pre¬
activation peptide by itself is not the rate-limiting step
but that the conformational change in the plasminogen
molecule, induced by this cleavage, is rate-limiting.
Activation studies were performed with glu-plasminogen,
lys-plasminogen and glu-plasminogen in the presence of
EACA (causing the conformational change) (Claeys and
Vermylen, 1974). Under the experimental conditions
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selected, the intermediate proenzyme lys-plasminogen was
fully activated whereas glu-plasminogen was only 50%
activated. In the presence of EACA, glu-plasminogen
behaved as the intermediate plasminogen, suggesting that
the conformational change in the plasminogen molecule is
rate-limiting.
The main pathway of formation of lys-plasmin is in dispute.
Many authors favour lys-plasminogen as the intermediate,
with the associated conformational change causing increased
affinity for fibrin and the related enhancement of reaction
rate. However, physical and kinetic studies led Castellino
and Violand (1977) to propose a mechanism for the activation

















There is no universally accepted theory on the activation
of the human plasma fibrinolytic system by streptokinase
(SK). Christensen (1945) demonstrated that the lysis of
fibrin clots in the presence of streptokinase was attribut¬
able to an enzyme normally present in human serum or plasma
in an inactive state, and not to streptokinase, which alone
had no demonstrable proteolytic activity in this test system.
It was observed that streptokinase was able to activate
the human euglobulin fraction, whereas it has no effect,
or a very slight effect, on proenzyme in the euglobulin
fraction of other species such as the cow and rabbit.
Addition of traces of human euglobulins, containing
human plasminogen, to bovine plasma made it susceptible to
activation by streptokinase. These basic facts led to
varying interpretations and the discussion of these
different theories is still open.
n
Muilertz (1955) proposed the proactivator theory. Accord¬
ing to this theory, bovine plasminogen preparations would
contain large amounts of plasminogen and little or no
proactivator
Proactivator + SK ^-Activator
Plasminogen- Plasmin
and thus bovine plasmin would not be formed upon addition
of streptokinase. Human plasminogen preparations would
contain large amounts of proactivator and relatively small
amounts of plasminogen, by addition of streptokinase,
large amounts of activator and small amounts of plasmin
would therefore be formed. Several attempts were made to
isolate from human plasma both plasminogen and proactivator.
Some authors postulated that human plasminogen was the pro¬
activator itself (Ablondi and Hagan, 1957; Kline and
Fishman, 1957). Supporting this latter view is the
observation that in mixtures of streptokinase and human
plasminogen, mainly plasmin was formed when plasminogen
was in excess, and mainly activator when an excess of
streptokinase was present. Zylber et al (1959) suggested
that human plasmin and streptokinase combine to form a
complex which is capable of converting bovine plasminogen
to plasmin, thus excluding the existence of the pro¬
activator, but rather considering it to be human plasminogen
or plasmin.
Davies et al (1964) showed that an equimolar mixture of
highly purified streptokinase and human plasminogen produced
a complex of molecular weight 130,000, which was very
close to the combined molecular weights found by the same
authors for plasminogen (84,000) and streptokinase (47,000).
They affirm that the observed complex could actually be a
streptokinase-plasmin complex. Barg et al (1965) found
that after an equimolar interaction of streptokinase and
plasminogen a main product ivas identified, in electro¬
phoresis, with a migration rate intermediate between those
of the two proteins. When either component was present in
excess of a molar ratio 1:1, stainable protein correspond¬
ing to the excess was detected. The streptokinase-
plasminogen complex undergoes a time and temperature
dependant change generating an active site (McClintock and
Bell, 1971).
Summaria and co-workers (1968) were able to distinguish
between the human plasminogen-streptokinase complex and
the human plasmin-streptokinase complex. It was possible
to shoxv, in the complex isolated at 0°C, that plasminogen
was one of its components. After xvarming at 25°C, this
plasminogen-streptokinase complex was quantitatively
converted to a plasmin-streptokinase complex. The active
site of the latter activator complex is single, and pro¬
bably identical to the active site of plasmin. It was
therefore suggested that during the complex formation a
conformational modification of the plasmin molecule
occurred, leading to a concomitant change in the enzymic
specificity.
In 1969 Summaria et al showed that streptokinase could
activate plasminogen directly, a previously controversial
point, although probably the predominant mechanism of
activation is via the plasmin(ogen)-streptokinase complex.
Kline and Ts'ao (1971) also showed that the conversion of
plasminogen to plasmin by catalytic amounts of strepto¬
kinase proceeded independently of the availability of pre¬
formed plasmin. Spontaneous plasmin activity was removed
almost completely from human plasminogen by extraction with
insolubilized soybean trypsin inhibitor (SBTI) and treat¬
ment with DFP.
Using the active site titrant, PNPGB, Reddy and Markus
(1972) established that an active centre appears in the
streptokinase-plasminogen complex even before proteolytic
activity develops; that is before cleavage of the arginine-
valine bona in plasminogen to produce the streptokinase-
plasmin complex. The appearance of this active site was
interpreted as being due to a streptokinase induced con¬
formational rearrangement in the plasminogen moiety which
makes available the proteolytic potential of the zymogen.
It appears the transitory streptokinase-plasminogen complex
plays a dominant role in the streptokinase activation of
human plasm inogan, as its formation does not depend on the
presence of spontaneous plasmin.
Two distinct pathways of the streptokinase-mediated
activation of human plasminogen were described by McClintock
et al in 1974. Conversion to plasmin using catalytic
amounts of streptokinase results in the cleavage of two
characteristic peptide bonds yielding plasmin containing
three peptide chains (Plasmin, „ , the order of^ ^ v 60, 20, 5
cleavage being exclusively Plasminogen - Plasminogen^ r
Plasmin
^ ,;q ^ (where superscript "a" denotes a PNPGB-
titratable active site and the subscripts indicate the
approximate molecular weight, in thousands, of peptide chains
involved.) Interaction of plasminogen with stoichiometric
amounts of streptokinase leads to the plasminogen activator
3
complex streptokinase^ ^ 4 - Plasmin 2Q ^ Bond
cleavages of plasminogen within this complex occur entirely
3 3
by the reactions plasminogen g^ - plasminogen ^ ~
p] asmin _ This order is the reverse of thatr dU; 20, 5.
found in catalytic activations. The streptokinase peptide
bond splits within the complex, occur in the order
streptokinase47 - streptokinase^ 4 - streptokinase^ 6
End group studies of isolated peptides from the complex
show the peptide orders to be N-SK^-SKg^-SK^-C for
streptokinase47 and N-Plg^-Plg,Q-Plg9Q-C for plasminogengg
Native streptokinase does not activate bovine plasminogen.
It has been well established, however, that human plasmin¬
ogen or plasmin reacts with streptokinase to form an
equimolar complex which is an activator of bovine plasmin¬
ogen. Taylor and Beisswenger (1973) and Kline and Bowlds
(1971) have reported that- a streptokinase derivative
virtually free of plasmin activity, can be isolated from
the streptokinase-plasmin complex and that this modified
streptokinase (SK^) contains the active centre for the
conversion of bovine plasminogen to plasmin. But Re-ddy
and Kline (1975) used affinity chromatography to remove
the last detectable trace of plasmin from the SIC preparat¬
ion and found that bovine plasminogen activator activity
disappeared. The addition of preformed plasmin restored
bovine activator activity, supporting the theory of Reddy
and Markus (1972) that streptokinase is not an enzyme but
functions by inducing an active centre in human plasminogen
as a result of complex formation with it.
Robbins et al (1977) have isolated the human plasmin-
derived light (B) chain and found it to be functionally
active. It is both a proteolytic and esterolytic enzyme,
but it has no plasminogen activator activity. It reacts
with streptokinase to form an equimolar complex which
has both human and bovine plasminogen activator activities.
The binding site for streptokinase is located on the light
(B) chain of plasmin. The light (B) chain-streptokinase
complex is an effective activator in in-vitro clot lysis
systems using crosslinked fibrin clots. The light (B)
chain adsorbs to fibrin clots resulting in accelerated
lysis of these clots by activators.
i
Reaction between streptokinase and plasminogen, when the
former is in a molar excess, results in the extensive
degradation of streptokinase (Brockway and Castellino,
1974; Summaria et al, 1974). The effect of this breakdown
is to yield a modified plasmin molecule carrying none of
the characteristics of streptokinase, yet retaining the
capacity to activate both bovine and human plasminogen.
c The Effects of w-Aminocarboxylic Acids on the
Activation and Conformation of Plasminogen, and
Subsequent Effects on Fibrinolysis
The related w-aminocarboxylic acids, L-lysine, epsilon-
aninocaproic acid (EACA or 6-AHA), p-aminomethylbenzoic
acid (PAMBA) and trans-4-aminomethylcyclohexanecarboxylic
acid (trans-AMCHA) have similar effects on activation of
Diasminocen and on the catalytic effect of plasmin. Their
relative potency increases in the order given and varies
-virhin a factor of 100, when determined on a molar basis
(Baumgarten, 1972; Landmann, 1973; Lukasiewicz et al, 1968;
Ckanoto et al, 1968; Thorsen and Astrup, 1969; Thorsen and
Mullertz, 1974).
Studies show that the native form of plasminogen, glu-
plasminogen, undergoes a gross conformational change upon
binding EACA and its analogues. Sedimentation velocity
measurements show that lys-plasminogen, prepared by removal
of a peptide of molecular weight 6-8,OOO, possesses a
strikingly dissimilar gross conformation compared to glu-
plasminogen (Violand et al, 1975). However, the overall
conformation of lys-plasminogen is very similar to the glu-
plasminogen-EACA complex, as shown by the circular dichro-
tr
ism spectra of the two species (Sjoholm et al, 1973).
Although lys-plasminogen retains its full capacity for
binding EACA, no additional gross conformational alteration
results as a consequence of saturating the binding site of
lys-plasminogen with this amino acid.
EACA and analogues, produce identical effects with glu-
and lys-plasmin as with glu- and lys-plasminogen# These
results illustrate the importance of the amino terminal





of the molecule as well as controlling the
achieved upon saturation by compounds such
The effect of the amino acids on activator-induced fibrin¬
olysis may greatly depend on the source of activator (Kok
and Astrup, 1972; Thorsen and Astrup, 1959). The enhance¬
ment of fibrinolysis induced by the tissue activator over
fibrinolysis induced by urokinase is related to the much
higher affinity for fibrin of the tissue activator than of
urokinase (Thorsen et al, 1972), associated with a marked
accelerating effect of fibrin on the rate of plasminogen
activation by the tissue activator (Camiolo et al, 1971;
Wallen, 1978). The effect of EACA on urokinase-induced
fibrinolysis in the presence of lys-plasminogen may mainly
be die to an inhibition of the catalytic effect of plasmin.
This is consistent with the fact that inhibition of fibrin¬
olysis effected by urokinase, and inhibition of fibrinolysis
effected by plasmin begin at the same concentrations of
-5 -4
amino acid (betxveen 10 and 10 M) (Thorsen et al, 1974).
EACA mainly inhibits proteolysis of fibrin by competing
with fibrin for sites on plasmin, which are different from
the active centre (Ixvamoto, 1975; Landmann, 1973) and most
likely located on the heavy chain (Rickli and Otavsky,
1975). This prevents a functional interaction betxveen the
active centre on the plasmin light chain and fibrin. A much
more pronounced inhibition by the w-aminocar'ooxylic acid
of the activity of plasmin toxvards fibrin than towards
fibrinogen, casein or synthetic esters (Ambrus et al, 1970;
Landmann, 1973; Lukasiewicz et al, 1968; Skoza et al,
1968; Thorsen et al, 1974) suggests that plasmin possesses
specific substrate binding sites for fibrin. An effect
of EACA on urokinase may only to a small extent contribute
to the inhibition by the amino acid of urokinase-indueed
fibrinolysis because the dissociation constant for urokin¬
ase and amino acid (Geratz and Cheng, 1975; Landmann,
1973; Lorand and Condit, 1965; Walton, 1967) is 20-70
times the dissociation constant for plasmin and amino acid
(Skoza et al, 1968).
The difference in effect of EACA on urokinase-induced
lysis with native and proteolytically degraded plasminogen
may mainly be explained by the difference in rate of
activation of the two forms of plasminogen. EACA causes
uniformly increasing inhibition of fibrinolysis
-5 -4
(beginning between 10 and 10 EACA), whether the
fibrinolysis is due to plasmin or urokinase in the
presence of proteolytically degraded plasminogen. Thus
it is evidence that the enhancement of urokinase-
_ 3
induced fibrinolysis (maximum of 10 M EACA) in the
presence of native plasminogen is related to the increased
rate of activation due to the complex formation between
amino acid and plasminogen (Thorsen and Astrup 1974;
Thorsen et al, 1974).
The effects of w-aminocarboxylic acids on fibrinolysis
induced by activators may be summarized as follows
(Thorsen, 1978)
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1 They form reversible complexes with plasmin and
plasminogen which leads to:
a a dissociation of the complex between fibrin and
the specific substrate binding sites on plasminogen;
b a dissociation of the complex between fibrin and
the specific substrate binding sites on plasmin;
c conformational changes of the plasminogen molecule,
leading to an increase in rate of activation.
2 They may react with activators and competitively
inhibit their catalytic effect on plasminogen.
3 They may react with fibrin and change its structure.
\
The w-aminocarboxylic acids have a much higher affinity
for plasmin(ogen) than for activators and fibrin. Con¬
sequently, the effect of the amino acids on fibrinolysis
is mainly related to the effect on plasmin(ogen).
B PLASMIN
Piasmin is a proteolytic enzyme of the endopeptidase type
with properties rather similar to trypsin. It cleaves, or
hydrolyzes, proteins and peptides at arginyl and lysyl
peptide bonds (Wallen and Iwanaga, 1963; Groskopf et al,
1963; Wainstein and Doolittle, 1972), basic amino esters
( Wainstein and Doolittle, 1972; Sherry et al, 1966; Robbins
f!
et al, 1965) and amides (Christensen and Mullertz, 1974).
Piasmin appears to have a preference for lysyl bonds in
both protein and ester substrates (Weinstein and Doolittle,
1972).
Piasmin is a proteolytic enzyme of wide specificity, and
can digest many proteins including fibrinogen and fibrin;
in purified systems fibrinogen is digested as readily as
fibrin, but in the presence of inhibitors the relative
substrate specificity for fibrin is conferred on piasmin
(Ratnoff, 1953). Other proteins digested by piasmin
include prothrombin and Factor V (Alagille and Soulier,
1956), Factor VIII (Lewis et al, 1949), glucagon, ACTH
and growth hormone (Mirskey et al, 1959) and certain com¬
ponents of complement (Pillemer et al, 1952). Piasmin
when incubated with plasma in vitro can produce a bradykinin-
like substance, and can also release a plasma kinin with
vasodilator properties in vivo (Back et al, 1963). Why
piasmin has such a wide specificity is not known but it may
be of consequence for biological functions other than
fibrinolysis.
Plasmin consists of two polypeptide chains of different
size, a heavy and a light chain connected by at least one
bisulphide bond. A molecular weight of 48,800 is found
for the heavy chain by Summaria et al (1971), 63,000 by
hinan and fallen (1973), and 55,000 by Walther et al
(1974); whereas evaluation of the molecular weight of the
light chain differs only slightly from one laboratory to
the other: 25,000 to 26,000. Like other proteases, plasmin
undergoes autolytic degradation, which explains certain
analytical difficulties.
The complete amino acid sequence of the heavy chain of
human plasnin (residues 1-560) has now been established
(Sottrup-Jensen et al, 1977). The complete sequence of the
light chain is also accounted for, see Fig 4 (after
fallen, 1973).
A single DFP-sensitive serine residue (Summaria et al,
1967) and a single TLCK-sensitive histidine residue
(Bobbins et al, 1973) have been found in the active centre
of human plasmin, and both residues are located on the
light (B) chain of the enzyme (Summaria et al , 1967). The
partial amino acid sequence of a 31-residue tryptic peptide
containing the active centre serine residue was determined
to be Val-Glx-(Ser-Thr, Glx)-Leu-(Gly, Ala)-His-Leu-Ala-
Cys-Asn-(Thr, Gly, Gly)-Ser-Cys-Gln-Gly-Asp-Ser*-Gly-Gly-
Pro-Leu-Val-Cys-Phe-Glu-Lys- (Groskopf et al, 1969). The
N-terminal 21-residue sequence obtained from the light (B)
chain and containing the active centre histidine residue
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One Letter Amino Acid Abbreviations:
V = Val P - = Pro R = Arg K = Lys
G = Gly S == Ser T = Thr Y = Tyr
C = Cys W == Trp F = Phe N = Asn
A = Ala Q == Gin M = Met D = Asp
H = His L == Leu E = Glu I = He
FIG 4 THE AMINO ACID SEQUENCE OF THE LIGHT (B) CHAIN
FROM HUMAN PLASMIN
The two incomplete disulphide bonds to the
right (residues 5 and 105) represent the
connections to the heavy (A) chain.
was determined to be His-Phe-Cys-Gly-Gly-Thr-Leu-Ile-
Ser-Pro-Glu-Trp-Val-Leu-Ser-Ala-Ala-His*-Cys-Leu- (Robbins
et al, 1973). This sequence contains the "histidine loop"
of human plasmin, and it is homologous to the "histidine
loop" sequences of other serine proteases.
C ACTIVATORS
a Vascular Activator
Vascular plasminogen activator, sometimes known as blood
or plasma plasminogen activator, is the activator mainly-
responsible for physiological plasma fibrinolytic activity
Blood fibrinolytic potential has a diurnal variation,
with lower levels during the night (Fearnley et al, 1957;
Rosing et al, 1970). This fluctuation appears to diminish
with increasing age (Buckell and Elliott, 1959; Rosing et
al, 1970). The plasminogen activator content of plasma
falls precipitously during the latter part of the second
trimester of pregnancy to return again to normal within
minutes of placental separation (Bonnar et al, 1969;
e
Astedt, 1972). In the newborn the activator content is
high but falls within hours of delivery (Elcelund et al,
1970).
i Localization
Certain organs may play significant roles in either the
manufacture of circulating plasminogen activator or its
removal. Thus the kidney (Januszko et al, 1966; Marsh,
1970), brain (Menon et al, 1970), stomach and intestine
(Cox et al, 1967; Eras et al, 1970; Gans et al, 1971) have
all been implicated as contributing to the activator input
whereas the liver and lung may play a role in its removal
(Januszko et al, 1966; Menon et al, 1968; Menoa et al,
1959).
In 1959 Todc! described his fibrinolytic autograph tech¬
nique, which involved incubating a tissue section over-
layed with a film of fibrin, thus enabling the lysis areas
of the fibrin to be correlated with specific areas in the
section. In most tissues, except the liver, zones of
fibrinolysis appear on incubation. These zones are related
almost exclusively to veins and venules. In the normal
liver practically no lysis occurs, but in cirrhosis or
carcinoma of the liver there is lysis around the newly-
formed vessels in the scar tissue.
In 1967, Pandolfi et al showed that the fibrinolytic
activity was higher in arm veins than in leg veins and
that blood fibrinolysis stimulated by stasis is higher
in the arms than the legs. Fibrinolytic activity in
veins is localized mainly to the vasa vasorum of the
adventitia (Pandolfi et al, 1967), the media is moderately
active but the intimal cells are active only when detached
(Pandolfi et al, 1968).
In 1969 Pandolfi et al studied the fibrinolytic activity
in the vein walls of patients with thrombosis. The
findings showed that the fibrinolytic activity of un¬
affected veins in the legs of patients with thrombosis is
significantly lower than that of veins in normals. They
concluded that low fibrinolytic activity of the vessel
walls predisposes to thrombosis.
There has been some dispute as to whether the vascular
activator is generated by the endothelium or if the
endothelial cells merely store activator that has been
produced elsewhere. Lack and Ali (1964) raised the
possibility that plasminogen activator ivas associated
in some way with lysosomes. They fractionated rabbit
and mouse kidney and liver and found plasminogen activator
in the lysosomal fraction. Activity was enhanced by
exposure to Triton X-lOO, saponin or endotoxin all of which
are believed to release lysosomal enzymes.
Isacson and Nilsson (1969) studied fibrinolytic activity
in biopsy specimens of superficial veins, from patients
who had been bilaterally nephrectomized and treated with
haemodialysis for 3-15 months. They could not substantiate
earlier reports of an essential role of the kidney in
maintaining fibrinolysis of the blood and concluded that
plasminogen activator forms in the vessel walls.
Further evidence that the endothelium can produce plasmin¬
ogen activator was obtained by Pandolfi in 1970. Explants
from human veins were cultured in a fibrinolytically
inactive medium; after three weeks fibrinolytic activity
was detected, by the fibrin overlay technique, confined to
the vasa vasorum, suggesting that small blood vessels are
able to synthesize plasminogen activator.
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Generally more plasminogen activator is found in veins
and venules than other vessels, but it is found in
similar amounts .in arteries and arterioles supplying
very active tissues such as the retina, myocardium and
kidney. In other systemic arteries endothelial activator
seems less important and any activator seen is usually
due to weaker activators released from leucocytes. Many
kinds of cells may be made to release activator-like
substances from lysosomes. The fibrinolytic activity of
non-endothelial cells, however, tends to be weak and in¬
consistent, probably due to the release of non-specific
proteolytic enzymes which, like trypsin, can activate
plasminogen (Todd, 1972).
Noordhoek Hegt (1977) was able to correlate sites of low
fibrinolytic activity with the presence of a fibrinolytic
inhibitor, whereas inhibition was absent in areas showing
strong fibrinolysis. Fibrinolysis is related to end¬
othelial cells, while inhibition is related to smooth
muscle cells. Thus differences in endothelial fibrin¬
olysis may result from differences in inhibition caused
by variations in the number of smooth muscle cells present
locally.
ii Release
Systemic fibrinolysis and stress have been linked since
the early observation of an association between violent
death and post nor tern fluidity of blood. Subsequently
exercise (Biggs et al, 1947), surgical operations
(Macfariane and Biggs, 1946), electroconvulsive therapy
(Fantl and Simon, 1943), and even acute mental stress
(Macfariane and Biggs, 1946) were also shown to enhance
the fibrinolytic potential in man. Systemic catecholamine
release is a common feature of all these stimuli. Thus
acute mental stress (Elmadgian et al, 1957), surgery
(Franksson et al, 1954) and myocardial infarction (Wallace,
1 ?6S) have all bean reported to be associated with a rise
in circulating catecholamines.
Thus the study of local receptor systems began with
catecholamine infusions; this was advanced by the intro¬
duction of a concept of specific catecholamine (adrenergic)
receptor sites (Ahlquist, 1943), and the arrival of a group
of compounds which selectively block these receptor sites
(Fitzgerald, 1969). This approach has led to the definit¬
ion of cx- and (3- adrenergic receptors in the body and to
the concept that p-adrenergic receptors can be divided
into p^ and p^ types, the former being associated with p~
effects on the heart and intestinal mascle and the latter
with muscle of the bronchi, uterus and vessel walls.
Studies show that the plasminogen activator response to
catecholamines appears to be a p-mediated phenomenon, and
that the receptor involved is probably a p^-type (Gader
et al, 1973a). Evidence that the catacholamine-induced
release of plasminogen activator is probably a direct
effect on endothelial cell release has been obtained from
experiments in which intra-arterial epinephrine
(adrenaline) was shown to stimulate a prompt increase in
plasminogen activator content of the venous effluent of
the infused limb (Cash, 1972).
The results of studies using p-adrenergic antagonists
indicate that the catecholamine-mediated plasminogen
activator response may be associated with three different
receptor sites or three components of one site (Gader
et al, 1974 ) .
Studies during the early 1950's suggested that the
hypothalamus and in particular the release of vasopressin
might play a role in the control of fibrinolysis in man.
Schneck and von Kaulla (1961) demonstrated that admin¬
istration of intravenous pitressin, an animal posterior
pituitary polypeptide extract which included vasopressin,
was followed by a significant shortening of the euglobulin
lysis time, suggesting a considerable release of plasminogen
activator. Because pitressin contains several other poly¬
peptides, it was not possible to conclude with certainty
that the fibrinolytic response was related to vasopressin.
However, this was recently verified using synthetic
preparations of vasopressin (Gader et al, 1973b; Mannucci
and Barbi, 1973). Unlike adrenaline, vasopressin does
not appear to give rise to a local release of plasminogen
activator when infused into a brachial artery (Cash, 1978).
Therefore the conclusion is that the endothelial cells, at
least in the forearms of humans, do not contain specific
vasopressin receptor sites. Moreover, the studies of
Mannucci et al (1975) have clearly shown that the path¬
ways by which adrenaline and vasopressin give rise to a
release of plasminogen activator appear to be quite
distinct, although Barker et al (1972) demonstrated a
possible connection in that |3-adrenergic stimulation may
give rise to the release of vasopressin.
Benetato and Dumitrescu-Papahagi (1964) showed that
following electrolytic lesions and hypothalamic ultra¬
short wave stimulation in man, there was a significant
systemic plasminogen activator release. Apart from this
there is no other clear evidence of central (CNS) control
mechanisms associated with the peripheral release of
plasminogen activator in man. Nevertheless, the way in
xvhich plasminogen activator is released in so many stress¬
ful events, including mental stress makes this seem highly
probable. Moreover it has also been shown in man that
prolonged mental stress can have a marked overriding
influence on the subsequent fibrinolytic response to
physical exercise.
Certainly adrenal medulla secretion of catecholamines
is closely concerned with central mechanisms via neurogenic
pathways and this provides a link with the brain. However,
the magnitude of the role of catecholamines in plasminogen
activator release, at least in the low stress situation,
seems likely to be small.
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It is unlikely that vasopressin is the natural specific
neurohormone concerned with the physiological release
of plasminogen activator. Firstly the doses of synthetic
material required to produce a systemic plasminogen
activator response appear to be too high to have physio¬
logical relevance, and secondly, there is no evidence of
peripheral vasopressin plasminogen activator receptor sites,
although it is conceivable that they might be present in
endothelial cells other than those in the upper limb.
However, a substance closely related structurally to vaso¬
pressin may well be important.
Cash (1978) hypothesized that the release of plasminogen
activator from the endothelial cell with respect to
normal daily* activities may be explained on the basis of
localized (and therefore high concentration) release of
a vasopressin-like substance in the hypothalamic area
which triggers off the release of an as yet unknown
neurohumoral substance that has a direct effect on the
endothelial cell, and that the catecholamine pathway, for
which there is good evidence for specific endothelial
receptors, is only involved in particularly severe stress¬
ful situations.
iii Purification and Some Properties
Aoki and von Kaulla (1971a) were the first xvorkers to
describe the extraction of cadaveric vascular plasminogen
activator. They cannulated the femoral artery and vein,
and perfused the vascular tree with warm buffered saline.
They obtained an average of 9,621 CTA (Committee on
Thrombolytic Agents) units per leg at an average of 14.5
units per ml. They observed no correlation of activator
yield with age, cause of death, or time elapsed after
death before extraction.
Aoki and von Kaulla (1971b) reported a molecular weight
of 65,000 for the vascular activator, but Aoki (1974)
later reported a value of 80,ODD; both values ivere
determined by gel filtration. Aoki (1974) purified the
crude vascular activator 20O-fold by ammonium sulphate
fractionation, zinc precipitation and ethanol fractionat¬
ion folloived by DEAE-cellulose chromatography and Sephadex
G-200 gel filtration. Using this preparation he found
tint the activator was labile and rapidly lost its activity
at pH values above 8 and below 4. The stability of the
activator was dependant on the salt concentration of the
medium in which the activator was dissolved; higher salt
concentrations tended to stabilize the activator which was
inactivated by dithiothreitol. The activator preparation
did not possess any proteolytic activity when tested on
fibrin, casein and denatured haemoglobin, but readily
activated plasminogen to plasmin with zero-order kinetics.
Ogston et al (1976) partially purified a circulating
plasminogen activator obtained after venous occlusion of
the upper arm. No activator was recovered when plasma
obtained without venous occlusion was subjected to the
same procedures. The activity of the activator preparat¬
ions was markedly more stable at 37°C than that in the
original plasma, and was inhibited by exposure to PMSF
but not by exposure to TLCK, TPCK or iodoacetamide. Ogston
et al also reported that the plasma activator was adsorbed,
to a much greater extent than urokinase, to fibrin during
its formation.
b Tissue Activator
Fibrinolytic activity of tissues was first reported by
Fleisher and Loeb (1915). Astrup and Permin (1947) later
demonstrated that the activity was due to the presence of
plasminogen activators. Most tissues contain a certain
amount of a plasminogen activator which is readily soluble
in saline (Albrechts'en, 1957) and a certain amount of
another activator which is less soluble and has to be
extracted with potassium thiocyanate (Astrup and Stage,
1952). The former activator is a labile type, which
might be derived from the tissues but could also be identical
with the vascular plasminogen activator present in the
blood. The latter activator, in contrast, is very stable
and its content varies widely in different tissues.
The physiological role of these tissue activators is not
clear, but presumably they play a role in the lysis of
extravascular fibrin. The relationship of tissue activator
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to vascular activator has been a subject of great interest,
and it has been suggested that vascular activator is a
product of the tissue activators. In view of the recent
advances in knowledge concerning vascular activator, this
is unlikely and as proposed by Astrup (1975) it seems
highly probable that there are separate humoral and
cellular systems of plasminogen activation. The cellular
system's role being the regulation of tissue repair and
wound healing and the humoral system's role being the
maintenance of vascular patency, with a contribution to
wound healing.
Tissue activator is not extractable from tissues under
physiological conditions and it is assumed that its
insolubility in common aqueous media at neutral pH is
due to its close association with certain intracellular
elements, possibly the microsomes. Lack and Ali (1964)
reported that the highest activity was in the lysosomal
fraction.
A method has been developed for the assay of the tissue
activator that is selective for the stable activator,
since it makes use of an acid precipitation, xvhich destroys
the labile activator. In a survey of human organs
Albrechtsen (1957) found that the organs could be grouped
according to their average content. Some have high
activity; uterus, adrenals, lymph nodes, prostate and
thyroid are all above 300 u/g fresh tissue. Of medium
activity are lung, ovary, pituitary, kidney, skeletal
muscle, all between 100 and 300 u/g. The heart and brain
are between 30 and 100 u/g, and there is little or no
activity in testes,, spleen and liver. It is also seen
that the activity of the individual specimens varies
between extreme ranges. Albrechtsen's results on human
material have been confirmed by Ende and Auditore (1961).
The greatest obstacle in the purification of tissue
plasminogen activator has been the strong adherence of
the activator to cellular components, making it insoluble
under usual conditions. The inability to extract the
activator from tissues with saline was observed by Fleisher
and Loeb (1915) and has been confirmed by later investigat¬
ions. Permin (1947) tried unsuccessfully to extract the
N
activator with phosphate buffer ( /15, pH 5.6-8.3), acetic
acid (1% and 5%), hydrochloric acid (0.01N), ammonium
hydroxide (0.01N), sodium hydroxide (O.OlN) and glycerol
(87%) containing 0.5% acetic acid. The activator with¬
stands drying with acetone and ether, and treatment with
chloroform, indicating that it is free from lipids. The
necessity of using concentrated solutions of potassium
thiocyanate suggests that the activator is closely bound
to other proteins by hydrogen bonding. One of the most
important chemical properties of the tissue activator is
its great stability at acid pH; at pH3 it is resistant to
heating for 30 minutes at 70°C (Astrup and Sterndorff,
1956).
The major advances in purification of tissue activator
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have been using the pig heart. Bachmann et al (1964)
extracted the activator from acetone-dried pig heart
powder with 0.3M potassium acetate pH4.2. Subsequent
steps involved ammonium sulphate precipitations of pH4.2
and 50% saturation, and at pH8 and 35% saturation,
followed by precipitation at low ionic strength in the
2 +
presence of 0.3mM Zn . Further substantial purification
was obtained by gel filtration through Sephadex columns
and precipitation with acetone. The method was reproducible
and gave overall yields from 15-25%. The final preparations
exhibited specific activities of 12,000-25,000 CTA u/mg
protein, representing a 1,700-fold purification over the
crude extract.
An improvement on the above procedures was reported by
Wallen and Wiman in 1975a. Using the same initial steps,
they took a fraction obtained between 14 and 66% saturation
with ammonium sulphate dissolved in phosphate buffer at
pH7 and adsorbed it xvith fibrin. The activity was eluted
with 2M potassium thiocyanate, and then subjected to
hydrophobic interaction chromatography on phenylethyl-
Sepharose. The activity was eluted with a potassium
thiocyanate gradient, yielding a preparation with a
specific activity of 33,000 CTA u/mg.
A further improvement in the purification of pig heart
tissue activator was obtained by two affinity adsorbtions
involving two different sites in the activator molecule
(Wallen and Ranby, 1977). Firstly the activator was
adsorbed to fibrin and eluted in two steps with potassium
thiocyanate and phenylethylamine. This was followed by
affinity chromatography on Sepharose-arginine. The final
product gave a single band on SDS-polyacrylamide gel
electrophoresis of molecular weight 63,000 dalton before
reduction, and 31,000 dalton after reduction. The highly
purified activator (specific activity ^ 150,000 CTA u/mg)
was labile in neutral solutions of low ionic strength but
was stabalized by increasing the ionic strength to 1. The
firm and specific adsorbtion of tissue activator to fibrin
is presumably of physiological importance, and attempts
are being made to study sites in fibrin(ogen) with affinity
for tissue activator. Preliminary experiments (Wallen and
Ranby, 1977) indicate that one site is situated in the
part of the Asc chain which is released at an early stage
in the plasmin digestion of fibrin(ogen).
c Urinary Activator (Urokinase)
It has been known since 1885 that urine shows a proteolytic
activity; an activity attributed by Sahli to formed pro¬
teolytic enzymes. Specific fibrinolytic activity was noted
by Macfarlane and Pilling (1947), this effect being
demonstrated by Williams (1951) to be due to the presence
of a plasminogen activator in urine; the name urokinase
was suggested by Sobel et al (1952).
Early purification of urokinase was by ammonium sulphate,
alcohol or acetone precipitation (Macfarlane and Pilling,
1947) or precipitation at pH4.5 in the cold (Celander et
al, 1955). Celander et al (1955) also developed a foam
technique in which urine was shaken, by hand for two
minutes to produce a foam in which the urokinase was con¬
centrated between 10 and 40-fold.
Ploug and Kjeldgaard (1957) employed adsorption on silica
gel, followed by chromatography on Amberlite 1KC-50 to
purify urokinase, although the preparations were still
inhomogeneous by electrophoresis. Sgouris et al (1962)
used the cation exchanger cellulose phosphate, an ethanol
precipitation and the ion exchange resin XB-97; these
procedures gave urokinase of specific activity 1,COO CTA
u/mg, and electrophoresis on starch gel gave one major
band associated with the activity, and four minor bands.
Lesuk et al (1965) prepared crystalline urokinase starting
with aqueous solutions of highly purified material.
Crystallization was induced by cautious adding of sodium
chloride with gentle stirring. These procedures resulted
in specific activities of 104,000 CTA u/mg protein and
gave a molecular weight of 54,000 and an N-terminal amino
acid residue of isoleucine (Lesuk et al, 1967).
Ogawa et al (1975) used a five-step purification procedure
involving an initial adsorption on a synthetic acrylonitrile
fibre followed by ammonium sulphate precipitation and three
chromatography steps on Amberlite CG50, Sephadex G-100 and
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C-' Sephadex respectively, giving urokinase preparations
v.*ith specific activities of over 215,000 CTA u/mg.
H j1nber g et al (1976) further purified commercial urokinase
preparations by affinity chromatography on benzamidine-
Sepharose.
According to Holmberg et al (197o) there are two molecular
forms of urokinase; they have molecular weights of 54,000
and 31,000, whereas Ong et al (1976) claim molecular
•..eights of 47,000 and 33,400. The high molecular weight
form appears to be composed of two protein chains, one
of which is the low molecular weight form, or light chain,
been Holmberg et al (197o) ran their preparation in SDS
gel electrophoresis after reduction with mercaptoethanol
a 20,000 molecular weight band appeared. However, a
monospecific antiserum was raised on immunization, thus it
appears that the light chain of the 54,000 molecular weight
urokinase contains only antigenic determinants that are
present in the heavy chain. Holmberg et al also reported
that electrophoretic mobility in agarose of both chains
appeared to be similar. Ong et al (1976) determined the
molecular weight of the light chain to be 18,600.
The high molecular weight form can be converted catalytically
to the low molecular weight form (Ong et al, 1977); Lesuk
et al (1967) also reported that urokinase could be cleaved
by trypsin to give an active fragment of molecular weight
36,OOO. Some proteases, other than trypsin, were found to
liberate still smaller active fragments which await further
characterization, while other proteases yield only
inactive fragments.
It is likely that urokinase belongs in the class of
enzymes utilizing the Asp His Ser triad for their catalytic
action. The two active site residues so far identified,
serine and histidine, are present in the low molecular
weight form, and are located in the heavy chain of the
high molecular forms (Ong et al, 1976).
Ong et al (1977) reported that at low plasminogen levels
the high molecular weight form showed greater fibrinolytic
activity than the low molecular weight form, suggesting
that it may be more effective therapeutically. As a follow
up to this Suyama et al (1977) showed that the concentrat¬
ion of high molecular weight urokinase necessary to induce
50% lysis of artificial thrombi was approximately half that
of low molecular weight urokinase. Also Lormeau et al
(1977) showed that high molecular weight urokinase is about
2.5-fold more active than low molecular weight urokinase
towards glu-plasminogan.
Painter and Charles (1962) cultured monkey and dog kidney
cells, "and showed that they accumulated a fibrinolytic
agent which was shown to be a soluble plasminogen activator
with properties similar to urokinase. Bernik and Kwaan
(19&7) cultured explants from human kidneys and a plasmin¬
ogen activator was produced and released by cells which
emerged from small vessels. No significant fibrinolytic
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activity was exhibited by tubular cells, fibroblasts,
macrophages or lymphocytes in the outgrowths. The titre
of the plasminogen activator in the culture media increased
after repeated changes of fluid, indicating a continuous
production and release of activator. This was found to
be a function of living cells and was not observed in
cells that died during culture. Preliminary immunological
investigation of the activator showed it to be identical
to urokinase. Barlow and Lazer (1972) using cultured
human embryo kidney cells confirmed the identity of the
activator with urokinase in all properties studied.
Primary cultures of kidney confirmed that this organ is
a rich source of urokinase; it is produced in the early
stages of gestation and in increasing amounts thereafter
(Bernik and Kwaan, 1969). But the ability to produce
urokinase is not limited to the kidney but is a function
of cells distributed widely in body tissues. Activator
antigenically identical to urokinase accumulated in
culture supernates of faetal lung and ureter and in renal
blood vessel cultures of adults.
9
Astedt (1975) attempted to locate the actual site of
production of urokinase in the kidney. Isolated glomeruli
that were fibrinolytically inactive (by the fibrin slide
technique) were obtained and cultured; during culture a
marked release of fibrinolytic activators occurred. After
culture histochemical examination showed the glomeruli to
be fibrinoiytically active. This means that the fibrinolytic
defe±ice system of the draining pathways begins at least
at the epithelial surface of the glomeruli.
0
Astedt et al (1977) using organ and cell cultures of
human faetal kidneys found that early cultures produced
the high molecular weight urokinase, whereas late cultures
produced low molecular weight urokinase. It is possible
that the kidney cells lose their ability to link the two
chains or, more probably, are not able to synthesize the
light chain.
Bsrnik (1973) showed that deposition of fibrin on cells
in culture was followed by a 2 to 6-fold increase in
urokinase in the supernates and rapid disappearance of
the fibrin. It appeared that the enhanced urokinase yields
were mediated through plasmin and thrombin. Inactive
material, which gave rise to urokinase upon exposure to
proteolytic enzymes and which may represent a urokinase
precursor, was found in cultures of kidney, lung, spleen
and thyroid (Bernik, 1973). Nolan et al (1977) also found
evidence for a trypsin-activatable proactivator in human
embryonic kidney cell cultures.
Harder et al (1977) have shown clearly that the pharma¬
cologic effect of tissue culture urokinase, from human
kidney cells, is the same as that of urinary urokinase,
and it is reasonable to expect that both materials will
be equally effective therapeutically.
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d Factor XII Mediated Fibrinolytic Activity
Iatridis and Ferguson (1961) and Niewiarowski and
Prou-Wartelle (1959) showed that fibrinolytic activity
could be generated in normal plasma (but only to a limited
extent in factor XII deficient plasma) following incubat¬
ion with kaolin after acidification and reduction in
ionic strength. These and other observations have brought
about considerable interest in the reaction sequence between
the activation of factor XII and the activation of plasmin¬
ogen, and in the interrelationships between this reaction
and the activation of the coagulation, the kallikrein-kinin
and the complement systems. It is now clear they are all
interrelated and that factor XII occupies a key position
in the reactions. The implications of this second humoral
activator system on the overall fibrinolytic mechanism
and the mechanism of thrombolysis in vivo, are still largely
unknown.
Recently, Hageman factor (factor XII), in the presence of
kaolin, has been ascribed a hitherto unsuspected function;
that is, the direct activation of plasminogen (Goldsmith
et al, 1978). Prior to this it was accepted that the inter¬
action of a surface with at least three plasma proteins
was a necessary requirement for factor XII dependant fibrin¬
olysis. The three plasma proteins are factor XII, prekal-
likrein and high molecular weight (HMW) kininogen (see
Fig 5). Plasmas that are deficient in any one of these





























Prekallikrein and HMW kininogen circulate as a complex
and molecular weight considerations suggest that the
binding is lmole/mole. This complex then interacts with
factor XII when they are bound to a negatively charged
surface. There is a reciprocal activation that occurs
between factor XII and prekallikrein. Thus factor Xlla
converts prekallikrein to kallikrein while kallikrein
enzymatically activates factor XII. The reaction rate in
both directions is augmented by HMW kininogen. The surface
and HMW kininogen bring the two proenzymes together in an
optimal fashion; however, it is not known which factor
possesses the active site that initiates the reaction.
Kallikrein digests factor XII into two main fragments.
The 28,000 molecular weight fragment contains the active
site of factor Xlla, while the 52,000 molecular weight
fragment is the portion that binds to surfaces. Initially
cleavage occurs such that the two pieces are disulphide
linked and bound to the surface and a secondary cleavage
liberates the Hageman factor fragments. Kallikrein also
digests the cofactor HMW kininogen to liberate bradykinin,
and it also directly converts plasminogen to plasmin, with
prekallikrein acting as a plasminogen proactivator.
In addition factor XI circulates bound to HMW kininogen
and factor XI and Hageman factor also activate each other
with HMW kininogen acting as a cofactor. However, the
activation of Hageman factor by factor XIa is only about
10% as effective as kallikrein.
Kaplan and Austen (1972) described a Hageman factor
substrate that, upon activation, directly converted
plasminogen to plasmin. This factor was clearly disting¬
uished from factor XI, but was similar to prekallikrein
in molecular weight and isoelectric point. Laake and
?»
Vennerod (1974) were unable to separate prekallikrein from
plasminogen proactivator and concluded that these were one
and the same molecule.
Kaplan et al (1976) when fractionating human plasma found
two peaks of plasminogen proactivator activity, one
fractionated along with prekallikrein, while the second
was superimposable upon factor XI. This second activity
may be factor XI or a different plasminogen activator that
fractionates with factor XI.
A Hageman factor dependant factor that functions in fibrin¬
olysis was reported by Ogston et al (1969) to be a $-
globulin of 160,000 molecular weight. Plasma adsorbed
with crushed glass was found to possess a fibrinolytic
defect that could be corrected by addition of the above
plasma fraction. The properties of this factor most
closely resemble the plasminogen activator associated with
factor XI. However, glass-adsorbed plasma has been shown
to be deficient in prekallikrein (Wuepper, 1973) and since
the Hageman factor cofactor preparations utilized contain
prekallikrein (Ogston et al , 1969) it appears that the
correction may merely represent the requirement for pre¬
kallikrein in the activation of Hageman factor.
The activation of plasminogen to plasmin by the Hageman
factor dependant plasminogen activator appears to be
similar to that seen with urokinase rather than strepto¬
kinase.
e Bacterial Activators
Plasminogen activator activity is produced by many micro¬
organisms including streptococci, B coli, staphylococci,
Claustridia and pseudomonas pyocyaneo. . Of the bacterial
activators, the most important is streptokinase produced
by streptococci.
Streptokinase is an extracellular protein produced during
the growth of several strains of beta-haemolytic strepto¬
cocci, and it functions in the conversion of plasminogen
to plasmin (see section 2Abii). Up to now the only
substrates known for streptokinase are purified plasminogens
and plasmins from human, monkey, baboon, chimpanzee, cat,
dog and rabbit plasmas.
Streptokinase shares with other streptococcal proteins the
ability to act as an antigen in man. Immune antibodies to
streptokinase are present in all individuals, probably as
a result of previous streptococcal infection, but the
amount of this inhibitor varies considerably throughout
the population. Streptokinase reacts immediately with this
antibody and is rendered biochemically inert; the complex
formed is then cleared rapidly from the circulation.
Thus during the induction of a thrombolytic state with
streptokinase, sufficient drug must be given to neutralise
the circulating antibodies before its specific effect on
the fibrinolytic enzyme system can take place (Johnson and
McCarty, 1959). During treatment, the antistreptokinase
titre remains essentially constant, but after 8-9 days it
rises rapidly in most patients to 50-100 times the normal
level, and returns to normal only after a period of 4-6
months or more.
The method of choice for purification of streptokinase
depends upon the quality of the starting material. The
most suitable starting material available commercially
is Kabikinase. This material has plasma albumin as its
major protein impurity, added as a stabilizer, this can
be removed by blue-dextran-Sepharose chromatography
(Castellino et al, 1976). Crude streptokinase can be
purified by affinity chromatography on insolubilized DFP-
plasmin (Comp, 1976). The bound streptokinase is eluted
with citrate buffer at pH3. The streptokinase produced
has a single N-terminal amino acid and runs as a single
band on gel electrophoresis. Yields of over 95% have
been obtained with no loss in streptokinase activity as
measured on fibrin agar plates.
Purified streptokinase is stable indefinitely in the
lyophilized state or in aqueous solution in the frozen
state. When thawed, the material is stable over several
hours in an ice bath. The molecular weight of strepto¬
kinase has been determined by various groups, and values
ranging from 45,000 (Brockway and Castellino, 1974) to
50,000 (Taylor and Botts, 1968) have been obtained.
Streptokinase is a protein consisting of a single subunit
with very little carbohydrate and no lipid. The N-terminal
amino acid sequence is NH^-Ile-Ala-Gly-Pro-Glu-Trp-Leu-
Leu-Asp-Arg-Pro-Ser and the C-terminal residue is lysine
(Brockway and Castellino, 1974). The amino acid composit¬
ion is consistant with the formula: Asp,0-Thr„~-Ser^ . -*08 30 24
Glu46-Pro20-Gly21-Ala23-Val23-Met3-Ile22-LeU40-Tyr20"
Phe.. -Lys„ -His^-Arg -Trp for a molecular weight ofJL5 9^11
47,754 (De Renzo et al, 1967).
f Tumour-Associated Fibrinolysis
Since the early observation by Fischer (1925) that explants
of chicken tumours caused lysis of plasma clots, many
investigators have examined the association between raised
levels of fibrinolysis and neoplastic transformation.
In 1973 Unkeless et al showed that chick embryo fibroblast
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cultures develop fibrinolytic activity after transformat¬
ion by Rous sarcoma virus (RSV); the same was found by
Ossowski et al (1973) for chick, hamster, mouse and rat
embryo fibroblast cultures transformed by either DNA or
RNA viruses. This activity is not present in normal
cultures of these cells and it does not appear after
infection with either non-transforming strains of avian
leukosis viruses or cytocidal viruses, and is therefore
related to transformation rather than to virus infection or
cell lysis.
Cells infected with a temperature-sensitive mutant of RSV
and grown at 41°C are normal both by morphological and
biochemical criteria, whereas these cells grown at 36°C
are transformed by the same criteria (Kawai and Hanafusa,
1971). Changes occur very rapidly following temperature
shifts, and the formation of plasminogen activator in
such cultures is one of the earliest observable events
associated with transformation (Christman et al, 1975b;
Rifkin et al, 1975); indeed its appearance precedes
morphological change (Ossowski et al, 1973).
Unkeless et al (1973) demonstrated the requirement for
mRNA synthesis to precede plasminogen activator production
folloiving downward temperature shifts to conditions per¬
missive for transformation, and Rifkin et al (1975) showed
a comparable requirement for RNA synthesis to precede
termination of activator formation in the converse situation,
but the nature of the relevant RNA species is unknown.
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Christman et al (1975a)demonstrated that plasminogen
activator production is also co-ordinated with tumourogan-
icity. By growing a tumourogenic line of mouse melanoma
cells in the presence of bromodeoxyuridine, it is possible
to convert them to a non-tumourogenic state, and by remov¬
ing the drug to allow reversal to the original state. A
close link was observed between appearance of tumourogenicity
and the production of plasminogen activator by these cells.
Thus, circumstantial involvement of production of this
enzyme with both tumourogenicity and transformation has
been established.
Svanberg et al (1975) histochemically examined ovarian
tumours obtained at laparotomy for local fibrinolytic
activity and also determined the fibrin(ogen) degradation
products (FDP's) in the serum. The fibrinolytic activity
was confined, mainly to vessels of both malignant and
benign tumours; however FDP's were found in the serum of
13 out of 14 patients with malignant tumours, but in none
with benign tumours. The difference in occurrence of
FDP's in patients with malignant and benign tumours
might be due to the invasive growth of the malignant tumours
with the entrance of thromboplastic substances, fibrinolytic
activators or locally formed FDP's into the bloodstream.
Determination of FDP's may therefore make it possible to
differentiate between malignant and non-malignant tumours.
FDP's are found invariably and in high concentration in
malignant ascitic fluid (Astedt et al, 1971; Svanberg and
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Astedt, 1975), and the fibrinolytic activity in malignant
ascitic fluid is due to an activator rather than plasmin
(Svanberg and Astedt, 1975).
Several plasminogen activators have been partially or
completely purified. They are all serine proteases.
Christman and Acs (1974) have purified an activator from
transformed hamster cells to apparent homogeneity. It
has a molecular weight of 50,000 and it consists of sub-
units linked by disulphide bridges. The subunit contain¬
ing the active site has a molecular weight of 25,000.
Evidence suggests that the enzyme is probably firmly
associated with the plasma membrane of transformed cells
as well as being released into the medium.
Hikeless et al (1974a)have partially purified an activator
from RSV transformed chicken fibroblasts. It is an
arginine-specific protease of 39,000 molecular weight.
The cell factor that is detected in the supernatent culture
fluid also occurs in a cell-associated form in transformed
but not in normal cells. This form is tightly bound in a
postnuclear cellular particulate fraction and can be
solubilized by SD3 or Triton X-iOO.
Rifkin et al (1974) isolated two activators from human
melanoma cells; the major component has a molecular weight
of 48-50,000 and the minor species 60,000.
Wu and Yunis (1976)using a human pancreatic carcinoma cell
line have purified an activator 2,000-fold. The purified
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enzyme shares many properties with urokinase including a
molecular weight of 54,000, electrophoretic mobility, heat
stability, inhibition by DFP, stability over a wide pH
range and its mode of activation of plasminogen. The
intracellular enzyme is membrane bound and can be solubilized
by SDS or Triton X-100. Solubilized activator has a
similar molecular weight to that of the secreted enzyme
as determined by SDS gel electrophoresis.
Thus the presence of plasminogen activator within trans¬
formed cells could serve a regulatory function, while the
presence of this enzyme in the surrounding medium affords
the transformed cell a mechanism for changing its chemical
milieu, an action by which it might exert a profound effect
either on its own fate or that of its normal neighbours.
g Miscellaneous Plasminogen Activators
i Polysaccharide Sulphate- and Flufenamate-Activated
Fibrinolysis
The first observations about polysaccharide sulphates and
activation of fibrinolysis are those of Ungar and Mist
(1949). Some acid mucopolysaccharides like hyaluronic
acid, chondroitin sulphuric acid and heparin produced
fibrinolytic activity in the euglobulin fraction of guinea
pig serum, when added at low ionic strength before
euglobulin precipitation at acid pH. This activity is
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similar to that produced by peptone, cellulose sulphate,
dextran sulphate and a number of synthetic or semi¬
synthetic polysaccharides. A number of these substances
are also active in human plasma.
Martin (1975) attributed the activity elicited in human
euglobulins, in vitro, by a pentosan sulphate to the
increased amount of precipitable material and to the higher
plasminogen content of the euglobulin fraction. However,
on top of this , pentosan sulphate can elicit fibrinolytic
activity after in vivo administration, both in the
euglobulin fraction and in whole plasma (Coccheri et al,
1963). Moreover, antiplasmin activity of plasma is de¬
creased by these substances (Coccheri et al, 19&3).
It is possible that these negatively charged substances
induce a physical separation between plasminogen activators
and their inhibitors, allowing availability of free fibrin¬
olytic activity, thus changes in the precipitation
pattern of proteins and in the amount of plasminogen and
activators recovered in the euglobulin precipitate may be
a consequence of the alterations induced by the poly¬
saccharides rather than being the mechanism primarily
responsible for the production of fibrinolytic activity.
Astrup and Rosa (1974) described a potent fibrinolytic
system, activated by polysaccharide sulphates, occurring
in human blood. This system was found to generate
considerably more activity than produced by glass activation
of factor XII, and in fact Astrup and Rosa showed the
system to be activatable in the absence of Hageman factor.
The same system or mechanisms may be operating in the
flufenamate induction of fibrinolysis. Tomikawa and
Abiko (1973) described the isolation of a latent plasminogen
activator activity from human plasma by gal filtering
the supernatent of a euglobulin precipitate on Sephadex
G-20G followed by isoelectric focusing. The component
was immunologically different from B^C-globulin, plasmin¬
ogen and plasmin (thus excluding the possibility of an
antiplasmin-plasmin complex), and was present in the ratio
3:7 in the euglobin: euglobulin supernatent, although it
could only be detected in the supernatent after removal
of antiplasmins . Plasminogen activator activity ivas
liberated from the component by treatment with flufenamate.
There have been few reports on the mechanism of this
chemical induction of fibrinolysis. It has been postulated
that inactivation of antiplasmin (von Kaulla, 1963) or
antiactivators (Aoki and von Kaulla, 1969a) or a possible
modification of B^C-globulin (Aoki and von Kaulla, 1969b)
may be responsible. Baumgarten et al (1970) also showed
that serum proteins were required for chemically induced
fibrinolysis. Kluft (1978) has shown that the extrinsic
activator (vascular activator) is resistant to Cl-inactivator
and that no extra resistant activity is generated in vitro
with dextran sulphate. However, there is also present an
activity that is susceptible to Cl-inactivator. This
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activity appears to originate from intrinsic proactivator
systems, and it is this susceptible intrinsic activity
that can be fully revealed by the combined effects of
dextran sulphate and flufenamate. Kluft also points
out that the extrinsic activity has the capacity, at least
in vitro, to initiate activation of the intrinsic system,
although it is not clear whether the active agent is plasmin
or plasminogen activator . A mechanism such as this in
vivo would have great implications for current concepts of
thrombolysis.
ii Blood Cells
Unkeless et al (1974b) reported that cultured thioglycollate-
stimulated peritoneal macrophages synthesize, accumulate,
and continually release high levels of plasminogen activators,
whereas cultures of unstimulated macrophages do not.
The higher specific activity of released as opposed to
cell-associated enzyme suggests that the activators are
actively secreted. The major macrophage plasminogen acti¬
vator is a serine protease of molecular weight 48,000, and
thus resembles the comparable enzyme released by virally
transformed fibroblasts. Macrophages release a second
plasminogen activator, of molecular weight 28,000, that is
also a serine protease.
Kopitar et al (1974) isolated a plasminogen activator from
disrupted pig leukocytes with the aid of DBAE-chromatography,
gel filtration and CM-cellulose chromatography. The
molecular weight of the activator was determined by gel
filtration to be 28,000-30,500, and the activity was
-2
inhibited 100% when tested on a fibrin plate with 10 M
EACA and 20 KlE/ml Trasylol.
Granelli-Piperno et al (1977) reported that purified
human polymorphonuclear leukocytes (FMN's) secrete a
plasminogen activator. Results show that the activator
production by FMN's is controlled by agents that affect
inflammation, and that this control is not shared by
other lytic enzymes knoxvn to be associated with these
cells. This suggests a particular role for plasminogen
activator in the response pattern of PMN's and also
supports the concept, previously developed for macrophages,
that the secretion of activator is correlated with cell
migration in vivo.
iii Body Fluids
As well as the well documented plasminogen activators
present ih blood, urine and many tissues in the body
Albrechtsen et al (1953) found activity in cerebrospinal
fluid, ascitic fluid, synovial fluid, hydrocele fluid,
lymph and fluid from blisters. Sweat appeared inactive.
Storm (1955) found lacrymal fluid to contain small amounts
of a plasminogen activator and large amounts of a pro-
activator, which is converted into a plasminogen activator
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by streptokinase. A similar system was described in human
milk by Astrup and Sterndorff (1953). According to
Okamoto et al (1974) plasminogen activator activity was
higher in colostrum than in mature milk, was inhibited by
AMCHA and had a molecular weight of 80,000.
There is a proactivator present in human saliva, but there
has been some dispute as to whether or not a plasminogen
activator is present. Albrechtsen and Thaysen (1955)
found an activator, whereas Nitta et al (1967) did not.
Moody (1976) consistently found plasminogen activator
activity in mixed native saliva, but eliminated a soluble
activator, showing the activity to reside in the epithelial
cells of the salivary pellet.
Oshiba et al (1977) showed human bile to contain a plasmin¬
ogen activator, termed bilokinase, as well as a proactivator.
The bilokinase activity of human bile was weak in comparison
with that of certain other species and no significant
relationship between biliary and plasma fibrinolysis was
observed.
h Comparison of Activators
As the first pure preparations of a plasminogen activator
were of urokinase, most of the comparitive work has been
against this enzyme. Ali and Evans (1968) showed rabbit
kidney cytokinase to be very similar, if not the same, as
hunan urokinase. The molecular weight is similar, the
inhibition profile the same and starch gel electrophoretic
behaviour identical. Barlow and Lazer (1972) compared the
activator isolated from cultured human embryo kidney cells
with urokinase. They found that physical, chemical and
immunological studies showed all properties of the two
activators as being identical. The comparison between
urokinase and the cultured kidney cell activator was
extended to include the activator associated with ovarian
tumour cultures by Astedt and Holmberg (1976, 1978). All
three activators gave two active peaks on Sephadex G-100
gel filtration at molecular weights 35,000 and 52,OQO. The
activators from the kidney and ovarian carcinoma cultures
were both neutralized by anti-urokinase IgG fractions,
and all three gave lines of identity between each other
in double diffusion experiments.
Kok and Astrup (1969) described a difference in molecular
weight between urokinase (32,000 and 54,000) and tissue
activator from pregnant hog ovaries (60,000). Thorsen
and Astrup (1969) compared the activators using the
inhibitors EACA, AMCHA and PAMBA. Inhibition of porcine
tissue activator increased uniformly with increasing con¬
centrations of inhibitor, whereas with urokinase, an early
phase of inhibition at low inhibitor concentrations was
followed by a phase of enhancement of fibrinolysis, turning
into a second phase of inhibition. This biphasic inhibition
of urokinase distinguishes it from porcine tissue activator.
However, EACA produces a slightly biphasic pattern of
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inhibition with plasminogen activator from human uterine
tissue (Kok and Astrup, 1972).
Nieuivenhuizen et al (1977) used synthetic substrates to
demonstrate a difference between tissue activator and
urokinase xvith respect to their substrate requirements.
Tissue activator has a pronounced preference for a substrate
xvith a C-terminal arginyl residue, xvhereas urokinase has
a less pronounced preference for this, and a blocked
N-terminal amino group is a minimal substrate requirement
for the tissue activator, whereas it is not essential for
urokinase.
Camiolo et al (1971), Thorsen et al (1972) and Thorsen and
Astrup (1976) noted differences in the fibrin affinity of
the activators. Whereas urokinase was reported to be
slightly, or not at all, adsorbed on fibrin (Back et al,
1961; Blix, 1962; Brakman and Astrup, 1963) other activators
were found to be strongly adsorbed. This applies to tissue
activator from the pig heart (Brakman and Astrup, 1963),
the activator in human blood produced by exercise (Blix,
1962), the activator produced in human blood by strepto¬
kinase (Blix, 1962; Brakman and Astrup, 1963; Lassen,
1958), and the activator activity present in human cadaver
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blood (Mullertz, 1953b).
A thorough investigation of various activators xvas carried
out using antiserum against purified human urokinase by
Kucinski et al in 1968. The anti-urokinase neutralized
purified human urokinase, native urokinase in urine and
the activator (urokinase) from human kidney cultures.
They found partial cross-reaction against urokinase from
primates such as the rhesus monkey and baboon; and also
against rhesus monkey kidney culture supernatents.
However, results established the lack of immunological
identity of human urokinase with streptokinase, staphy-
lokinase, urokinase from non-primate mammals (eg dog, pig,
rabbit and guinea pig), tissue activator and tissue culture
supernatents of porcine origin, human milk activator,
human adrenal tissue activator and the human vascular
activator .
A further comparison between the human vascular activator
and urokinase was made by Aoki and von Kaulla (1971b).
They found the molecular weights to be different, determin¬
ing urokinase to be 55,000 and the vascular activator to be
65,000. The Km values for both activators were the same
for the activation of plasminogen, but different for the
hydrolysis of AGLMe. Both enzymes are inhibited, to
different degrees, by the placental urokinase inhibitor.
Furthermore, an immunological distinction between urokinase
and the vascular activator was revealed using the IgG
fraction of a urokinase antiserum. Whereas this fraction
inhibited urokinase up to a dilution of 1:2,560, it had no
effect on the vascular activator.
D PROACTIVATOR
Streptokinase is a good activator of plasminogen in the
human fibrinolysin system (Tillet and Garner, 1933), but
not in other species (Norman, 1957; Meyers and Burdon,
1?57; Sherry, 1954; Chattopadhyay and Cliffton, 1965).
The species difference was further investigated by
Mullertz and Lassen (1953), who found that bovine plasmin¬
ogen was not activated by streptokinase alone, but reacted
if a small amount of human plasma globulin was added.
Accordingly, it was suggested that human plasma contains
a proactivator, which is converted to an activator by
streptokinase. Bovine plasma, and, to some extent, that
of other animal species, was thought to be deficient in
proactivator, and hence not responsive to streptokinase.
However, the controversy as to whether human proactivator
has a separate identity to human plasminogen is still
open to debate.
Kline (1966) reported that when the streptokinase con¬
centration was carefully controlled a strong covarience
relationship was found between the plasminogen and pro¬
activator concentration in 12 normal human plasma samples.
Kline suggested that the lack of such control had led
earlier investigators to the erroneous conclusion that
they had demonstrated the presence of a proactivator
other than plasminogen or plasmin in human plasma.
Harkus and Werkheiser (1964) and Werkheiser and Markus (1964)
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suggested that two types of plasminogen-SK complexes can
be formed, one of which acts primarily as an activator of
bovine plasminogen, whereas the other can activate both
human and bovine plasminogen. Ling et al (1965) have
also suggested that an SK-plasmin complex may be respons¬
ible for activation of bovine plasminogen.
However, a great deal of work has been done by Takada and
Coworkers which supports the view that there is at least
one proactivator distinct from plasminogen. Takada Y et
al (1969) found two peaks of proactivator activity when
they fractionated human plasma or its euglobulin on
Sephadex G-200. They termed these proactivators A and B.
Proactivator A was of large molecular weight and could
be isolated free of plasminogen, ivhereas proactivator B
was smaller and contaminated with plasminogen.
Takada Y and Arnbrus (1969) reported that proactivator A,
in the presence of streptokinase, lyses standard bovine
fibrin plates, but not heated bovine plates. Whereas
without streptokinase, there is no lysis of either type
of bovine plate. Proactivator A plus streptokinase does
not induce caseinolysis, but does activate human, bovine
and guinea pig plasminogen in caseinolysis tests. They
also demonstrated that fibrinolytic activity of proactivator
A-streptokinase shows no covarience with plasminogen or
plasmin, and immunodiffusion showed no cross-reactivity
between proactivator A and various human plasminogen
preparations.
80
Takada A et al (1970) showed that small amounts of
streptokinase converted the proactivator to activator,
which in turn converted human plasminogen to plasmin,
but the same amounts of streptokinase could scarcely
activate plasminogen in the absence of added proactivator.
Very large amounts of streptokinase, however, activated
plasminogen equally well in the presence or absence of
proactivator.
Takada A et al (1972) determined a molecular weight of
300,000, by gal filtration, for the proactivator. It
migrates in the QC^ region in electrophoresis, but there is
no cross-reaction with either anti-OC^ Macroglobulin or
ant i-{3-lipoprot ein.
Thus it appears that experimental evidence is accumulating,
to support the concept that there is a functional proactivator
molecule in plasma distinct from plasminogen.
E PHYSIOLOGICAL INHIBITORS
Proteolytic activity is generated following activation
of the fibrinolytic system and to ensure that this activity
is not generated inappropriately, the organism has a
system of antiproteinases. Inhibitors of the fibrinolytic
system may act at txvo levels, either by inhibiting formed
plasmin or by inhibiting plasminogen activation.
a Inhibitors of Plasmin
i OC^-Antiplasmin
Prior to the discovery of oc^-ant iplasmin, it was generally
believed that oc^-macroglobulin and oc^-anti tryps in were
the main plasmin inhibitors in human plasma. However,
Collen et al (1975a)showed that gel filtration of urokinase
or streptokinase activated fresh human plasma, containing
a trace of radiolabelled plasminogen, gives two radioactive
peaks, one eluted at the void volume, and one Just before
the globulin peak. The first peak was identified as a
plasmin-oc^-macroglobulin complex. The second peak had a
molecular weight of 120-140,000 and did not cross-react
with antisera against any of the main protease inhibitors
in plasma.
ti
In 1976 Collen, Mullertz and Clemmensen, and Moroi and
Aoki all described the new inhibitor, oe^-antiplasmin.
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Collen (1976) showed that the complex in the second peak,
referred to above, reacted with antisera to plasminogen,
and with antisera to the complex, adsorbed with purified
plasminogen. The latter antisera also reacted against a
single component in plasma, and specific removal of this
component from plasma by immunoadsorption resulted in
the disappearance of the fast-acting antiplasmin activity,
whereas oc^-macroglobulin was found to represent the slow-
reacting plasmin-neutralizing activity.
Gallimore (1975) partially purified a fibrinolytic inhibitor
from human serum that he called inter-oc-ant iplasmin.
Further work (Hedner and Gallimore, 1977; Gallimore and
Hedner, 1977) indicates that this preparation contains a
mixture of cc9-antiplasmin and the inhibitor of plasminogen
activation described by Hedner (1973), which in turn is
different from oc^-antiplasmin (Hedner and Collen, 1976).
Upon activation in plasma, the formed plasmin is first
preferentially bound to oc^-antiplasmin. Only upon
complete activation of plasminogen (concentration in
plasma 1.5pM), resulting in saturation of the cc2-antiplasmin
(concentration in plasma lpM), is the excess plasmin
neutralized by oc^-macroglobulin (Collen, 1976). In the
presence of normal concentrations of these two inhibitors
the other plasma protease inhibitors do not play a role
ft
in the inactivation of plasmin (Collen, 1976; Mullertz,
1974).
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To date four methods have been described for the purificat¬
ion of oc^-antiplasmin from plasma. Moroi and Aoki (1976)
used a combination of ammonium sulphate precipitation,
DEAE-Sephadex chromatography, affinity chromatography on
insolubilized plasminogen and hydroxyapatite chromatography
of plasminogen-depleted plasma, to purify the inhibitor
to homogeneity. Wiman and Collen (1977) used chromatography
on insolubilized plasminogen, DEAE-Sephadex and insolubilized
concanavalin A. This procedure resulted in a higher
u
yield and a more stable inhibitor preparation. Mullertz
and Clemmensen (1976) partially purified the inhibitor by
ammonium sulphate precipitation, then sequential chromato¬
graphy on DEAE-Sephadex, insolubilized concanavalin A,
gel filtration and a further DSAE-Sephadex. Collen et
al (1978) isolated the inhibitor by immunoadsorption
chromatography and gel filtration; however, the product
was mainly in an inactive form.
OCQ-antiplasmin is a single chain glycoprotein of 65-70,OOO
molecular weight estimated by SDS-gel electrophoresis and
ultracentrifugation (Moroi and Aoki, 1976; Wiman and Collen,
1977). On electrophoresis it migrates as an oc^-globulin.
The amino acid composition reported by Moroi and Aoki
(1976) and that reported by Wiman and Collen (1977)
correspond well for most amino acids, and the estimated
carbohydrate content of the molecule was determined as
11.7% and 13.7% respectively. The inhibitor is immuno-
chemically different from oc^-antitrypsin , oc^-macroglobulin
C^-esterase inhibitor, antithrombin III, oc^-antichymotrypsin,
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and inter-oc-trypsin inhibitor (Moroi and Aoki, 1976;
Wiman and Collen, 1977) and from the inhibitor of plasmin¬
ogen activation described by Hedner (Wiman and Collen,
1977; Hedner and Collen, 1976). The inhibitor is stable
in solution above pH 6.3 but is rapidly inactivated below
pH 6.0, and the N-terminal amino acid sequence has been
determined as Asn-Gln-Glu-Gly (Wiman and Collen, 1977).
In purified systems (Moroi and Aoki, 1976; Wiman and
Collen, 1977) and in plasma (Collen, 1976; Mullertz, 1974)
antiplasmin forms a 1:1 stoichiometric complex with
plasmin that is devoid of protease or esterase activity
and that cannot be dissociated by denaturing agents such
as urea, guanidine HCl, or dodecyl sulphate. SDS-gel
patterns indicate that complex formation occurs by strong
interaction between the light (B) chain of plasmin and the
inhibitor. Moroi and Aoki (1977b) reported that the complex
is dissociated by hydrazine, indicating an ester bond between
the active-site serine residue of plasmin and antiplasmin.
A peptide of molecular weight 11-14,GOO may be released
after formation of the complex. This finding has led to
the assumption that inhibition occurs by hydrolysis of a
specific peptide bond in the inhibitor followed by ester-
ification between the newly formed C-terminal residue of
the inhibitor and the active-site serine residue of
»»
plasmin (Collen, 1976; Moroi and Aoki, 1976; Mullertz and
Clemmensen, 1976). It has been shown that the release
of this polypeptide is not an essential step in complex
formation but the result of hydrolysis of the complex by
free plasTnin (Wiman and Co 11 en, 1977).
Antiplasmin was also shown to react with trypsin and slowly
with urokinase in purified systems (Moroi and Aoki, 1976).
Ivhen trypsin, chymotrypsin, thrombin and plasmin were
added to normal plasma, antiplasmin played a role in
the binding of plasmin and, to a lesser extent, trypsin,
but not of thrombin or chymotrypsin (Edy and Collen, 1977).
The principal role of antiplasmin seems to be the very
fast and irreversible neutralization of plasmin in the
circulation. However, antiplasmin also interferes with
the binding of plasminogen to fibrin and thus may have an
additional antifibrinolytic effect (Moroi and Aoki, 1977a).
ii CX^-Macroglobulin
The molecular weight of oc^-macroglobulin is variously
quoted in the range 725,000-845,000 and occurs at a
concentration of 2-5.8pM in human plasma. It can bind
trypsin, thrombin, kallikrein, chymotrypsin and elastase,
as well as plasmin and many other enzymes. None of the
other inhibitors of proteinases from plasma, or other
sources, share the apparent capacity of oc^-macroglobulin
to react with this whole functional group of enzymes.
Inactivated forms of the proteinases and zymogens are not
bound by oc^-macroglobulin (Barrett and Starkey, 1973), thus
plasminogen and DFP-plasmin are not bound (Steinbuch, 1975).
The trapped enzyme is irreversibly bound to the oc^-
macroglobulin molecule, and experiments to show any
reversibility of the binding, with reappearance of free
enzyme and native oc^-macroglobulin have failed (Barrett
et al, 1974).
Barrett and Starkey (1973) concluded that the available
evidence pointed to cc^-macro globulin binding proteinases
in general, in equimolar ratios. The idea that all pro¬
teinases are bound in the same ratio is supported by the
evidence that oc^-macroglobulin can be saturated with one
enzyme, so that it is unable to bind another. This is
demonstrated when oc^-macroglobulin is presaturated with
plasmin preventing inhibition of thrombin (Ganrot and
Nilehn, 1967); and pretreatment of oc^-macroglobulin with
trypsin prevented the binding of chymotrypsin and vice
versa (Berthillier et al, 1968).
CC^-macr oglobulin forms proteolytically inactive, but
esterolytically active complexes xvith plasmin, trypsin
and thrombin (Ganrot, 1967). Typically the 'bound'
enzyme may show 80-100% of normal activity with low
molecular substrates, but little or none against large
proteins. Furthermore, the bound enzyme is protected
from other high molecular weight inhibitors, thus protect¬
ing its remaining activity against low molecular weight
substrates. Soybean trypsin inhibitor (SBTI) in molar
excess almost completely inhibits the proteolytic and
esterolytic activity of plasmin, but it does not inhibit
the esterolytic activity of the cc^-raacroglobulin-plasmin
complex (Ganrot, 1967).
Harpel and Mosesson (1973) showed that after complex
formation with oc^-macroglobulin in plasma, plasmin retained
less than 0.1% of its fibrinogenolytic activity. However
they considered cx^-macroglobulin may modulate enzyme-
substrate interactions, such as these, by providing a
mechanism for the preservation and protection of a
portion, albeit small, of the enzymic activity in the
presence of other circulating inhibitors.
Barrett and Starkey (1973) put forward the 'trap hypothesis'
concerning the molecular mechanism of interaction of oc^-
macroglobulin with proteinases. They suggest that binding
is initiated by a proteolytic attack on the oc^-macroglobulin
molecule, and that this results in a conformational change
such that the enzyme molecule is irreversibly trapped
within the oc^-macroglobulin molecule. The inhibition of
enzymic activity results from the steric hindrance of
access of substrates to the enzyme in its enclosed
environment.
Physiologically the most important function of oc^-
macroglobulin appears to be this trapping mechanism of
proteinases, rather than their inhibition. The importance
lies in the extreme rapidity with which cx^-macroglobulin
complexes are cleared from the circulation, perhaps as a
result of the recognition of the altered oc^-macroglobulin
conformation} by mononuclear phagocytes. Complexes of
Oc,-macroglobulin with plasmin or trypsin are cleared
from the circulation in minutes, as compared with many
days for native oc^-raacroglobulin (Nilehn and Ganrot,
l?o7). In this way the protein plays an important role
in the regulation of extracellular proteolytic activity
resulting from coagulation and fibrinolysis, as well as
the release of proteinases from granulocytes and other
cells in inflammation (Barrett and Starkey, 1973). OC -
nacroglobulin has been identified on the luminal surface
of endothelial cells in sections of normal human arteries,
veins and lymphatics by an indirect immunofluorescent
technique (Becker and Harpel, 1976). The location at the
surface of the vessel wall suggests a protective role
acainst potentially injurous intravascular proteases.
iii OC^-Ant itrypsin
CC -antitrypsin has a molecular weight of approximately
55,000 (Gallimore, 1975) and occurs at a concentration of
IT
35-71pM in human plasma (Mullertz, 1978). It inhibits
trypsin, chynotrypsin, elastase, plasmin (Schwick et al,
1967), thrombin (Rimon et al, 1966) and kallikrein
(Clemmensen et al, 1976). It was claimed by Schwick et al
(1967) that cc^-antitrypsin represents 90% of the anti-
proteolytic activity of plasma, and it was regarded as the
slow reacting antiplasmin.
The inhibition of trypsin and chymotrypsin by cc^-antitrypsin
v.-as instantaneous and a stoichiometric reaction, xvhereas
the inhibition of plasmin and thrombin was time-dependant
and of a non-stoichiometric nature (Rimon et al, 1966).
It was suggested by Rimon et al (1966) that the latter
inhibition mechanism may be an enzymatic inactivation.
This inactivation xvas irreversible in the sense that no
enzymatic activity could be recovered after acid dis¬
sociation of the enzyme-inhibitor complex.
Crawford and Ogston (1974) showed oc^-ant itrypsin to inhibit
the caseinolytic and fibrinolytic activity of plasmin
and, in contrast to oc^-macro globulin, it also inhibits
esterase activity. They also reported that the fibrinolytic
and esterase activities of urokinase were not affected
by concentrations of oc^-antitrypsin that caused marked
inhibition of plasmin. However, Clemmensen and Christensen
(1976), using purified reagents, showed that the esterolytic
activity of urokinase was inhibited in a strong time-
dependant manner by oc^-ant itryps in . Complex formation
was demonstrated by crossed immunoelectrophoresis and by
SD3-polyacrylamide electrophoresis. The latter method
revealed the formation of 1:1 and 2:1 ratios of enzyme-
inhibitor complexes. Clemmensen et al (1976) went on to
show that oc^ —antitrypsin appears to be identical to the
inhibitor of urokinase-induced fibrinolysis that appears
during late pregnancy, and that although it inhibits
urokinase, it does not inhibit porcine tissue activator.
Raised levels of cx^-antitrypsin are found in plasma in
conditions with tissue damage. High levels are found in
patients with infection, with malignant disease and in
renal disease, in acute pancreatitis, in pregnancy and in
diabetes (Hedner, 1974).
iv C-^-Inactivator
C_-inactivator has a molecular weight of 105,000 and is
found at a concentration of 1.4-3.3pM in human plasma
U
(Mullertz, 1978). -inactivator is capable of inhibiting
plasmin, factor Xlla (and its active fragments) and
kallikrein (Trumpi-Kalshoven, 1978). It is present in
the euglobulin precipitate and may be the cause of
variability (Kluft, 1976).
Working with purified reagents in vitro, Trumpi-Kalshoven
(1978) reported that once the plasmin-C^ inactivator
complex is formed, it does not dissociate in the presence
of fibrin; this results in inhibition. Hoxvever , if
plasmin is generated in the presence of fibrin and C^-
inactivator, it has a higher affinity for fibrin and thus
little or no inhibition occurs.
Several investigators have found a decreased potency of
inhibitors when fibrinogen was converted into fibrin, which
resulted in the observation that fibrinolysis can occur
under conditions where fibrinogen is not degraded. The
inhibition of plasmin by C^-inactivator correlates with
this observation. However, there is complete inhibition
of plasmin after the visible lysis of fibrin (Trumpi-
Kalshoven, 1978).
v Antithronbin III
Ar.t ithrombin III has a molecular weight of 62,000 and
occurs at a concentration of 3.5-6.3pM in human plasma
f ?
(- 'ullertz, 1978). Antithrombin III Is the principal
inhibitor of thrombin in human blood and recently its
ability to inhibit factor Xa and other coagulation factors
has been demonstrated (Craxvford et al, 1975).
Highsmith and Rosenberg (1974) studied the interaction
of purified human antithrombin III and plasmin in the
presence and absence of heparin. Antithrombin III is a
progressive, time-dependant inhibitor of the proteolytic
and esterolytic activities of plasmin. Incubation of
plasmin with antithrombin III for 15-30 minutes resulted
in 90-100% inhibition of both activities of the enzyme.
The presence of heparin dramatically accelerated the rate
of interaction, with nearly complete inhibition within 30
seconds. SD3-gel electrophoresis of reduced and non-
reduced proteins indicated that antithrombin functions
as a potent antiplasmin by forming an undissociable
complex which is stable in the presence of denaturing or
reducing agents or both. This complex represents a 1:1
stoichiometric combination of enzyme and inhibitor.
Heparin increases the rate of formation of this complex
without affecting its dissociability or stoichiometry.
In the absence of heparin, less than 1% of plasma
antithrombin III participates in the binding of plasmin,
but as the heparin concentration is increased, more
antithrombin III binds to plasmin (Telesforo et al , 1975).
In the range of therapeutic anticoagulation (l-2u heparin/
ml plasma), 2.5-3.8% plasma antithrombin III is used in
the binding of plasmin, which corresponds to the binding
of 6-9% of generated plasmin (Telesforo et al, 1975).
Crawford and Ogston (1975) reported that antithrombin III
does not influence the activity of plasminogen activators
from tissue, blood or urine.
vi Inter-OC-Trypsin Inhibitor
Inter-oc-trypsin inhibitor has a molecular weight of
180,000 (Gallimore, 1975) and occurs at a concentration of
tt
1.2-4.4pM in human plasma (Mullertz, 1978) . It inhibits
plasmin, but provides only a minor contribution to the
total antiplasmin activity of blood.
b Inhibitors of Plasminogen Activation
Much evidence has been put forward for the existence of
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inhibitors acting both as antiplasmins and as inhibitors
of plasminogen activation, although assay methods,
generally relying on the action of formed plas.min, make
it difficult to distinguish between the two.
However, it is reported that a selective increase in the
inhibitors acting on plasminogen activation has been
demonstrated in patients with severe thrombotic disease
(Brakman et al, 1966; Nilsson et al, 1961; Pandolfi et al,
1970). In patients this inhibition does not correlate
with Oc^-macroglobulin, oc^-antitrypsin (Hedner and Nilsson,
1971) or xvith oc^-antiplasmin (Hedner et al, 1978).
The activation inhibitor was shown to be an oc^-globulin,
which was acid- and heat-labile (Hedner, 1973). After
gel filtration on Sephadex G-200 inhibitory activity
appeared in two peaks, one in the high molecular weight
region and one just ahead of the albumin peak (Hedner et
al, 1970). It was found that the second, low molecular
weight, peak varied with the serum activity of the inhibitor.
This low molecular weight inhibitor has been purified
by passage through haemoglobin-Sepharose (to remove
haptoglobin), DEAE-Sephadex chromatography, gal filtration
on Sephadex G-200 and preparative gel electrophoresis
(Hedner, 1973). The molecular weight of the oc^-globulin
was 75,000 and it did not react with antisera against
ex.,-macroglobulin , cx^-antitrypsin , antithrombin III, C^-
inactivator, inter -Oc-trypsin inhibitor or antichymotrypsin „
The inhibitor mainly inhibited plasminogen activation and
an antiserum was readily raised that was capable of
neutralising the inhibitor in serum (Hedner, 1973).
Hedner and Collen (1976) provided immunological evidence
for the non-identity of the antiactivator described above
and the cxr^-antiplasmin described by Collen et al (1975a);
the antisera against the antiactivator and that against
cc0-antiplasmin reacting with two different components in
human plasma. A cautionary note was added by Hedner et
al (1978) pointing out that the antiserum against Collen's
antiplasmin was raised against a complex and not against
the purified protein itself. A structural change of the
protein may, therefore, be responsible for a changed
immunochemical behaviour; this seems unlikely, however,
as Collen (1976) was able to remove the fast-reacting
antiplasmin activity from plasma by immuno-adsorption
and this would not be the case if his preparation of
antiserum only recognized the complexed form of oc^-
antiplasmin.
An additional inhibitor with a molecular weight of 80,000
has recently been described by Gallimore (1975). This
inhibitor inhibits both plasmin- and urokinase-induced
clot lysis and has been called inter-oc-antiplasmin.
However, it has been shown by Gallimore and Hedner (1977)
that partially purified inter-oc-antiplasmin contains
proteins cross-reacting with both antiactivator and oct¬
ant iplasmin antisera.
A further question mark was raised against Hedner1s
antiactivator by Collen et al (1977), who reported that
normal plasma showed inhibition in a clot lysis assay with
urokinase, but surprisingly this activity was virtually
absent in antiplasmin-depleted plasma containing a normal
amount of the inhibitor of plasminogen activation described
by Hedner (1973). However this anomoly was resolved when
it was later reported that Hedner's inhibitor was a fast
reacting inhibitor of factor Xlla (Hedner, 1978).
Aoki and von Kaulla (1971c)described the isolation of an
80,000 molecular weight moiety with antiactivator activity.
However, this preparation also exerted some antiplasmin
activity and with further work it appeared more likely
that it was cx^-antiplasmin (Moroi and Aoki, 1976). Beattie
et al (1976) described two inhibitors of plasminogen
activation by urokinase when they fractionated plasma by
gel filtration on Sephadex G-200. The low molecular
weight inhibitor was separate from the principal protease
inhibitors of plasma, and although active in a clot lysis
system, failed to inhibit the esterase activity of urokinase
Inhibitors of plasminogen activation have also been
partially purified from human placenta (Uszynski and
Abildgaard, 1971; Kawano and Uemura, 1971), and platelets
(Ogston et al, 1973; Moore et al, 1975; Joist, 1977).
There still remains some confusion concerning the number
and type of inhibitors of fibrinolysis present in the
Oc^-globulin fraction of human plasma. However, it appears
that there are at least two inhibitors of fibrinolysis
migrating in the oc^-globulin region (Hedner and Collen,
1976; Gallimore and Hedner, 1977; Gallimore, 1978).
3 FIBRIN : FORMATION AND LYSIS
A FIBRINOGEN
Fibrinogen is one of the largest proteins found in normal
plasma. Estimates of the molecular weight of circulating
fibrinogen (bovine or human) range from 245,000 to 700,000
However, values below 300,000 probably indicate determin¬
ations made on partially catabolized forms of the molecule
There is now general agreement that more "native" forms
of the molecule have molecular weights in the range
325,000-345,000 (Caspary and Kekwick, 1957; Endres and
Scheraga, 1971), and are found in plasma in concentrations
ranging from 200-500mg per 100ml plasma.
N-terminal analyses of fibrinogen indicate three types of
If
polypeptide chains (Blomback et al, 1966), and when fibrin
ogen is reduced and run in SDS-polyacrylamide electro¬
phoresis, it separates into three chains with molecular
weights 63,000, 56,000 and 47,000 (McKee et al, 1970).
Comparison of the molecular weight and the results of
quantitative N-terminal amino acid determinations has
revealed that the molecule consists of six chains, two
of each type, and thus the native molecule exists as a
dimer. The three chains are termed Aoc, pp and £; A and
B refer to the respective N-terminal peptides, removed by
thrombin during fibrin formation.
Although it was known that native fibrinogen was a dimer,
little was known about how the two halves were linked
together. The observation that fibrinogen's molecular
weight did not change in denaturing solvents suggested
that the chains were held together by covalent linkages.
Since reductive cleavage of disulphide bridges severed
all covalent connections betxveen chains (McKee et al,
1966), the covalent bridging must be accomplished solely
by interchain disulphide bonds.
!!
Blomback et al (1968) used cyanogen bromide cleavage to
prepare a fragment that contained the N-terminal regions
of all three types of fibrinogen subunit chains, joined
by interchain disulphide bonds. This structure was termed
n
the N-terminal disulphide. knot (N-DSK), and Blomback
proposed that this was the site at which both halves of
the fibrinogen molecule were joined together. This idea
was confirmed by Harder et al (1972) from studies on the
degradation products of fibrinogen produced by plasmin
(see Fig 6). They found that fragment E, the plasmin
resistant degradation product, was almost identical with
the disulphide knot region and similarly contained the
N-terminal portions of all six polypeptide chains. The
amino acid sequence of each of the constituent chains
of the N-terminal disulphide knot is now known, as are
the probable locations of the inter- and intrachain dis-
^ I! It
ulphide bridges (Wallen, 1971; Blomback and Blomback,
1972; Blomback, 1969). Doolittle et al (1977) reported
that human fibrinogen contains 29 disulphide bonds, only






























halves of the molecule together.
Henschen et al (1977) have reported the complete amino
acid sequence of the ^-chain consisting of 409 residues.
Bouma et al (1977) also working on the $-chain noticed
significant homologies with the oc- and {3-chains , especially
with regard to the arrangement of certain key cysteine
residues. Thus, the sequence at residues & 135-139 is
Cys-Gln-Glu-Pro-Cys and ^ 19-23 is Cys-Pro-Thr-Thr-Cys;
the occurrence of similar pentapeptide skeins in the oc-
and p-chains, in each case separated by about the same
number of residues, has both structural and evolutionary
connotations.
B THROMBIN
Thrombin, the natural coagulant of fibrinogen, appears in
blood following activation of the clotting system. Mann
et al (1973) have shown that there are at least three
forms of thrombin, oc, {3 and The {3 and % forms are
degradation products of the oc form. The molecular weight
of these different species are 39,000 (oc) and 28,000 (J3
and ^). The specific esterase activity of these three
forms of thrombin are the same, while only the oc form has
proteolytic activity on fibrinogen (Mann et al, 1971).
The amino acid composition and primary sequence of oc-
thrombin have been published (Magnusson, 1971). 0C-
thrombin is a two-chain protein with a light chain of 49
residues connected by a disulphide bridge to the heavy
chain which is made up of 260 amino acid residues. The
heavy chain also contains the serine active centre and a
carbohydrate residue.
C ACTION OF THROMBIN ON FIBRINOGEN
- FORMATION OF FIBRIN
Once thrombin is generated, it specifically cleaves two
pairs of unique arginine-glycine peptide bonds in fibrinogen
and initiates development of a fibrin clot (see Fig 7).
Cleavage by thrombin releases the N-terminal portions
of four of the chains as the A and B peptides, which have
If
molecular weights of 1,536 and 1,552 respectively (Blomback
et al, 1966).
When thrombin catalyzes the release of fibrinopeptides
A and B from fibrinogen, fibrinopeptide A (FPA) must appear,
followed, after a lag phase, by fibrinopeptide B (FPB),
for polymerization to occur. Preferential release of FPB
by an enzyme In copperhead snake venom (Agkistrodon
contortrix) does not result in normal polymer formation
unless FPA is also removed (Shainoff and Dardik, 1977).
Thus, it has been proposed that two sets of polymerization
IT
sites are involved in fibrin formation (Blomback and
it
Blomback, 1972); one set, A:a, is activated on release of
FPA and results in end-to-end polymerization; the other,
B:b, is activated on release of FPB and results in lateral
aggregation.
The removal of FPB acts as a switch; after it is removed
fibrin monomers assemble rapidly to form thick fibres
and gelation is fast, but when this peptide is still














FIG 7 PATHWAY OF FIBRIN FORMATION
(Coagulation abbreviated to show the common
pathway only.)
gelation is delayed (Shen et al, 1977). Shen et al
(1977) speculate that this delay may well be critical for
the complete digestion, by plasmin, of fibrin formed
during in vivo defibrination with Ancrod (removes FPA),
and of fibrin produced by very small amounts of thrombin
(which would still contain FPB), and that slow release of
FPB is part of a control mechanism for the regulation
of fibrin formation and prevention of intravascular
coagulation.
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D FACTOR XIII - CROSSLINKING OF FIBRIN
Although purified fibrin is soluble in urea, fibrin formed
in the physiological situation is not soluble in urea
(Robbins, 1944). The difference in behaviour is due to
the presence of factor XIII (Lorand and Jacobsen, 1958)
in the physiological situation. Human plasma factor XIII
has a molecular weight of 320,000 and is composed of two
types of subunit, an a chain of 75,000 daltons and a b
chain of 85,000 daltons. The native factor XIII has an
a„b subunit structure (Schwartz et al, 1973). The
activation of factor XIII by thrombin and other proteolytic
enzymes is accompanied by a decrease in the molecular
weight of the a chain of 4, OOO daltons, xvhich becomes
enzymatically active, while the b chain remains unchanged.
Activated factor XIII (factor Xllla) stabilizes fibrin by
enzymatically forming e- -glutamyl) lysine cross-links
between ^-chains and, secondarily, oc-chains of fibrin, by
transamidation. Under suitable conditions, approximately
six cross-links per mole fibrin are formed, provided the
fibrin substrate under study contains a high proportion
of intact oc chains (Finlayson et al, 1972). Of those six
cross-links, two occur rapidly between ^ chains of fibrin,
which on reduction of the fibrin yield dimers , and
four occur more slowly between the oc-chains of fibrin,
reduction yielding oc-polymers . The {3-chain of fibrin is
not involved in the cross linking reaction.
Doolittle et al (1972) have identified the residues involved
in the formation of the dimer and have found that $-
chains lie in an antiparallel arrangement. While Fretto
et al (1977) reported that crosslink acceptor sites of
the oc-chain reside in the middle third of the chain.
E LYSIS OF FIBRIN(OGEN)
T T
^
Mullertz (1953a) reported that plasmin from post mortem
blood split pure preparations of fibrinogen and fibrin at
nearly the same rates. Subsequently, Marder et al (1969)
looked more closely at the plasmin digestion of fibrinogen
(see Fig 8) and found that two high molecular weight
derivatives were produced on digestion. The first to
appear is fragment X, molecular weight in the region of
240,000. This fragment is slowly, but almost completely
(85%) clottable by thrombin. Fragment X then breaks down
to give fragments Y and D. Fragment Y, molecular weight
in the region of 155,000, is non-clottable by thrombin.
This fragment breaks down further to give another fragment
D, and fragment E, the plasmin-resistant core, molecular
weight approximately 50,000.
The N-terminal amino acid residues of plasmin-digested
human fibrinogen were determined by Marder et al (1972)
and compared with undigested fibrinogen. Fibrinogen and
fragments X, Y and E had primarily alanine and tyrosine
N-terminal residues, whereas fragment D clearly had a
different complement of N-terminal residues and was thought
to derive from the C-terminal part of the parent molecule.
Marder et al (1972) also compared fragment E with the
disulphide knot, a chemical derivative of fibrinogen,
containing the N-terminal region of the parent molecule.
Fragment E showed striking similarity of N-terminal amino
acid residues and antigenic determinants with the N-terminal
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Furlan and Coworkers (Furlan and Beck, 1972; Furlan et
al , 1975a; Furlan et al, 1975b) further elucidated the
events in the degradation of fibrinogen by plasmin (see
Figs 9A and 9B). They found that in the early phase of
plasmic hydrolysis large polypeptides are progressively
being split from the C-terminal part of the oc-chain.
These can be seen by PAGE of reduced fibrinogen chains,
following plasmin digestion, as polypeptide remnants of
various size (14-58,000). Thus fragment X was found to
be a heterogenous population of molecules differing in
the length of their oc-chains. Early X fragments seem
to have intact p-chains as opposed to late X fragments,
in which fibrinopeptide B is missing. The p and ft chains
are generally more resistant to attack than the oc-chains.
Fragment X splits into one molecule of fragment Y and one
molecule of fragment D. Fragment D is split assymetrically
from fragment X, as previously suggested by Marder et al
(1969), one half of fragment X remaining unchanged.
According to the degradation scheme of Marder et al (1969)
at least three peptide bonds must be broken in order to
produce fragments Y and D. It is conceivable that these
bonds are not split simultaneously. The same argument is
also valid for conversion of Y into D and E. A sequential
splitting of the individual polypeptide chains, while the
split remnants are still held together by disulphide



















































FIG 9A PROPOSED SCHEME OF PLASMIC DEGRADATION OF
FIBRINOGEN TO FRAGMENT Y
Vertical lines represent disulphide bonds.
Small arrows show sites of proteolytic
cleavage.
Potential F XIII cross-linking sites on















































FIG 9B PROPOSED SCHEME OF PLASMIC DEGRADATION OF
FRAGMENT Y
Vertical lines represent disulphide bonds.
Small arrows show sites of proteolytic
cleavage.
Potential F XIII cross-linking sites on
the ^-Chains (-GLN-LYS) are indicated.
(After Furlan et al, 1975b.)
sane molecular weights but different patterns of disulphide-
reduced chains.
Y fragments are composed of one molecule of fragment E
and one molecule of monomeric fragment D, linked together
by either one, txvo or three peptide bonds. It appears that
the splitting of fragment Y into fragments D and E starts
at the oe-polypeptide chain; from then on both p and ^-chains
appear to be equally susceptible to plasmin attack.
Fragment D, previously thought to be plasmin-resistant,
breaks down further to a 46,000 molecular weight species,
termed fragment d, which like fragment E is plasmin-
resistant (Furlan et al, 1975a).
Fragments released by plasmin from non-crosslinked fibrin
were electrophoretically similar to those found during
plasmin-fibrinogen interaction, namely X, Y, D and E
(Gaffney, 1973; Pizzo et al, 1973a). The only difference
being that fragments X, Y and E from the fibrin digest
will not contain fibrinopeptide A, whereas it may still be
present in the fragments from fibrinogen, depending on the
extent of digestion with plasmin.
The digestion of crosslinked fibrin yields core fragments
called D dimer (Gaffney, 1973) and E. Another component
has been identified as a complex of D dimer and fragment
E, which is dissociable on SDS gel-electrophoresis. The
D dimer has been shown to contain the crosslinked ^ chain
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remnants of the originating fibrin molecules. These
crosslinked peptides have been variously reported to have
molecular weights from 63,OO0 (Gaffney and Brasher, 1973)
to 81,000 (Pizzo et al, 1973b).
On digestion of fibrin containing covalent inter-molecular
^ chain crosslinks, one would expect to see crosslinked,
high-molecular-xveight fragments (eg X, Y) . However,
although possibly formed at some stage during the lytic
process, they are probably not soluble and thus are not
observed during SDS-gel electrophoresis of fibrin lysates.
These fragments should indeed be held together in a
polymer-like form by the combination of two plasmin-
resistant covalent types of bonding, the E-located (N-
terminal) disulphide bonds joining the two halves of the
fibrinogen dimer together, and the D-located, factor XIII-
mediated amide bonds binding the ^ chains of adjacent
fibrin molecules together. The complete estrangement of
these two forms of mutually supportive covalent bonds in
the crosslinked fibrin is necessary for the lysis of fibrin,
and thus only D dimer and E are observed as major products
during the digestion of crosslinked fibrin.
The oc chain crosslinks render fibrin resistant to lysis
by plasmin (Gaffney and Brasher, 1973). The preferential
attack by plasmin on the polypeptide chains of fibrinogen,
non-crosslinked fibrin and 8-8 crosslinked fibrin is in
the order ex, [3 and Q and the chain preference of plasmin
for totally-crosslinked fibrin (containing ^ and oc crosslinks)
is in the order p or ^ and then crosslinked oc chains
(Gaffney, 1973; Pizzo et al, 1973a; Pizzo et al, 1973b).
Indeed, the lysis of the crosslinked oc chains of fibrin
seem to represent a rate-limiting step during the digest¬
ion of fibrin clots.
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THE NORMAL FIBRINOLYTIC MECHANISMS IN VIVO
There are two principal theories of the mechanism of
thrombus dissolution by the fibrinolytic system.
Aikiaersig et al (1959) suggested that as fibrin poly¬
merizes, plasminogen is adsorbed preferentially to the
fibrin and is available in large quantities within a
thrombus which is comparitively free of inhibitors.
When an activator enters the circulation it diffuses
into the clot converting the plasminogen to plasmin in
situ and so promotes lysis. They reported that thrombo¬
lysis by exogenous plasmin action appeared to be relatively
unimportant. Ambrus and Markus (I960), however, proposed
that when plasmin forms in the circulation naturally or
during infusion of an activator it is normally bound to
the excess inhibitor present in blood. They suggested
that this plasnin-inhibitor complex is reversible and
dissociates in the presence of fibrin, its preferred
substrate, so allowing the plasmin to bring about fibrin
dissolution by "external lysis".
A third possible suggestion (Gottlob and Blumel, 1968;
Sharp, 1975) is that induced activator in the circulation
binds or adsorbs to the fibrin in a thrombus and that
circulating plasminogen is converted to plasmin within
the thrombus, thus initiating fibrinolysis.
Part of the controversy is due to the conflicting reports
on the binding of plasminogen by fibrin. Some groups have
found little or no affinity between the two proteins;
Fantl (1962) demonstrated that plasminogen levels are
essentially the same in plasma and serum, and that the
clasminogen content of thrombi formed in vitro is no
creater than the amount contained in entrapped serum.
Coders have found high affinity between plasminogen and
fibrin (Ball et al, 1971; Strachen et al, 1974;
Cederholm-Williams, 1977a). Warren et al (1973) reported
Tr.at the naturally occurring fibrin clot has been shown
o : contain sufficient plasminogen laid down during
the clotting process to ensure its own dissolution on
conversion to plasmin. Strachen et al (1974) showed
t :at although substantial amounts of plasminogen are bound
in the forming thrombus, this uptake is not total and
that additional circulating plasminogen can be taken up
without a proportional loss of intrinsic plasminogen.
The concept of activator binding as a mechanism of clot
n
dissolution is not new; Mullertz (1953b) showed the post
mortem activator to be strongly bound to fibrin and
Dalai et al (1969) were able to elute plasminogen activator
from a fresh unorganized native human thrombus. Other
activators also reported as having fibrin affinities
include the activator produced on exercise (Blix, 1962),
porcine tissue activator (Thorsen et al, 1972) and the
streptokinase-plasmin(ogen) activator (Lassen, 1958),
although Cederholm-Williams (1977b) reported that fibrin
binding is interfered with by the continued association
of streptokinase with plasmin(ogen). In contrast, however,
urokinase is generally considered not to possess this high
fibrin affinity (Blix, 1962; Ball et al, 1971; Thorsen
et al, 1972).
As well as the fibrinolytic enzyme system's role in the
removal of pathological intravascular and extravascular
fibrin, it has been suggested that even under physio¬
logical conditions there is a dynamic equilibrium between
coagulation, constantly laying down fibrin to seal defects
in the endothelium, and fibrinolysis, eliminating such
deposits after they have served their haemostatic function
(Astrup, 1956). The finding of activator activity in
normal blood (Flute, 1960), the presence of small amounts
of measurable fibrinogen-fibrin related antigen in
normal serum (Merskey et al, 1969), more specific fibrin/
fibrinogen degradation products in plasma (Gordon et al,
1973), and the presence of fibrinopeptide A in normal
plasma (Nossel et al, 1973) are all in favour of this
hypothesis.
Alternatively, it has been suggested that fibrinogen
degradation by low grade plasmin activity in vivo is a
major pathway for fibrinogen catabolism. Mosesson (1973)
claimed conclusive evidence that fibrinogenolysis in
rabbits accounts for 25% of the fibrinogen turnover, and
suggested no less a role for this pathway in man.
The basis of this suggestion has been attacked by others.
Collen et al (1974) pointed out that artefactual fibrinogen
degradation during preparation may have accounted for
some of the breakdown ascribed to fibrinogenolysis.
Collen et al (1974) found less than 5% of the Ajc chains
to be degraded in a sample of fibrinogen prepared by
affinity chromatography, with no special protective
procedures, from fresh frozen plasma. Collen et al also
point out that Mosesson has assumed that the coagulation-
fibrinolysis balance in humans and in rabbits operates
at similar rates; this may not be valid.
TT
Mullertz (1974) employed urokinase-activated human plasma
to study the relationship of the activation process to
the lysis of fibrin and fibrinogen. At low doses of
urokinase degradation of fibrinogen was low or absent,
but fibrinolysis occurred within 30 minutes. At higher
doses of urokinase fibrinolysis occurred in 10 minutes,
whereas fibrinogenolysis progressed between 3 and 10
hours.
Gurewich et al (1974a, 1974b, 1975) working with exercise-
induced activator, venous occlusion activator and the
activator obtained from cadaver limbs reported that
fibrinogen was not degraded in plasma by these activators
whereas fibrin was rapidly lysed, they deduced that
significant fibrinogenolysis does not occur. They also
found that these activators did not induce lysis of soluble
fibrin monomer complexes, whereas lysis did occur of
protamine sulphate-precipitated fibrinogen and protamine
sulphate or ethanol-induced gels of fibrin monomer. They
explained these results by saying a solid phase was
necessary to dissociate a hypothesized activator-inhibitor
complex.
However, in contrast to these last conclusions McKillop
et al (1975) studied in vivo production of soluble fibrin
complexes during defibrination by Ancrod infusion. SDS-
polyacrylamide gel electrophoresis showed that the component
units of the soluble complexes were markedly deficient
in intact Acc chain v;hen compared with the uncomplexed
material. They suggested that preferential digestion
of fibrin may occur while it is still in the soluble form.
Konttinen et al (1973) studied streptokinase-activated
plasma and found that degradation of soluble fibrin
monomer complexes proceeded at a much higher rate than
with fibrinogen. They concluded that the fibrinolytic
system has an essentially higher affinity to monomers
than to fibrinogen, but that the specificity of the
monomers as substrate may be limited to the early steps
of degradation. Further evidence of the susceptibility
of soluble fibrin to degradation was provided by Gaffney
(1978) who studied prolonged Ancrod defibrination in man.
The monomeric form of fragment D, rather than D dimer,
Wcxfounc rn plasma and, since 8-8 crosslinking of fibrin
occurs in conjunction with fibrin insolubilization under
physiological conditions, this allows the conclusion that
plasmin-mediated digestion of soluble fibrin polymers is the
likely plasma defibrinating mechanism induced by Ancrod
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infusion (Gaffney and Brasher, 1974).
The proteolytic enzyme plasmin has a broad specificity,
although in vivo its main target is fibrin. Various
hyootheses have been put forward to explain this spec¬
ificity, but results of subsequent research have often
cast doubts on the value of these theories. However,
curing the past few years specific interactions at the
molecular level have been demonstrated between the
different components of the fibrinolytic system. These
findings enabled Wiman arid Collen (1978b) to formulate a
molecular model for the regulation of fibrinolysis in
vivo. In purified systems it was found that glu-
plasminogen, the native form has a weak affinity for fibrin,
whereas the partially degraded, lys-plasminogen has a
stronger affinity (Thorsen, 1975). It was later demonstrated
that this interaction is mediated by way of structures,
in the plasminogen molecule, known as lysine-binding sites
(Wiman and Wallen, 1977). Rakoczi et al (1978) recently
determined that approximately 4% of native and 8% of
partially degraded plasminogen was specifically adsorbed
to the fibrin, when a whole plasma system was clotted.
Kir.etic and structural work both indicate that the
plasminogen molecule contains at least two lysine-binding
sites (Wiman and Wallen, 1977; Iwamoto, 1975; Sottrup-Jensen
et al, 1977). The higher affinity of the partially
degraded form of plasminogen for fibrin might be explained
by the fact that both its lysine-binding sites are available?
whereas in native plasminogen one of them is occupied
by an interaction with a specific site in the N-terminal
part of the molecule (Wiman and Wallen, 1975a).
Fibrin markedly enhances the activation of plasminogen
by tissue activator (Wallen, 1977). This seems to be
due to the adsorption of both plasminogen and activator
to the fibrin network. Plasmin added to, or formed in,
plasma is very rapidly neutralised by antiplasmin, which
is responsible for all of the fast-acting plasmin-
neutralising activity of plasma. Antiplasmin and plasmin
form a very stable stoichiometric 1:1 complex which is
devoid of enzymatic activity (Moroi and Aoki, 1976;
Wiman and Collen, 1977). Antiplasmin can also bind to
insolubilized plasminogen and can be specifically dis¬
placed by EACA, suggesting that this interaction is also
mediated by way of the lysine-binding sites in the
plasminogen molecule. Accordingly, it has been found in
purified systems that fibrin and antiplasmin compete for
the binding to plasminogen (Moroi and Aoki, 1977a). In
plasma systems, however, the binding of plasminogen to
fibrin is not significantly influenced by antiplasmin
(Rakoczi et al, 1978).
Plasmin which is bound to fibrin and involved in its
degradation, in contrast to free plasmin, is only slowly
inactivated by antiplasmin (Wiman and Collen, 1978a).
However, once formed, the plasmin-antiplasmin complex does
not seem to dissociate in the presence of fibrin (Wiman and
Collen, 1978a).
Thus, a molecular model for physiological fibrinolysis
can be deduced, which explains the restricted action of
plasmin in vivo. The system seems to be regulated at
two levels : localised plasminogen activation at the
fibrin surface; and sequestration of the formed plasmin
from circulating antiplasmin. The lysine-binding sites
in the plasminogen molecule play a key role in these
regulations. When fibrin is formed, a small amount of
plasminogen is specifically bound to it by way of its
lysine-binding site(s). Plasminogen activator present
in the blood or released from the vascular endothelium
is adsorbed on the fibrin surface and efficiently activates
the adsorbed plasminogen. The formed plasmin has its
lysine-binding site(s) occupied in complex formation
with fibrin and is also involved in fibrin degradation
by way of its active site, and would therefore only
react very slowly with antiplasmin. In contrast, plasmin
which is released from digested fibrin is rapidly and
irreversibly neutralised by antiplasmin in the circulation.
It can be seen from this model of physiological fibrinolysis
that the potential causes of a defective fibrinolytic
system may prove to be multitudinous, and thus therapeutic
approaches could be equally wide ranging. Present know¬
ledge of the biochemistry and physiology of the fibrin¬
olytic system does suggest that we are beginning to unveil
a system of immense importance, the functions of which may
ultimately prove to be more far-reaching than could
possibly have been envisaged.
Plasminogen, being a precursor of humoral origin is
ubiquitously available for activation in the organism, and
thus fibrinolysis becomes involved in many physiological
and pathological processes. The fibrinolytic system is
of fundamental importance in maintaining the patency of
the vascular system. Furthermore it appears to play a
role in neoplasia, tissue repair and certain types of
inflammation. If this is so, then the effects of
defective fibrinolysis may also prove to be multitudinous.
Thus the importance and the potential reward for advances
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1 PERFUSION OF CADAVERS
A METHODOLOGY
The method of perfusion developed by Aoki and von Kaulla
(1971a) was, with minor modifications, used initially.
The leg is incised, parallel to, and about 1 centimetre
above, the inguinal ligament, from the pubis to the
iliac crest of the ilium. A further incision is then
made from the midpoint of the first, to a point about
15 centimetres down the leg, over Hunters canal and taking
care to avoid the saphenous vein. The minor venous
branches are tied off, and the femoral vein and artery
dissected out. The femoral artery is then cannulated
with the tip of the cannula above the profunda artery
and a ligature proximal to the cannula. The femoral
vein is also cannulated and ligatured in a similar
posit ion.
The perfusion fluid is run into the femoral artery from a
height of four feet and the outflow is collected from
the femoral vein. In both cases a modified administration
set is used, with a bore of approximately 5mm. The leg is
massaged as the vascular system is perfused.
In the original method the perfusate was not collected
until the fluid was nearly colourless. However, when
sequential aliquots of perfusion fluid were tested for
activity and protein content (see Fig lO) it was found
that the initial vascular perfusates, although of low
specific activity, contained the greatest amount of
plasminogen activator activity and thus it was decided
to collect the total perfusate.
JIL 123^567890 Aliquotnumber(250mleach) FIG10GRAPHSHOWINGTHEACTIVATORCTIVITYNDPEC FICA I I EXTRACTEDINSEQUEN IALALIQUOTSOFCAD V RPE FUS ON
B DETAILS OF CADAVERS AND RESPECTIVE PERFUSATES
The lower limbs of nearly 80 cadavers have been perfused
during the course of this work. The protein and activator
content of the perfusates, as well as age, sex and cause
of death of the first 60 cadavers are given in Table 1.
Trasylol, a plasmin inhibitor, was incorporated into the
perfusion fluid used with the remaining cadavers, thus































































































































































































































































































































































































































































































































































































































































































*UpperLimbPerfusion +ContaminatedWithPl smin(NotI clud dAverages) NDotDetermined TABLE1(Cont)DETAILSOFCADAVERANDPERFUSATE
C PERFUSION FLUIDS TESTED
Various perfusion fluids have been tested during the
course of this work. They are described below, along
with any disadvantages encountered in their use.
a Saline
0.9%(W/V) saline was used from viaflex containers, which
was very convenient. The saline, as with all the perfus¬
ion fluids, was used at 37°C. This was to provide a
thermal "shock" in an attempt to release plasminogen
activator, from the endothelial cells coating the inside
of the vasculature. The saline worked ivell; it is of
physiological strength and thus osmotically compatible,
so no flow problems were encountered, except those caused
by thrombus blocking the vessels, which was minimised by
rejecting cadavers with a previous history of thrombotic
problems.
However, a serious disadvantage in using saline was that
in order to apply the perfusate to some ion-exchange or
affinity chromatography columns, dialysis was first re¬
quired to lower the sodium chloride concentration or an
ammonium sulphate precipitation followed by resuspension
in a buffer of lower ionic strength. These processes are
time consuming, which is not acceptable when dealing
with a labile molecule, and losses are unavoidable when
using dialysis membranes.
b Distilled Water
Use of distilled water overcame the ionic strength problem,
so that perfusates could be applied, after centrifugation,
directly to ion exchange or affinity chromatography
columns. Hoivever, flow problems were encountered with
distilled water that had not been present with saline.
These problems were probably caused, at least in part, by
the endothelial cells swelling up, due to water entering
them, causing blockage of the smaller vessels. Also, the
distilled water caused lysis of the red blood cells,
effectively giving a perfusate of lower specific activity.
c 5% Dextrose
This was the best fluid employed. It can be applied
directly to chromatographic columns, with no prior treat¬
ment , and also no flow problems were encountered during
its use.
Although initially the 5% dextrose was used alone,
subsequently Triton X-100, a mild detergent, was added in
an attempt to disrupt the endothelial cells . Various
concentrations of Triton X-lOO (0.1%, 0.2% and 0.4%) were
investigated and 0.1% gave the best activator yields and
flow properties.
Various other additives were tested during the course
of the work. Fibrin formation after perfusion occasion¬
ally caused problems, especially when very "fresh" cadavers
( <12 hours post mortem) were perfused; so heparin (lu/ml
and lOu/ml) and EDTA (lOmM) were added to the perfusion
fluid in an attempt to prevent fibrin formation, and to
abolish crosslinking of any fibrin formed, respectively.
The heparin did not prove very successful; it was found
more effective to avoid cadavers less than about 12 hours
post mortem. However, the EDTA ivas retained and it has
recently been reported as a stabilizing agent for activator
(Radcliffe and Heinze, 1978).
Trasylol, a plasmin inhibitor, was latterly added to the
perfusion fluid for two reasons. Firstly, to avoid the
degradation of the soluble fibrin polymers, believed to
be the species that the vascular activator is bound to
when obtained from the cadaver. The complex with soluble
fibrin polymers is desirable in that it confers a measure
of stability on the activator. Secondly, the Trasylol
also inhibits plasmin from degrading the activator itself.
Thus the final perfusion fluid that was employed was 5%
dextrose-O.1% Triton X-lOO-lOmM EDTA-lOu/ml Trasylol; this
was used at 37°C.
D DISCUSSION
Table 2 shows the wide range of protein and activator
activity extracted from the cadavers and the resultant
range of specific activities obtained as a crude starting
material for purification. The plasminogen activator
extracted varied from nothing, in one cadaver, up to
55,825 Ploug units, the average extracted being 15,451
Ploug units per cadaver. With such a wide range of values
it was hoped that it would have been possible to predict
"good" cadavers in terms of yield and then select only
the ones that were likely to give high activator levels.
However, by referring to Tables 3, 4 and 5 it can be seen
that this was not possible.
Table 3 shows the average activator levels extracted from
cadavers of varying lengths of time after death. There
seems to be a general trend that the longer the time
elapsed after death, the less the activator obtained.
However, the highest average activator extracted was obtained
from the group of over 49 hours post mortem.
Table 4 shows the average activator levels extracted from
cadavers of various age groups. It would appear from the
data that the age of the cadaver makes no difference to
the activator yield, except that again the oldest group,
81-90 years, yielded the highest amount of activator.
However, statistics on only 4 cadavers in this age group





























TABLE 2 RANGE AND AVERAGE VALUES OF PROTEIN AND
PLASMINOGEN ACTIVATOR EXTRACTED FRQM
CADAVERS AND THEIR SPECIFIC ACTIVITES




13 - 24 18,700 9
25 - 36 13,489 19
37 - 48 11,776 18
49 32,409 6
TABLE 3 AVERAGE PLASMINOGEN ACTIVATOR ACTIVITY EXTRACTED
FROM CADAVERS OF VARIOUS HOURS POST MORTEM
i
i
Age Group Average Activity-Extracted No of Cadavers
10,724 3
J
41 - 50 16,213 5
51 - 60 14,122 15
61 - 70 12,399 13




TABLE 4 AVERAGE PLASMINOGEN ACTIVATOR ACTIVITIES
EXTRACTED FRQM CADAVERS OF VARIOUS AGS GROUPS
Cause of Death Average Activity
Extracted
No of Cadavers
Brain Haemorrhage 16,742 4
Cancer 14,766 15





TABLE 5 AVERAGE PLASMINOGEN ACTIVATOR ACTIVITIES
EXTRACTED FRQM CADAVERS WITH DIFFERENT
CAUSES OF DEATH
Table 5 shows the average activator levels obtained from
cadavers with different causes of death. Again as can be
seen no distinct pattern emerges from the cadavers studied.
Only one cadaver failed to yield any activator at all;
the cause of death in this case was septicaemia. It is
unknown whether any real significance can be attached to
this result as only one cadaver with this cause of death
was studied.
Somewhat surprisingly, the highest yield of activator was
obtained from cadavers with myocardial infarction and
pulmonary embolism as their cause of death, both of which
are generally associated with a tendancy to thrombosis.
It has been demonstrated that this is related to low levels
of the vascular activator, thus it was a little surprising
to find high yields from these cadavers. This could be
explained by assuming that a faulty release mechanism,
rather than a low level of production, causes the low levels
of activator, such that perfusion of the vascular system
would still be able to harvest the physiologically unavail¬
able activator; alternatively it could be that these
patients had, before death, been on fibrinolytic therapy.
Other factors that could explain the wide variation in
yields and the absence of any predictable pattern could
include the type of death endured by the patient. It
is well known that in cases of sudden or violent death
high fibrinolytic activities are found in the blood, thus
if the activator were largely released into the blood on
death, the hours elapsing between death and perfusion of
the vascular system would provide ample time for the
degradation of the activator in an environment laden with
proteases. Whereas in cases of slow or quiet deaths, the
activator may remain in the relative safety of the end¬
othelial cell until extracted, although in some cases a
lingering death appears to result in the exhaustion of
the endothelial cell.
Another uncontrollable variable between cadavers is the
volume of the perfusate obtained. Thus it could be that
not all the activator is extracted in some situations
in which the vascular system is blocked with thrombus,
prematurely terminating the perfusion.
But probably the biggest factor in affecting the yield
obtained is insoluble fibrin, either preformed or formed
during or after perfusion. Apart from causing flow
problems during the perfusion, fibrin avidly adsorbs
vascular activator and reduces the yield.
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2 INITIAL PURIFICATION PROCEDURE
A TREATMENT OF CRUDE PERFUSATE
The crude perfusate is centrifuged as a first step, to
remove red blood cells and other debris, including any
thrombus present. The perfusate is centrifuged at lO,OOOg
and 4°C for 30 minutes, although neither the speed or time
are critical.
Initially, the ammonium sulphate precipitation step of
Aoki and von Kaulla (1971a) was used, as the saline
perfusate could not be applied direct to certain ion-
exchange or affinity chromatography columns. Solid ammonium
sulphate was slowly added, with mechanical stirring, to
a saturation of 45% (277g/litre). This was then left
stirring overnight at 4°C to precipitate.
The precipitate, after being removed by centrifugation,
was resuspended in a minimum amount of buffer, initially
containing sodium chloride, which was subsequently reduced
in concentration, in two stages, by dialysis. The gradual
reduction in sodium chloride concentration was designed to
overcome solubility problems; however, this was very time
consuming and was associated with large losses of activity.
The ammonium sulphate step gave variable results, probably
again due to solubility problems. The activator activity
retained in the resuspended precipitate generally varied
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from 60-8051, although sometimes less than this was recovered,
and approximately 30% of the protein reappeared in the
resuspended precipitate, representing a two-fold purifi¬
cation. With 25-30% of the total protein reproducibly
appearing in the resuspended precipitate, even if 100%
of the activity was retained in this portion, this would
still only represent a 3 to 4-fold purification.
I". an attempt to overcome solubility problems and activator
losses, the ammonium sulphate precipitation step was pH
controlled. The pH after adding the ammonium sulphate to
the perfusate, in the region of pH5.0-5.5, was adjusted
to pH7.5. However, this did not have the desired effect
and the ammonium sulphate step was discontinued when the
perfusion fluid was changed to distilled water and then
5% dextrose. With both of these fluids it is possible to
apply the perfusates, after centrifugation, directly to
ion-exchange or affinity chromatography columns.
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B PURIFICATION PROCEDURE (AND COMPARATIVE BEHAVIOUR OF
OTHER FIBRINOLYTIC COMPONENTS)
Various chromatography media were tested before a satis¬
factory combination was evolved for the purification of
the activator. DEAE-cellulose, later available as DSAE-
acarose, was investigated initially. The activator had
a low affinity for this gel, eluting at approximately
O.IM sodium chloride. This resulted in very little
purification as all the bound protein eluted early in the
sodium chloride gradient. In one run the pH of the
buffers was increased from pH7.4 to 8.5 in an attempt to
improve binding, but this was unsuccessful.
CM-cellulose and heparin-Sepharose were tried, although
neither gave good results. The activator did not separate
from bound protein using heparin-Sepharose, while no
activity was recovered from the CM-cellulose column,
possibly due to the pH (6) of the acetate buffers that
the column was eluted with. The behaviour of the activator
was also investigated on various gel filtration media
including Ultrogel AcA 22, Ultrogel AcA 34, Biogel A5M
and Sepharose 4B.
The initial purification procedure developed is shown in
Figures 11, 12 and 13. The crude perfusate after centri-
fugation was adsorbed directly with lysine-Sepharose gel
while stirring for 1 hour at 4°C. The gel was then removed
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(pH7.5). The wet gel was repacked into a column (2.5 x
15cm) and eluted at 4°C with an exponential gradient of
0-0.5>I lysine in 0.025M tris (pH7.5) at 30ml/hour. 7.5ml
fractions were collected and were assayed for protein in
a spectrophotometer at 280nm, the lysine concentration ivas
determined in every fifth fraction by measuring the re¬
fractive index in an Abbe refTactometer, and the fractions
were also screened on normal (containing plasminogen)
fibrin plates to assay for plasminogen activator activity
and on plasminogen-free fibrin plates to screen for non¬
specific or direct (due to plasmin) proteolysis. The
activator activity was expressed in Ploug units after
calibrating the plates with Leo urokinase. The activator
reproducibly eluted in two peaks at 0.15M lysine (range
0.11-0.17M) and 0.32M lysine (range 0.28-0.34M).
The active fractions were pooled and concentrated to 5ml
us ing an Amicon ultrafiltration system; this was diluted
with 0.025M tris buffer (pH7.5) and again concentrated to
5ml to reduce the lysine concentration of the sample.
The concentrated fraction was applied to a protamine-
Sepharose column (2.5 x 25cm) and eluted at 4°C with an
exponential salt gradient from 0-2.CM NaCl (see Fig 12)
in 0.025M tris (pH7.5) at 30ml/hour. The fractions were
again screened at 280nm and on normal and plasminogen-
free fibrin plates; the NaCl concentration was determined
by conductivity measurements.
The activator eluted from protamine-Sepharose at 0.9M NaCl
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(range 0.75-1.04M). The active peak was pooled, concentrated
to 5ml and applied to a Sephadex G-200 column (2.5 x 100cm)
and eluted at 4°C with 0.025M tris pH7.5 containing 1.5M
NaCl (see Fig 13). Void volume and solvent volume (V and
respectively) were determined by adding blue dextran
and glucose to the sample before chromatography. The
activator activity eluted at a of 0.48, and was not
associated with any detectable peak of absorbance when
measured at 280 or 220nm.
For comparative purposes the plasminogen activator appearing
in the blood after venous stasis was purified according to
the same scheme outlined above. 130mls of blood were
collected from two arms, of the same subject, after 15
minutes of venous occlusion. The blood was collected
into citrate and after centrifugation the plasma was
purified on lysine-Sepharose, protamine-Sepharose and
Sephadex G-200.
Only one peak appeared on lysine-Sepharose, eluting at
0.38M lysine with a peak activator activity of 6 Ploug
units/ml. The activator eluted from protamine-Sepharose
at 1.1M NaCl with a peak activity of 25 units/ml, and
eluted from Sephadex G-200 with a K of 0.32 and a peak
activity of 3 units/ml.
The binding of plasminogen activator, plasminogen and
plasmin to the same batch of lysine-Sepharose was compared.
The plasminogen activator eluted at 0.30M lysine, plasmin
(Kabi) eluted at 0.24M lysine and plasminogen (Kabi)
eluted at 0.22M lysine.
C DISCUSSION
The vascular perfusate is most easily applied to lysine-
Sepharose by bulk adsorption, as very often large volumes
are involved. Both 1 hour and overnight adsorptions were
investigated and the shorter adsorption time proved
adequate.
As already stated the activator eluted reproducibly in
two peaks from lysine-Sepharose; one peak associated with
the bound protein and one, with a higher affinity, associated
with very little protein. Various theories have been
considered to explain the elution of the activator at two
distinct lysine molarities. Firstly, as lysine has two
amino groups it is conceivable that when it is linked to
the Sepharose, two sites of different affinity for the
activator, may be produced. However, this is unlikely as
the pK values are different for the two amino groups (pK
for oc-amino group = 9.2, and for e-amino group = 10.7) and
thus, at the pH (9) used for the reaction, lysine should be
coupled mainly through the cx-amino group. Another possibil¬
ity considered was that the lower affinity binding was
due to the cyanogen bromide linkage acting as an ion
exchanger. However, this was disproved by preparing a
lysine-Sepharose column using an adipic acid dihydrazide
(ADH) linkage, which still gave two peaks of activator.
A more feasible explanation could be that the lower affinity
activator represents a partially degraded molecule.
However, the most probable explanation is that the two
peaks represent complexed and free vascular activator.
The lower affinity material would represent activator in
a complex with some sort of carrier, later believed to be
soluble fibrin polymers (see Section 3 of this Chapter
and Chapter 4), and the higher affinity material would
represent free activator. Both of these peaks when run
separately on Sephadex G-200 in 0.025M tris buffer (pH7.5)
elute in the Vq position, indicating a larger molecular
weight than the native molecule. This elution position
was expected for the low affinity peak, hypothesised to
be an activator complex, but was initially surprising for
the higher affinity material. However, it is quite likely
that sufficient carrier molecules from the first peak
tail into the second peak, to allow recombination of the
activator and carrier on removal of lysine (the binding
of the activator to fibrin is believed to be mediated
through lysine binding sites). In fact a preparation of
soluble fibrin polymers (SFP's) was later found to bind
to lysine-Sepharose (see Chapter 4) and elute at a lysine
molarity similar to the low-affinity peak of activator,
and sufficient tailing of the SFP's was observed on elution
to account for the above explanation.
More supportive evidence for this theory was obtained
when the low-affinity peak alone was pooled, concentrated
and the lysine concentration lowered sufficiently to allow
the sample to be re-applied to the lysine-Sepharose column.
On elution, two peaks were again observed. This would
155
suggest that on applying a sample of activator containing
soluble fibrin to a lysine-Sepharose column, there is
competition between the soluble fibrin and the insolubilised
lysine for the lysine binding site of the activator. A
state of equilibrium is reached whereby some of the activator
is bound via the SFP's and some is bound directly to the
lysine-Sepharose.
However, whether or not this latter explanation is
substantiated, the two peaks, when tested separately in
the remainder of the purification procedure, behaved
identically. Thus all the active fractions eluting from
lysine-Sepharose are pooled and treated as one.
Various concentrations of NaCl (0.025M-2.OM) were incorpo¬
rated into the tris buffer of the Sephadex G-200 step,
before 1. 5M NaCl proved to be the most satisfactory. The
problem to be overcome was the apparent heterogeneity of
the activator in the last stage of purification, when the
G-200 column was operated in a buffer with physiological
salt concentration. The V or high molecular weight elution
o
positions of the activator were thought to be due to
aggregation. Also the activator eluted after on several
occasions due to an interaction with the gel matrix.
However, a concentration of 1.5M NaCl in the buffer effected
the elution of activator as a homogenous peak. It was
later realised that the soluble fibrin polymers, of various
molecular weights, were causing some of the variation in
elution positions. 1.5M NaCl obviously broke this
association down, but later 1M lysine was found to be more
effective, as the binding would be mediated through the
lysine binding sites.
The activator appearing in the blood after venous stasis
was purified in the same scheme as the cadaveric activator
ana generally behaved in an identical manner. However,
there were some slight, but possibly significant, differences.
The venous occlusion activator eluted in only one peak
from lysine-Sepharose, which corresponded to the high
affinity material from the cadaver. The absence of the
low-affinity peak can be explained in two ways. If it is
accepted that a degraded molecule is the cause of the low-
affinity of cadaveric activator then it is not surprising
that this was absent when the source of the activator
was as "fresh" as venous occlusion plasma. Alternatively,
if the "complex-theory" is the correct one then again it
is quite likely that there would be very little or no
SFP's present in normal plasma, and thus the activator would
bind to lysine predominantly in the free form.
The venous occlusion activator eluted from lysine and
protamine columns at slightly higher lysine and NaCl
molarities respectively, than the reported ranges for the
cadaveric activator. Also it gave a lower value on
Sephadex G-200 indicating a larger molecular weight. Thus
it could be that the venous occlusion activator represents
a more native molecule than the cadaveric activator. The
venous occlusion activator also appeared to give a better
percentage recovery as the peak activity value of the
lysine-Sepharose step was only 6 Ploug u/ml and yet a
peak value of 3u/ml was obtained from the Sephadex G-200
run. Experience in the purification of the cadaveric,
activator shows that the activity of the peak fractions
of the G-200 run is approximately one-tenth that of the
lysine-Sepharose run.
Finally the binding of the activator, plasminogen and
plasmin to lysine-Sepharose, was compared. All three
molecules are believed to possess lysine binding sites,
and differences in their binding to lysine may reflect
their relative affinities for fibrin. The activator had
the highest affinity, eluting at 0.3CM lysine, while
plasmin and plasminogen eluted at 0.24M and 0.22M respect¬
ively. The higher affinity of the activator over plasmin¬
ogen, for fibrin, was confirmed by later studies.
In conclusion, the purification scheme works very well,
giving a product with biological activity but no detectable
protein either by absorption at 280nm or 220nm or when
run on polyacrylamide gel electrophoresis and stained.
Many experiments, which will be described in later sections,
were carried out on this material.
3 IMPROVED PURIFICATION PROCEDURE
A INTRODUCTION
Although purification of the vascular plasminogen activator
on lysine-Sepharose, protamine-Sepharose and Sephadex
G-200 gives a pure product, the final yields obtained
are very small indeed.
Thus after the observation that a sample of concentrated
(20-fold) crude perfusate when run on Sephadex G-200
eluted at V , it was realised that the vascular activatoro'
was being obtained from the cadaver in the form of a
complex. As it appeared that this complex was more stable
than the ftee enzyme, studies were initiated to purify the
activator in its complexed form, using dissociation of
the complex only as a last step. To these ends polyethylene
glycol precipitation was investigated since it is known to
preferentially precipitate larger molecules.
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B POLYETHYLENE GLYCOL PRECIPITATION
Addition of polyethylene glycol (PEG) to a mixture of
proteins will cause the high molecular weight species to
come out of solution first, and on increasing concentrat¬
ions of PEG, more protein, of progressively lower molecular
weight, will precipitate out. This is because, with
increasing concentrations of PEG, the effective amount of
solvent available to maintain the proteins in solution is
progressively reduced. Thus as the activator is obtained
as a high molecular weight complex from the cadaver, PEG
precipitation was investigated.
Initially PEG 6000 was employed. 8% PEG 6000 was sufficient
to bring 90-100% of the activator down in the precipitate.
However, this was soon replaced by PEG 400 which gave a
slightly better purification; the results were more
reproducible and PEG 400, as a liquid, is easier to use
than the solid PEG 6000.
PEG 400 was investigated at various concentrations (5-35%)
in 5ml aliquots of a crude perfusate. Folin protein
assays and fibrin plate assays for activator activity
were carried out on the supernatents (after precipitation)
and resuspended precipitates. As can be seen by reference
to Table 6, 15% PEG 400 causes precipitation of all of













30% lOO 10. 8
35% lOO 13.3
TABLE 6 EFFECT OF VARIOUS
ON THE PERCENTAGE
PRECIPITATED
CONCENTRATIONS OF PEG 400
OF ACTIVATOR AND PROTEIN
Table 7 gives the results obtained using 15% PEG 400 with
the crude perfusate of one cadaver, given as an example.
Under 4% of the total protein is precipitated, whereas
nearly 80% of the activator occurs in the resuspended
precipitate. Actually 100% of the activator activity is
precipitated, as there is no detectable activity in the
supernatent after precipitation, but only 80% of this is
resuspended. The remaining activity can probably be
accounted for by the losses associated with binding to
insoluble fibrin, sometimes seen to form on precipitation.
However this still represents a 20-fold purification with
an increase of the specific activity from 0.43 to 8.8 Ploug
units per mg.
Thus PEG 400 was introduced as the first step in the
purification procedure. To the centrifuged crude perfusate
is added PEG 400 to a final concentration of 15%. This
is stirred overnight at 4°C to facilitate precipitation.
The precipitate formed is removed by centrifugation and
is generally resuspended in 100-250ml (depending on amount
of precipitate) of 25mM tris, ImM EDTA 3.8mM borate 0.15M
NaCl at pH8.8. However if the sample is to be applied to a
particular column, the precipitate may be resuspended in
























TABLE7FIGUR SRELATINGO15%PEG400RECIPITATION (FIGURESORONCADAVERGIVENSNEX MPLE)
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C PURIFICATION PROCEDURES (AND COMPARITIVE BEHAVIOUR OF
OTHER FIBRINOLYTIC COMPONENTS)
In the initial procedure developed the PEG precipitate
was resuspended in as small a volume of 25mM tris, ImM
EDTA 3.8mM borate, 0.15 NaCl (pH8.8), as possible. The
sample, with glucose added as a marker, was then
applied to a Sepharose CL-6B column (5 x 80cm). This was
eiuted at 4°C with 25mM tris, ImM EDTA, 3.8mM borate,
0.15M NaCl, pH8.8; 30ml fractions were collected at
125ml/hour (see Fig 14). The fractions were screened
for protein at 280nm and for activator activity on normal
and plasminogen-free fibrin plates. The active fractions,
eluting at Vq, were pooled and concentrated to 5ml by
ultrafiltration; to this was added lysine, to a final con¬
centration of 1 molar, and glucose as a V marker. This'
s
sample was then applied to a Sephadex G-200 column and
eiuted at 4°C with 0.025M tris - 1M lysine (pH7.5) buffer;
7.5ml fractions were collected at 15ml/hour (see Fig 15).
The activator eiuted with a K. of 0.42 and was not assoc-
d
iated with any detectable peak of absorbance when measured
at 280 or 220nm.
This purification, by effecting a size change of the
activator activity using lysine as the dissociating agent,
gives an excellent purification in just two chromatographic
steps. However, the purification obtained is very much
dependant on the Vq elution position in the Sepharose 6B



































always of higher molecular weight than free activator,
is often heterogeneous and elutes in a broad peak, or
numerous peaks. Thus alternative methods were investigated.
The purification of a resuspended PEG precipitate was
investigated on octyl-Sepharose, Lens culinaris-Sepharose
and hydroxyapatite chromatography. The activator complex
did bind tightly to the first two columns, but was
difficult to elute, and on elution the activator activity
was not associated with fibrinogen related protein. It
appeared that the Lens culinaris column was binding the
carrier protein so strongly that, for elution, the activator
had to be dissociated from its carrier (1M NaCl or lysine
was able to do this), leaving the fibrin bound to the
column. Hydroxyapatite, however, gave the most satisfactory
results, being easy to handle and giving a good purification,
and was thus used as the first step after PEG precipitation.
The resuspended PEG precipitate was applied to the hydroxy-
apatite column (7 x 15cm). The adsorbed protein was
eluted with an exponential gradient of 5-500mM Na2HP04 at
pH7 (see Fig 16). 30ml fractions were collected at 150ml/
hour and screened for protein (at 280nm) activator activity
(normal and plasminogen-free plates) and the phosphate
gradient was measured by conductivity. The activator
activity eluted as a single peak at 23QmM phosphate
(range 200-270mM). The active fractions were pooled,
concentrated by ultrafiltration to approximately lOml,
glucose added and the sample applied to a Sepharose CL-6B
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column (5 x 80cm). The sample was eluted at 4°C with 25mM
tris, lmM EDTA, 3.8mM borate, 0.15M NaCl pH8.8 (see Fig
17). The fractions were assayed for protein and activator
activity. The elution position of the activator activity
at this stage was variable, but always showed that the
activator was still in the complexed form.
The active fractions were pooled, concentrated by
ultrafiltration, then diluted two-fold with 0.025M tris
(pH7.5) to reduce the effect of saline, before being
applied to lysine-Sepharose (2.5 x 15cm) at 4°C. The
adsorbed protein was eluted with an exponential gradient
of 0-1M lysine in 0.025M tris, pH7.5 (see Fig 18). 7.5ml
fractions were collected at 30ml/hour and screened for
protein, activator activity and the lysine gradient was
determined by refractometry. The activity elutes from
lysine-Sepharose at approximately 0.32M lysine, as
previously determined. The activity at this stage can
sometimes be seen to be associated with a very small peak
of protein.
An alternative to this last step in the purification is
provided by fibrin-Sepharose. Fig 19 shows the excellent
purification obtained when a resuspended PEG precipitate
is applied direct to fibrin-Sepharose. The majority of
the protein does not bind to the column, and the small
amount that does bind has a lower affinity for fibrin than
the activator, which elutes at 0.44M lysine. A column








































Section 1) to Sepharose, gave a very similar profile to
xi'orin-Sepharose, the activator activity eluting at 0.41M
lysine.
One further ligand that is worthy of mention is benzamidine
A resuspended PEG precipitate ivas purified on lysine-
Sepharose, and it is the high affinity peak that is further
purified on benzamidine-Sepharose, shown in Fig 20. The
adsorbed protein is eluted by an exponential lysine
gradient from 0-1M in 0.025M tris (pH7.5). The activator
elutes at 0.6M lysine (range 0.57-0.62M lysine), and some
interesting comparisons have been made on various fibrin¬
olytic components using this column (see later).
Some interesting comparisons were made between the vascular
activator and other fibrinolytic components, with regard
to their behaviour in the purification procedures developed
A sample of cadaveric vascular activator (crude eluate, a
gift from Dr A Todd) was purified in the scheme developed
for our own activator. It behaved in an identical manner,
being wholly precipitated by 15% PEG 400, binding to
hydroxyapatite and eluting at 255mM phosphate, within the
range obtained for our activator. It also gave two peaks
of activator activity on Sepharose CL-6B, one at Vq and
one with a K. of 0.22, which shows it was in a complexed
form and is consistent with the behaviour observed with our
own activator. Unfortunately insufficient activity was
present to carry out the final step on lysine or fibrin-
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identical to our own activator.
The precipitation of plasminogen by 15% PEG 400 was studied
in two ways. Firstly, a sample of radioactive plasminogen
was added to a crude perfusate and samples were taken
before and after precipitation and of the resuspended PEG
precipitate for counting. Secondly, plasminogen was
determined in the crude perfusate and resuspended PEG
precipitate by Laurell rocket electrophoresis, using
dilutions of normal plasma as standards. The results
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were contradictory; 74.7% of the added I-plasminogen
was precipitated and appeared in the resuspended PEG
precipitate, whereas only 37.3% of the intrinsic plasmin¬
ogen was in the resuspended PEG precipitate.
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When the resuspended PEG precxpxtate containing I-
plasminogen was applied to a hydroxyapatite column, the
plasminogen eluted slightly before the activator at 210mM
phosphate (the activator activity eluted at 235mM phosphate)
125
When I-plasminogen was incorporated in a sample of
crude activator and applied to Sepharose CL-6B the plasmin¬
ogen eluted with a K of 0.43, after the activator" (K. =a d
0.37), indicating a slightly lower molecular weight;
however the elution position indicates a molecular weight
higher than native plasminogen, thus it must be complexed.
The comparison between plasminogen and activator on lysine-
Sepharose has already been discussed in the previous section
I-plasminogen has also been compared with the vascular
activator in its binding to fibrin- and SFP-Sepharose
columns. In both cases plasminogen has a lower affinity
than the activator. Plasminogen elutes at 0.29M lysine
from fibrin-Sepharose, and 0.36M lysine from SFP-Sepharose,
whereas the activator elutes at 0.44M and 0.41M lysine
respectively.
An interesting comparison emerges when binding to
benzamidine-Sepharose is compared. As already stated the
activator elutes from benzamidine-Sepharose at 0.6M lysine
(see Fig 20). In contrast plasminogen (Kabi) elutes at
0.14M lysine, plasmin (Kabi) elutes at 0.82M lysine and
an activator present in melanoma culture supernatent (gift
from Dr G Barlow) eluted in two peaks at 0.30M and 0.62M
lysine. The melanoma activator did not show any binding to
lysine-, fibrin- or SFP-Sepharose.
D DISCUSSION
PEG precipitation has proved to be a very satisfactory
purification step. Apart from reducing the volume of
sample from 3 litres or more to lOQmls, it also appears
to stabilize the activity. Also it gives a very useful
20-fold purification; this compares favourably with the
I
2 to 4-fold purification obtained with ammonium sulphate
precipitation.
The studies on the precipitation of plasminogen by 15%
PEG 400, as stated, were contradictory. However, the more
accurate value is provided by the radioactivity precipitated,
rather than by the Laurell rocket technique. The plasmin¬
ogen, iodinated by the chloramine T method, showed that
74.7% of the counts were precipitated, whereas only 37.3%
of the intrinsic plasminogen antigen in the perfusate
appeared in the resuspended PEG precipitate. The actual
value of plasminogen in the crude perfusate (3500mls) was
49% of that in normal plasma and a value of 320% that of
normal plasma was obtained in the resuspended PEG precipitate
(20Qmls). One explanation for the higher value of the
radiolabelled plasminogen is that the chloramine T iodination
may have damaged the molecule, or induced a conformational
change (possibly by damage) that gave the molecule a higher
affinity for the precipitated fibrin. The figure obtained
for the precipitation of the iodinated plasminogen is
almost exactly twice that obtained for the intrinsic
plasminogen. By coincidence Rakoczi et al (1978) found
the sane ratio for the relative affinity of lys- and glu-
plasminogen for fibrin. However, the actual figures were
8% and 4% respectively.
Another possibility is that some of the plasminogen was
converted to plasmin during iodination, or activated to
plasmin after addition to the perfusate. This ivould tend
to increase the radiolabel precipitated (due to the
higher affinity of plasmin for fibrin) and also decrease
the immunoreactivity towards the anti-plasminogen used in
the Laurell rocket electrophoresis technique. It is worth
noting that while only a fraction of the plasminogen is
precipitated by 15% PEG 400, 100% of the activator is
precipitated. This provides another indication of the
relative affinities of the two for fibrin.
The purification of the activator by PEG precipitation
and then chromatography on Sepharose 6B and Sephadex
G-200 was the shortest purification scheme developed and the
most satisfactory from the point of view of achieving
maximum purification. However, it was less satisfactory
from the point of view of reproducibility. It made use
of a molecular weight change for purification. The
activator, while complexed with high molecular weight
soluble fibrin polymers, eluted at Vq on Sepharose 6B.
When re-run on Sephadex G-200 in a buffer containing 1M
lysine, the contaminating protein still elutes at V
o'
while the activator, dissociated from the SFP's, elutes
in its normal position (0.4-0.5), separated from the
protein. For the purification to work, the activator
ccnplex must elute at V on Sepharose 6B (to enablef o
separation from the protein on dissociation); unfortun¬
ately this is not always so.
The activator is obtained from the cadaver in a complex
with SFP's, and these are subject to degradation. Thus
generally what is seen is a heterogeneous collection of
carrier molecules exhibiting a range of molecular weights.
Trasylol was incorporated into the perfusion fluid, and
later in the column buffers, in an attempt to avoid
proteolytic breakdown of the SFP's by plasmin. This was
partially successful, but produced assay problems. One
further problem encountered was that the maximum sample
size that could be applied to the Sepharose 6B column
used (5 x 80cm) was 50ml. The PEG precipitate could not
always be resuspended in 50ml and sometimes had to be run
as two samples. However, if the method was being used
routinely the column dimensions could be scaled up.
The of the activator purified by this latter method is
slightly lower than the of the activator produced by
the initial purification procedure. This represents a
slightly larger molecular size and could be a result of
the greater stability of the complexed, as opposed to the
free enzyme.
The final purification scheme developed involved a PEG
precipitation and then chromatography on hydroxyapatite,
Sepharose 6B and lysine-Sepharose or fibrin-Sepharose.
One advantage of this scheme was that the samples could
be applied to the subsequent column without prior treatment
this was not the case in the initial purification scheme
(lysine-Sepharose, protamine-Sepharose, Sephadex G-200).
The yields with both methods using dissociation of the
complex as a last step, were superior to the yields of the
initial purification scheme. A value of 20 Ploug u/ml
ivas generally obtained at the peak of the last step of
the improved procedures, and although this was measured
in lysine buffers (an inhibitor - this work) it is still
2-3 times the values obtained by the initial procedure.
The activator showed a higher affinity than plasminogen
to fibrin- and SFP-Sepharose. The activator eluted at
0.44M and 0.41M lysine respectively, whereas plasminogen
eluted at 0.29M and 0.36M lysine respectively. This, as
expected, mirrors the relative affinity of the two for
lysine-Sepharose (activator 0.3M lysine, plasminogen 0.22M
lysine); also as expected the affinity for the lysine
binding site of fibrin is higher than the lysine ligand
which attempts to mimic it.
The results of the binding to 4-amino-benzamidine-Sepharose
are interesting. Holleman et al (1975) reported a
p-aminobenzamidine binding site on plasminogen that was
separate from the lysine binding site. This was considered
not to be an active site, or potential active site inter¬
action, as PNPGB inhibited plasmin behaved identically to
plasminogen when adsorbed to lysine- or p-aminobenzamidine
Sepharose. The p-aminobenzamidine site, presumed to be
an arginine site in vivo, was implicated in the inter¬
action with fibrin.
The results obtained with the binding studies of plasmin¬
ogen, plasmin, vascular activator and melanoma activator
to 4-aminobenzamidine-Sepharose indicate that the arginine
binding site does not play a dominant role in the inter¬
action with fibrin. Of the proteins tested, plasminogen,
plasmin and the vascular activator are known to have a
high affinity for fibrin and all bind to lysine-Sepharose.
However, although plasmin (elutes at 0.82M lysine) and
vascular activator (elutes at 0.6M lysine) bind strongly
to 4-aminobenzamidine-Sepharose, plasminogen (0.14M lysine
is only weakly bound. Conversely, the melanoma activator,
which does not bind to lysine-, fibrin-, or SFP-Sepharose,
binds quite strongly to 4-aminobenzamidine-Sepharose,
eluting in two peaks at 0.3M and 0.6M lysine. Urokinase
is another example that has a low affinity for fibrin,
but binds quite strongly to 4-aminobenzamidine-Sepharose.
Thus it would appear that the lysine binding site is the
controlling influence in the binding to fibrin. A more
likely interpretation of benzamidine binding therefore is
that it does reflect binding at the active site of the
serine proteases (plasmin, vascular activator and melanoma
activator) since plasminogen does not shoiv strong binding.
4 ALTERNATIVE SOURCES OF HUMAN PLASMINOGEN ACTIVATOR
INVESTIGATED
A UMBILICAL CORD
An umbilical cord was obtained fresh from a Caesarian
delivery. The cord was cannulated and one litre of
0.15M NaCl was passed through its length and the effluent
collected. The first 50-lOOml was run through, and then
thrombin was added to the remaining saline to a final
concentration of 5u/ml, which was then also run through
the cord.
The 1 litre of effluent was collected and spun, before
ammonium sulphate was added to 45% saturation; this
was stirred overnight at 4°C to precipitate. The
precipitate was removed by centrifugation and resuspended
in 2Qml 0.15M NaCl. ' Samples were taken for fibrin plate
and folin (protein) assays. The resuspended precipitate
contained 1 Ploug u/ml of activator activity with a
specific activity of 0.5u/mg.
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B MILK
iChil of unheated human milk was de-fatted by centrifugat-
ion, before samples were applied to a normal and plasminogen-
free plate. The milk was active giving a value of 47
Ploug u/ml on the normal fibrin plate, of which 16u/ml was
contributed by a direct proteolytic enzyme rather than an
activator, as evidenced by the plasminogen-free plate.
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C SALIVA
Samples of pooled saliva were centrifuged and separated
into a pellet and supernatent. The pellet was frozen
( -40°C) and thawed twice, suspended in distilled water
and sonicated for 1 minute. Samples of the resuspended
sonicated pellet and the supernatent were applied to a
normal and plasminogen-free fibrin plate.
The supernatents tested gave no lysis on either type of
plate; the treated salivary pellets gave values of
1-5 Ploug u/ml on normal plates and no lysis on plasminogen-
free plates.
D ASCITIC FLUID
Samples of ascitic fluid were tested from 12 patients
with ovarian carcinoma or alcoholic cirrhosis of the
liver. The ascitic fluid and its euglobulin were tested
on normal and plasminogen-free fibrin plates. Very little
( <1 Ploug u/ml) or no activity was found in any of the
samples.
L LUNG
One lobe of human lung was washed free of blood with
saline and then chopped up and homogenized in 250ml of
saline. This was magnetically stirred for 1 hour and
then ammonium thiocyanate was added to a final concentrat¬
ion of 2M, This was stirred for a further 1 hour before
being centrifuged and dialysed against two changes of
saline. The final product contained a heavy precipitate,
which was removed by centrifugation. The supernatent
when tested gave an activity of less than 1 Ploug u/ml
on the normal fibrin plate and no lysis on the plasminogen-
free plate.
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F CULTURED MELANOMA SUPERNATENT
The supernatent of cultured human melanoma cells was the
gift of Dr G Barlow. This was tested on normal and
plasminogen-free fibrin plates. The melanoma activator
was very active giving a value of 150 Ploug u/ml, of
which only 3 Ploug u/ml was due to a direct proteolysis.
A number of experiments were carried out on this activator
which will be described later.
G CRYOPRECIPITATE
22 units of cryoprecipitate were taken, the supernatent
removed and the precipitates added to lOQml 25mM tris,
ImM EDTA, 3.8mM borate, 0.15M NaCl pH8.8 containing
lOu/ml heparin. This was kept at 37°C for half an hour
to solubilize the precipitate. To this was added 15%
PEG 400 and the mixture stirred overnight at 4°C. The
precipitate was removed by centrifugation and redissolved
in 100ml 25mM tris, ImM EDTA, 3.8mM borate, 0.15M NaCl
pH8.8. All the activity was precipitated, as the super¬
natent was inactive, while the resuspended PEG precipitate
gave an activity of 6 Ploug u/ml, giving a total of 600
Ploug units from 22 units of cryoprecipitate.
H INDUCED ACTIVITY IN BLOOD
Three procedures that induce raised levels of the vascular
activator in the blood were investigated. They were
venous occlusion (15 minutes), exercise (15 minutes) and
drug infusion (adrenalin 300pg over 30 minutes or DDAVP
20p.g over 30 minutes) . In each case the plasma and
euglobulin precipitate were tested on normal and plasminogen
free fibrin plates and in each case an increase of activity
over a control plasma sample was noted. However, the
increases were not of sufficient magnitude, bearing in
mind the limitations on sample size, to be of any use for
a source of activator activity for purification.
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DISCUSSION
The majority of the alternative sources of plasminogen
activator investigated gave very little activator activity.
Hov;ever, two sources did give high yields - human milk
(4~ Ploug u/ml) and the melanoma supernatent (150 Ploug
v/r.l) . Unfortunately the amount of human milk that could
be obtained would be very much less than required to
attempt a purification of activator from this source.
The cultured melanoma supernatent xvas a valuable source of
activator activity and many experiments have been carried
out with this activator (which will be reported elsewhere).
However, fundamental differences from the cadaveric vascular
activator render it only useful for comparitive purposes.
Thus the cadaver remained the best source of plasminogen
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1 PHYSICOCHEMICAL STUDIES
A CALIBRATION OF SEPHADEX G-200 AND DETERMINATION OF
STOKES RADIUS ( r ) AND DIFFUSION COEFFICIENT (D)
The Sephadex G-200 column was calibrated with standards of
known Stokes radius ( r ) under identical elution conditionsv s'
that were employed for the last step of the initial
purification procedure. The column (2.5 x 100cm) was run
at 15ml/hour at 4°C in 25mM tris, lmM EDTA, 3.8mM borate,
12 5
1.5M NaCl pH7.5. Three standards were used, I-labelled
albumin, ovalbumin and cytochrome c. The distribution
coefficients (K^) determined for the standards were 0.387,
0.517 and 0.715 respectively. These values of the
were converted to the inverse error function (erfc"^1-K^))
by reference to the "Tables of the Error Function and Its
Derivatives" (1954). The calibration curve shown in Fig
21 was then constructed by plotting the known r~s values
of the standards against the value obtained for erfc-"*"
U-Kd).
The activator purified by the initial purification
procedure (Fig 13) had a K of 0.48 (inverse error
function = 0.500); this gives a value of 2.97nm for the
Stokes radius of the activator by interpolation on the
calibration curve (Fig 21). The diffusion coefficient (D)
for the activator was determined by substitution of the P
s
value into the Stokes-Einstein equation and a value for
D of 7.22 Ficks was obtained.
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FIG 21 CALIBRATION OF SEPHADEX G-200
The Stokes radius of the activator purified from venous
occlusion plasma, which had a of 0.32 (erfc "'"(l-K^ =
0.703), can be read from the calibration curve (Fig 21)
and has a value of 4.08nm. This corresponds to a value
of 5.26 Ficks for D.
The same calibration curve can also be used to determine
r_ for the activator purified by PEG precipitation,
Sepharose 6B and Sephadex G-200 (Fig 15), although the
last step of this was carried out in 0.025M tris-lM lysine
pH7.5. V and V are unaffected by changes in ionic
OS
strength and pH over a wide range, and the properties of
the gel are unaffected by the change in solvent. This
activator had a of 0.42 (erfc(1-K^) = 0.570), which
corresponded to values of 3.35nm and 6.4 Ficks for I" and
D respectively.
B DETERMINATION OF SEDIMENTATION COEFFICIENT
Linear sucrose density gradients, over the range 6% -
307 "/v, were made up in 25mM tris , ImM EDTA, 3. 8mM borate,
1.5M NaCl pH7.5. Three 6ml gradients were set up in
12 x 70mm polycarbonate tubes, and allowed to diffuse
at room temperature for approximately 4 hours
The samples were layered on the surface of the gradient.
Gradients 1 and 2 (Figs 22 and 23 respectively) contained
1
20pi ^I-albunin (lOmg/ml), lOOjul cytochrome c (lOmg/ml)
and lOOpl of an activator preparation. Gradient 1 con¬
tained an activator sample from the high-affinity peak
shown in Fig 11, while Gradient 2 contained an activator
sample from Fig 13. Gradient 3 (Fig 24) contained 20pl
125
"I-albumin (lOmg/ml) and 20Opl ovalbumin (lOmg/ml).
The gradients were centrifuged at 4°C and 200,000g for
20 hours, then fractionated and assayed for radioactivity
protein (folin assay) and activator activity.
The distances sedimented from the origin were measured
from the graphs (Figs 22-24) and plotted against the known
S°„„ values of the standards, to construct a standard2 O, w
curve (Fig 25). From this curve an S°0_ value of 4.40v ^ ' 20,w
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FIG 25 CALIBRATION OF SUCROSE DENSITY
GRADIENTS WITH STANDARDS OF KNOWN S$0iW
C CALCULATION OF MOLECULAR WEIGHT AND FRICTIONAL RATIO
The molecular weight was calculated from the sedimentation
and diffusion coefficients by the Svedberg equation. A
value of 54,545 was determined for the molecular weight
of the plasminogen activator shown in Fig 13, and a value
of 1.18 was calculated for the frictional ratio ("*Vfo)«
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D DISCUSSION
The physical data determined for the vascular plasminogen
activator purified by the initial purification method
(Figs 11-13) is shown in Table 8. The accuracy of the
determined l"s value is dependant on the elution position
of the molecule in question and the accuracy of the T
values of the standards. Ideally the molecule whose rg
value is to be determined should elute with a Kd as near
to 0.5 as possible. Various gels of different pore size
can be used to achieve this. The Sephadex G-200 column
was ideal for the activator which eluted with a Kd of
0.48.
The molecular weight of the activator purified by the
initial purification scheme (Figs 11-13) was determined
to be 54,545. An accurate estimate of the molecular
weights of the activator in the improved purification
scheme (Figs 14 and 15) and the venous occlusion activator
could not be made as the sedimentation coefficients of
these activators were not determined. However, as accurate
diffusion coefficients were calculated for these activators,
a rough estimate of molecular weight can be made using the
S°0(_, value determined for the activator in Fig 13. This20, w ^
gives molecular weights of 61,500 for the activator
produced by the improved purification scheme (Figs 14 and
15) and approximately 75,000 for the activator produced
by venous occlusion.
Stokes Radius (r ) nmv s' 2.97
Diffusion Coefficient (D° ~ ) Fick'sv 20,w' 7.22
Sedimentation Coefficient (S0^ w) Svedberg's 4.40
Molecular Weight (Mr) 54,545
Frictional Ratio (^/f0) 1.18
TABLE 8 PHYSICAL PROPERTIES OF THE VASCULAR PLASMINOGEN
ACTIVATOR
The frictional ratio of 1.18 calculated for the activator
shows that the molecule is of compact shape. Globular
proteins generally have values up to about 1.3; values
greater than 1.3 cannot be accounted for by hydration and
indicate asymmetry of the molecule.
In the range of sucrose concentrations used to determine
the sedimentation coefficient, the viscosity increases
in an almost linear manner; only at higher concentrations
does the viscosity increase become significantly non¬
linear. S°0„ refers to the sedimentation coefficient20, w
corrected for density and viscosity to water at 20°C.
The method used is self-correcting for temperature deviat¬
ions from 20°C. This means that the determination of the
sedimentation coefficient at 4°C by comparison with
standards of known S°„~ , also run at 4°C, gives S°__20,w' ' 20,w
directly. Also temperature differences within the gradient
have no effect on the results obtained; the accuracy of the
results are dependant mainly on the accuracy of the S°w
values of the standards.
2 ELECTROPHORETIC STUDIES
A POLYACRYLAMIDE ELECTROPHORESIS
Polyaerylamide gradient gels, of 4-30% acrylamide, were
used to investigate many activator preparations, both pure
and impure.
The samples to be run were concentrated (if necessary)
firstly by ultrafiltration under pressure and then by
using Minicon A25 concentrators (Amicon). Using these
the samples could be reduced in volume to 25pl or less.
To this was added 10pl of a bromophenol blue/sucrose
mixture, before the sample was applied to the gel. The
bromophenol blue acts as a marker enabling visualisation
of the movement of the leading edge during electrophoresis ,
and the sucrose is to increase the density of the sample
to avoid mixing with the tank buffer.
The gels were normally run at lOO volts (although 50 volts
and 75 volts were also used). The buffer was circulated
through a cooling tank at 4°C„
After electrophoresis the gels were placed in distilled
water for half an hour to remove the buffer salts . They
were then sliced into two equal halves (front - back);
one half could then be stained for protein while the other
half was assayed for activator activity. The stain used
was 0.04% Coomassie blue G-250 in 3% HCIO^. The activator
activity was assayed in a number of ways. Firstly the gel
was simply overlayed with fibrin (the same reagents were
used as for the fibrin plate), incubated at 37°C, and lysis
visualised with bromothymol blue dye in 5C% (V/v) methanol.
The activity was also localized by slicing the gel into
30 equal slices (approximately 2.5mm wide) and extracting
the activity by macerating each slice into 0.5ml 0.025M
tris-lM NaCl pH7.5 and freezing and thawing. The extracts
were then screened on fibrin plates (see Fig 26a). Finally
a radiolabelled sample of activator was run, the gel was
cut into 15 equal slices (approximately 5mm wide) and each
slice counted for iodine-125 (see Fig 26b).
The purest samples always showed no detectable protein
bands on staining, but still had biological activity.
The activator activity was not sharply localized, but was
usually smeared from the point of application down through
the gel. Fig 26a shows the result of a fibrin plate screen
of activator extracted from 30 slices of a polyacrylamide
gel; as can be seen all the activity is in the first 5
slices from the point of application.
Fig 26b shows the ^-count of 15 slices of a polyacrylamide
gel after an iodinated activator sample had been run.
Again most of the counts appeared in the first two slices
from the point of application, but also a small peak appears
at slice number 11. This could represent labelled activator
but also could be a labelled impurity, such as albumin.
Slicenumber
FIG26SCREENINGOFL CEDPOLYACRYLAMIDEG S
At .first the reason for the majority of the activity
remaining at or near the point of application was thought
to be aggregation. It was only later when it was realised
that the activator was obtained complexed with soluble
fibrin polymers that it was clear that this could also
explain the activator's behaviour on polyacrylamide gel
electrophoresis. It would only require a trace of soluble
fibrin to recombine with the activator when lysine was
removed to reform an activator complex of high molecular
weight and account for its slow mobility in the gel.
Furthermore, if the activator was combined with soluble
fibrin polymers (SFP), the heterogeneity of the activator,
due to the breakdown of the carrier fibrin polymers, would
account for the smearing of activity observed when the
gel was overlayed with fibrin.
B CELLULOSE ACETATE ELECTROPHORESIS
Cellulose acetate electrophoresis was used to investigate
the mobility of the activator.
Concentrated crude perfusates and an iodinated activator
sample with plasma added were run, and in every case the
fibrinolytic activity and ^-counts were located at the
origin. Originally this was thought to indicate
mobility of the activator; however this could also be
explained by the activator existing in a complex with
soluble fibrin. This would certainly be the case with the
crude perfusate samples, thus the limited porosity of
cellulose acetate and the slow electrophoretic migration
of fibrin(ogen) would combine to give ^-mobility.
C AGAROSE GEL ELECTROPHORESIS
Electrophoresis of the activator was carried out in 1%
agarose gels.
Duplicate samples were run to allow, after division of the
gel, staining for protein as well as fibrin overlay for
location of activator activity. Fibrin overlay revealed
the activator activity was again at the origin.
D DISCUSSION
Originally it was thought that the ^-mobility determined
for the activator was a true observation as mobility was
the same whether the substrate was cellulose or agarose,
and in 0.5M tris as well as 0.025M tris. However when
it was appreciated that the activator was being obtained
as a complex with soluble fibrin polymers, the electro-
phoretic behaviour of the activator became explicable.
The heterogeneity and inability to sharply localize the
activator activity was directly attributable to the break¬
down profile of the carrier fibrin polymers , giving the
activator activity a wide range of molecular weights on
polyacrylamide electrophoresis. The high molecular weight
complexes could also be responsible for the apparent
mobility on cellulose acetate and agarose gel electrophores
3 BEHAVIOUR WITH VARIOUS CHROMOGENIC SUBSTRATES
Synthetic chromogenic substrates are a series of tri- and
tetra-peptide structures terminated in a p-nitroanilide
(pNA) group (see Table 9). The synthetic substrates, to
some extent, mimic the susceptible bond(s) in the natural
substrates of a range of enzymes. The enzyme cleaves the
synthetic substrate releasing the pNA group giving rise to
a change in optical density at 405nm.
Various synthetic chromogenic substrates have been invest¬
igated for use as an assay system for the vascular plasmin¬
ogen activator. The method for the determination of
activity is based on the difference in optical density
between the pNA formed and the original substrate. The
rate of pNA formation, measured by the increase in optical
density per second at 405nm, is proportional to the
enzymatic activity. •
Fig 27 compares the activity of a sample of activator on
various chromogenic substrates. The activator sample used
in this comparison was a resuspended PEG precipitate
purified on lysine-Sepharose; it had an activity of 50
Ploug u/ml of which approximately 5 Ploug u/ml were later
found to be due to plasmin contamination. This sample
is also contaminated by a non-specific enzyme activity
which cleaves most of the synthetic substrates tested,
even in the presence of lOmM DFP. However this activity
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FIG27ACTIVITYOFRESUSPENDEDPEGREC ITATE ONVARIOUSCHROM GENICSUBSTRATES
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Thus at first glance at Fig 27 it would appear that S-2251
(plasmin substrate) and S-2302 (kallikrein substrate) were
the best substrates for the vascular activator. However
S-2251 was used at 3mM, whereas the other substrates were
used at 1 or 2mM and also when the activator sample was
tested on normal and plasminogen-free fibrin plates it
was found to be contaminated with plasmin. When the
reaction was set up again containing the plasmin inhibitor
Trasylol at a final concentration of 100 kiu/ml the
change in optical density in 3 minutes with S-2251 was the
lowest obtained with any of the substrates tested. (Trasylol
does not inhibit the activity of the vascular activator on
synthetic substrates - see next Section.) So the large
change in optical density was due to the trace plasmin
contamination which has a very high activity towards
S-2251.
The high change in optical density obtained with S-2302,
although only used at ImM, can largely be attributed to the
uncharacterized non-specific activity present in many of
the activator samples tested. Reference to Table lO shows
that S-2302 is particularly susceptible to this activity.
The same observation can be made for S-2238 (thrombin
substrate), although the change in optical density is much
smaller. This leaves S-2444, S-2322 and S-2227, all
urokinase substrates, as the best for the vascular activator.
Table 10 compares the activity of a resuspended PEG






































TABLE10ACTIVITYOFRESUSPENDEDPEGRECIPITATEW THV RIOUSCHROM NICSUB TRA ES (WITHANDITHOUTlOmMDFP)
w H
In
plate) on various synthetic chromogenic substrates. The
non-specific activity appears to be resistant to DFP at
lOmM (1 hour at RT) . Thus by comparing the change in
optical density, with and without 10mM DFP, the relative
activity of the vascular activator (sensitive to lQmM DFP)
for the various substrates can be ascertained. As already
stated S-2302, S-2251 and S-2238 have low specificity for
the activator as shown by only 30.7%, 39.5% and 49.4%
respectively of the activity being inhibited by lQmM DFP.
Whereas over 88% and nearly 75% of the cleavage obtained
with S-2322 and S-2444 respectively, is due to a DFP
inhibitable activity, that is probably largely, if not
entirely, represented by the vascular activator.
This non-specific activity was first encountered when
attempting to quench the activity of various plasminogen
activators with a range of antisera, and measuring the
residual activity oh chromogenic substrates. Rather than
quenching the activity, the antisera-treated activators
had far greater optical density changes than controls that
had not been treated with antisera. This activity was
still present when IgG fractions were prepared by protein
A affinity chromatography. The activity was also present
in normal human serum and rabbit serum and was only partia
inhibited by lOmM or 20mM DFP either after 1 hour or
overnight incubations. However, 1-li hour incubation at
56°C removed nearly all the activity from both normal
human serum and IgG fractions of antisera. By contrast
very little of this uncharacterized activity was present
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in normal human plasma.
An attempt was made to screen the fractions of column
eluates using chromogenic substrates. Hoxvever this was
largely unsuccessful due to the presence of non-specific
activities. The fractions obtained on elution of a
resuspended PEG precipitate from hydroxyapatite were
screened with S-2444 and two peaks of activity were
obtained. One broad peak that did not bind and one
smaller peak that overlapped the vascular activator as
judged by a fibrin plate screen. A similar result was
obtained when S-2444 was used to screen a lysine-Sepharose
elution; in this case the sample was activator remaining
in the supernatent after fibrin formation (from added
fibrinogen and thrombin) in a resuspended PEG precipitate.
The peak: that did not bind could be due to the added thrombin.
When the fractions from the hydroxyapatite run (above)
were further purified on lysine-Sepharose, the fractions
were screened with S-2322. Only one peak of activity was
obtained and this did not bind to lysine-Sepharose.
However the activity of the vascular activator was low (as
judged by a fibrin plate screen) and was possibly too low
to be detected by S-2322 with the incubation time used.
Thus it would appear that for the synthetic chromogenic
substances to be of use in screening fractions of column
eluates the non-specific enzymatic activities must firstly
be identified and secondly specific inhibitors be incor¬
porated into the assays. So far none have been found to
be entirely satisfactory.
4 INHIBITION STUDIES
A USING THE FIBRIN PLATE
The vascular activator has been further characterized by
treatment with a range of inhibitors. Both purified and
crude activator samples (after excluding plasmin con¬
tamination on a plasminogen-free fibrin plate) have been
investigated, and the results obtained are the same.
When purified samples of activator were used, 2jil of
inhibitor were added to 0.2ml of sample. Whereas when
crude samples of activator were used, generally resuspended
PEG precipitates, the volumes used were scaled up, making
dialysis easier. In these cases lOOpl of the inhibitor
was added to 0.9ml sample and this was incubated for 18
hours at 4°C. Then Tween 20 vvas added to a final con¬
centration of 0.1% and the mixture dialysed at RT for 6
hours, against 2 (x 5 litre) changes of 25mM tris , ImM
EDTA, 3.8mM borate, 0.15M NaCl pH8.8. In some cases a
longer period of dialysis was required and this was
against further changes of the same buffer .
Precipitation problems were encountered with some of the
inhibitors using dimethylsulphoxide (DMSO) as solvent.
These were set up again using 0.5ml sample and 5pl of
a more concentrated inhibitor solution. The same incubat¬
ion and dialysis conditions were used.
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After dialysis, the mixtures and urokinase standards were
screened on fibrin plates, incubated for 20 hours at 37°C.
Solvent controls of distilled water and DMSO were set up
and treated in exactly the same way as the tests, to correct
for any non-specific effects.










Val-Pro-Arg CH2C1 O.lmM 6 98
Trasylol lOOkiu/ml 6 92
30 53
54 4
*SBTI lOug/ml 6 32
30 29
54 25
EACA lQmM 6 11
30 16
L-Lysine lOmM 6 16
30 O
L-Arginine lOmM 6 O
DFP lOmM 6 98
PMSF lOmM 6 87
ImM 6 22
DTT lOmM 6 80
TPCK lOmM 6 34
ImM 6 O
TLCK lOmM 6 3
ImM 6 O
I'odoac etamide lOmM 6 O
*PNPGB lOmM 6 30-100
ImM 6 70-100
See text for explanation of values obtained.
TABLE 11 PERCENTAGE INHIBITION OF THE VASCULAR
ACTIVATOR ASSAYED ON THE FIBRIN PLATE
B USING CHROMOGENIC SUBSTRATES
To obtain a meaningful inhibition profile of vascular
activator with synthetic chromogenic substrates the sample
of activator used must be free of any non-specific
activities which are likely to cleave the substrate and
also be affected by the inhibitors. For most of the
studies S-2322 was used; however S-2444 was used with the
melanoma activator.
The inhibitor was added to the sample and incubated at
37°C. At 30 minute intervals 50pl of this reaction
mixture was removed and added to 50pl buffer and lOOpl
chromogenic substrate (also at 37°C). Approximately
150pl of this was transferred to a micro cuvette in a
thermostatted cell (37°C) and the change in optical
density at 405nm recorded at regular time intervals.
The inhibition obtained after half an hour, one hour, one
and a half hours and two hours incubation altered very
little.
Inhibition of the vascular activator is shown in Figs 28
and 29. Inhibition of urokinase (Figs 30 and 31) and the
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C DISCUSSION
Strong inhibition of the vascular activator was obtained
on the fibrin plate with the synthetic inhibitor Val-Pro-
Arg-CH^Cl (gift from Dr Shaw), with the serine protease
inhibitors DFP and PMSF and also with the disulphide bond
reducing agent DTT.
Strong inhibition (92%) was found with Trasylol after 6
hours dialysis; however this was reduced to 53% after
30 hours and 4% after 54 hours dialysis. Trasylol is
very slow to dialyse due to its molecular weight (6,500);
the molecular weight cut off point of the dialysis tubing
is in the region of 14,000. The apparent inhibition seen
initially is mediated through Trasylol's inhibition of
the plasmin formed in the fibrin plate. The same situation
occurs with SBTI, which is also a plasmin inhibitor. The
molecular weight of SBTI is 24,000 and thus is non-
dialysable.
A modest inhibition is seen with EACA which appears to
increase slightly on further dialysis. If this sample
was applied to a fibrin plate, prior to dialysis, then
considerable inhibition would result. Some activity may
still be measurable as the EACA (molecular weight 131.18)
diffuses through the fibrin plate more quickly than the
vascular activator (molecular weight 54,500) and this
tends to lower its local concentration. However if EACA
is incorporated into the fibrin plate at lOmM, then total
inhibition is seen, of all but the most active samples.
Trans-AMCHA gives the same inhibition at a lO-fold lower
concentration. EACA affects the components of the
fibrinolytic system in a number of ways. It can induce a
conformational change in the native plasminogen molecule
that causes it to be more easily activated to plasmin.
It is also involved in the interactions of plasminogen and
the vascular activator with fibrin, which are mediated
through the lysine binding sites. L-lysine exerts a
similar effect, although EACA is effective at a lower
concentration. The slight inhibition seen with L-lysine
after 6 hours dialysis, is abolished after further
dialysis. However this does have implications for the
screening of column fractions, when the elution gradient
is of L-lysine and the fractions are screened on fibrin
plates without dialysis. No inhibition was seen with
L-ar ginine.
TLCK, a trypsin inhibitor that also inhibits plasmin,
gave no inhibition at ImM and only 3% at lOmM. However,
TPCK, a chymotrypsin inhibitor, although giving no inhibit¬
ion at ImM gave 34% inhibition at lOmM; the significance
of this remains unclear. Precipitation problems were
encountered with some of the DMSO-soluble inhibitors,
TPCK was one of these; another was PNPGB (plasmin active
site titrant). The results with PNPGB were very variable.
lQmM PNPGB gave 30-100% inhibition and ImM gave 70-100%
inhibition, but an immediate yellow colour and a heavy
precipitate ivere always obtained, and the inhibition
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observed could be due to precipitation of activator
activity rather than inhibition.
Most importantly, no inhibition was seen with lOmM
iodoacetamide xvhich clearly distinguishes the vascular
activator from urokinase, which is totally susceptible to
iodoacetamide.
The inhibition profile of the vascular activator determined
with S-2322 (Figs 28 and 29) was generally consistent
with that obtained using the fibrin plate, although there
were a few discrepancies. Strong inhibition was again
obtained with the synthetic inhibitor (Val-Pro-Arg-CH^Cl),
DFP, PMSF and DTT. No inhibition was seen with Trasylol
and only very slight inhibition with SBTI, in both cases
their plasmin-inhibition could not be exercised in this
system. There was no inhibition seen with EACA using
chromogenic substrates, as the lysine binding sites play
no part in the interaction between the vascular activator
and S-2322. As with the fibrin plate screen, the vascular
activator was unaffected by lOmM iodoacetamide and ImM
PNPGB caused considerable inhibition. The discrepancies
involved TLCK and TPCK. TLCK which had shown 0% and 3%
inhibition (at ImM and lOmM respectively) on the fibrin
plate, gave 52% and 76% inhibition respectively, using
chromogenic substrates; and TPCK which at lOmM gave 34%
inhibition using fibrin plates, but gave no inhibition when
used at the same concentration on S-2322. The significance
of these results, if any, is not known, but solvent artefacts
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are a possibility.
The inhibition profile of urokinase (Leo) determined with
S-2322 (Figs 30 and 31) produced some interesting com¬
parisons with the vascular activator„ As with the vascular
activator, Trasylol, EACA and SBTI showed little or no
inhibitory activity. lOmM PMSF and lOmM TLCK gave
considerable inhibition of urokinase, as with the vascular
activator. However, the most interesting differences
involved lOmM iodoacetamide and lOmM DTT. Iodoacetamide
which gave no inhibition of the vascular activator, either
on fibrin plates or with S-2322, gave 96% inhibition of
urokinase; and conversely DTT which gave 80-90% inhibition
of the vascular activator gave no inhibition of urokinase.
The inhibition profile of the melanoma activator determined
with S-2444 (see Fig 32) was similar to the vascular
activator and urokinase in that it showed no inhibition
with Trasylol and strong inhibition with DFP. However,
the melanoma activator was not inhibited by lQmM iodo¬
acetamide which implies a closer relationship with the
vascular activator than with urokinase.
Thus in conclusion the vascular activator is a serine
protease that relies on disulphide bonds to maintain its
tertiary structure for enzymic activity. EACA and lysine
show slight inhibition of the vascular activator on the
fibrin plate due to an interaction with the lysine
binding sites, and no inhibition is seen with iodoacetamide.
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Urokinase does not rely on disulphide bonds for its
activity, and in contrast to the vascular activator and
melanoma activator is inhibited by iodoacetamide.
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5 IMMUNOLOGICAL STUDIES
A INHIBITION OF ACTIVATORS BY VARIOUS ANTISERA
The quenching of a range of activator activities by-
various antisera was investigated. Two substrates were
used to measure residual activity; one was the synthetic
chromogenic substrate S-2444, the other was the fibrin
plate.
The activator and antiserum to be tested were mixed and
incubated for 1 hour at 37°C in a 1:1 ratio. A control
of activator and saline was treated in the same way.
After incubation 50pl of each of the incubation mixtures
was taken and added to 50pl 50mM tris, 38mM NaCl pH8.8
and lOOpl 2mM S-2444 (also at 37°C) . After mixing, 150jal
of this was transferred to a thermostatted (37°C) micro-
cuvette and the change in optical density at 405nm
recorded at regular time intervals. A further 30pl of
each of the incubation mixtures was taken and activity
measured on normal fibrin plates calibrated with Leo
urokinase.
a Using Chromogenic Substrates
In every case where measurement of residual activity was
made on S-2444, the activator-antiserum mixture gave an
increased rate of cleavage over the activator-saline control.
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This was due to a non-specific activity present in the
antisera, which was very active on S-2444 and was not
inhibited by lQmM DFP. In an attempt to remove the non¬
specific activity, IgG fractions of the antisera were
prepared by affinity chromatography on protein A-Sepharose,
but this was unsuccessful. The non-specific activity
was however susceptible to incubation at 56°C for 1 hour
(35% inhibited). The non-specific activity was also present
in normal human serum and was 75%, 92% and 96% inhibited
after half an hour, one hour and one and a half hours
respectively, at 56°C. However, even when the heat-treated
IgG fractions of the antisera were used to quench the
various activator activities, the residual activity, when
measured on S-2444, was still greater than the controls.
Thus the results are not presented.
b Using the Fibrin Plate
The results obtained using the fibrin plate are summarised
in Table 12. Two antisera were raised against partially
purified vascular activator preparations. The first
antiserum (anti-VPA 1) was raised against a perfusate
purified on lysine-Sepharose and Sephadex G-200, and the
second antiserum (anti-VPA 2) was raised against a re-
suspended PEG precipitate purified on lysine-Sepharose.
The anti-human urokinase and anti-pig heart tissue activator















































respectively. The pig heart tissue activator (PHTA) was
a gift from Dr E Cole.
The IgG fraction of anti-VPA 1 appears to inhibit a
resuspended PEG precipitate (47%), has no effect on the
melanoma activator and stimulates urokinase activity by
a factor of 2. However, when the IgG fraction of this
antiserum had been heated at 56°C for 1 hour (to remove
the non-specific activity) its inhibitory activity against
a resuspended PEG precipitate (a different sample) was
reduced to 8% and it gave no inhibition of a purified
sample of vascular activator. This fraction gave 14%
inhibition of the melanoma activator and 30% inhibition
of PHTA. Furthermore, it gave 49% inhibition of plasmin.
The IgG fraction of anti-VPA 2 gave some inhibition of all
the activities, except with urokinase when a 5-fold
stimulation was observed. The inhibition of the purified
vascular activator and the resuspended PEG precipitate
(21% and 37% respectively) were lower than the inhibition
of plasmin (41%), the melanoma activator (44%) and PHTA
(46%).
The IgG fraction of anti-urokinase gave 38% inhibition of
urokinase, 27% inhibition of the melanoma activator and
6% inhibition of a resuspended PEG precipitate. Thus the
inhibition did appear to be directed mainly against
urokinase. The anti-PHTA gave complete inhibition of the
melanoma activator, urokinase, a resuspended PEG precipitat
and plasmin.
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B GEL DIFFUSION STUDIES
Four antisera were set up against a range of antigens.
In each case the IgG fraction of the antiserum was used.
The IgG fraction of anti-VPA 1 gave strong reactions
with normal human serum, normal human plasma, a resuspended
PEG precipitate, ascitic fluid, plasminogen and plasmin,
but gave no cross-reaction with the melanoma activator,
urokinase, PHTA, rabbit serum or the buffer control.
The IgG fraction of anti-VPA 2 gave similar results.
The IgG fraction of anti-PHTA only reacted with PHTA and
gave no cross-reaction with human serum, a resuspended
PEG precipitate, the melanoma activator, urokinase or
plasmin. The IgG fraction of anti-urokinase did not give
a precipitation reaction with any of the antigens tested,
including urokinase.
C DISCUSSION
Partially purified preparations, rather than the most pure
samples, were used to raise antisera against the vascular
activator. This was because the amounts of activator
present in the purest preparations xvere thought to be
insufficient for the raising of antisera. Thus it is not
surprising that the antisera do not appear to be very
specific.
From the gel diffusion results it can be seen that the
anti-VPA antisera raised give precipitation reactions with
a number of components in normal human plasma, normal
human serum and ascitic fluid as well as with resuspended
PEG precipitates. Anti-VPA 2 clearly reacts with two
antigens in a partially purified sample of vascular
activator. Both antisera cross-react with plasmin(ogen)
and are quite likely to recognise fibrin(ogen), as this
certainly would have been a contaminant in the samples
used to raise the second batch of antiserum, and possibly
also the first.
The most likely antigens that are being recognised in the
ascitic fluid are fibrin(ogen), the degradation products
(FDP's) and plasmin(ogen)„ No plasminogen activator
activity was found in any of the ascitic fluids tested on
fibrin plates. It is presumably these same antigens,
among others, that are recognised in normal human serum,
normal human plasma and the resuspended PEG precipitates.
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However, no cross-reaction was noted with the melanoma
activator, urokinase or PHTA.
The IgG fraction of anti-VPA 1 gives 47% inhibition of the
activity of a resuspended PEG precipitate, xvhile giving no
inhibition of the melanoma activator. The reaction between
the antiserum fraction and the resuspended PEG precipitate
was accompanied by an immediate precipitation. Thus, the
inhibition seen could at least partly be explained by
precipitation of fibrin, either immunologically or other¬
wise, and the associated precipitation of activator activity
due to its affinity for fibrin.
When the IgG fraction of anti-VPA 1 was incubated at 56°C
for 1 hour (to inactivate the non-specific S-2444 activity)
and then re-tested on fibrin plates with the activators,
some changes occurred. 14% inhibition of the melanoma
activator appeared (Table 12), and the inhibition of a
resuspended PEG precipitate dropped from 47% to 8%.
Hoxvever this was a different resuspended PEG precipitate,
and if the inhibition was due to precipitation of fibrin,
it could be that less was present in this particular
sample. Alternatively, an unknown thermolabile protease
inhibitor could have been responsible for the effect.
Hoxvever, this fraction still gave inhibition of PHTA (30%)
and plasmin (49%).
The IgG fraction of anti-VPA 2 gave inhibition of the
melanoma activator (44%) and PHTA (46%). This was unexpected
as no cross-reaction with these antigens was noted when
run in gel diffusion. However, the concentrations of
the antigens nay have been too low to detect a reaction.
This fraction gave 37% and 21% inhibition of a resuspended
PEG precipitate and a partially purified sample of vascular
activator respectively. However this antiserum, as did
the first raised, quenched the activity of plasmin, and
this raises the possibility that any quenching of the
activator activities, as Judged by the fibrin plate, may
be due to inhibition of formed plasmin.
The IgG fractions of both anti-VPA antisera produced a
stimulation of the activity associated with urokinase.
There was a two-fold increase with anti-VPA 1 and a five¬
fold increase with anti-VPA 2. This is difficult to explain
but could be due to the conversion of urokinase to a
more active form by a factor present in the IgG fraction.
However if this was the case, the agent is most likely to
be an enzyme, and the enhancing effect is still present
after incubation at 56°C for one hour. Other possibilities
include the presence of a cofactor in the IgG fraction or
that urokinase may activate a proactivator. As can be seen
from the foregoing discussion the vascular activator
antiserum inhibition studies are presently unsatisfactory.
The anti-PHTA gave 100% inhibition of the melanoma activator
urokinase, a resuspended PEG precipitate and plasmin when
assayed on a fibrin plate. However the whole antiserum
was used and not an IgG fraction, thus the inhibition
seen is most probably due to a plasmin inhibitor in the
serum acting on the plasmin formed in the fibrin plate.
The IgG fraction gave a precipitation reaction with PHTA
in gel diffusion and no reaction with human serum, a
resuspended PEG precipitate, the melanoma activator,
urokinase or plasmin. This substantiates the idea that
the inhibition seen with the whole antiserum was not
entirely immunological.
The IgG fraction prepared from anti-urokinase inhibits
urokinase 38% (although no precipitation reaction was seen
in gel diffusion), the melanoma activator 27% and the
activity of a resuspended PEG precipitate 6%. These
values suggest that the melanoma is immunologically more
like urokinase than the vascular activator, which is in
contrast to inhibition with iodoacetamide, which indicated
a closer relationship between melanoma activator and the
vascular activator than melanoma activator and urokinase.
6 RADIOACTIVE LABELLING OF THE ACTIVATOR
A IODINATION
Three different methods were used in an attempt to
125
iodinate ( I) the vascular activator. They were the
chloramine T method, succinimide ester iodination, and
the double enzyme method using lactoperoxidase and glucose
oxidase. The activator preparations that were initially
used for iodination were purified on lysine-Sepharose,
protamine-Sepharose and Sephadex G-200. However later
resuspended PEG precipitates, purified on lysine-Sepharose
were used as a source of partially purified vascular
activator. The preparations after labelling were run on
Sephadex G-25 to separate labelled protein, which elutes
at V , from uncoupled radioactivity.
The labelled preparations were run in the chromatographic
systems used for purification of the activator. When the
purified activator labelled by the chloramine T method
was added to a crude perfusate and adsorbed to lysine-
Sepharose approximately 30% of the counts were found to
bind and on elution with an exponential lysine gradient
the radioactivity was associated with the low affinity
peak of vascular activator. However, when this was
further purified on protamine-Sepharose, although 75% of
the radioactivity did bind, it eluted at a lower NaCl
concentration than the vascular activator activity, as
judged by fibrin plates. When the partially purified
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vascular activator sample was labelled by the chloramine T
method no binding to lysine- or benzamidine-Sepharose was
observed.
When a purified activator sample was labelled by the
succinimide ester iodination, applied to Sephadex G-200
and eluted in a buffer containing 1.5M NaCl, a large peak '
(75,000cpm) appeared at V , a smaller peak (9,OOOcpm) at
V and two very small peaks (2,000 and l,500cpm) with
values of 0.42 and 0.58 respectively. A partially purified
sample of activator was labelled by the succinimide ester
iodination and then applied to protamine-Sepharose but
no binding was observed. A further partially purified
sample of the activator was labelled by the double enzyme
method (lactoperoxidase/glucose oxidase), but showed no
binding to lysine- or benzamidine-Sepharose.
Kabi plasminogen was iodinated by the three methods
mentioned above as well as by the lactoperoxidase/H^O^
method. The best results, in terms of the binding of
radioactivity to lysine-Sepharose, were obtained with the
chloramine T and double enzyme methods, where •§--•§ of the
radioactivity generally was seen to bind. Kabi plasmin
was also labelled by the double enzyme method. When this
was run on lysine-Sepharose only j of the radioactivity




Partially purified samples of vascular activator were
reacted with both ^H- and "^P-DFP to label the active
site. The conditions of the reaction were varied to
optimise the reaction. Labelled DFP was used alone and
also used in conjunction with cold DFP to increase the
concentration to lOmM. The reaction time was varied from
one hour to overnight and carried out at 4°C, RT as well
as 37°C and at pH7.5. The "labelled" activator was
evaluated by chromatography on lysine-, protamine-,
fibrin-Sepharose, Sepharose 6B and Sephadex G-200.
Generally the "labelled" activator showed no binding to
lysine-, fibrin- or protamine-Sepharose. However on one
occasion, when radioactive DFP alone had been reacted
with the vascular activator at RT for 22 hours, a peak of
radioactivity did bind to lysine-Sepharose which was
associated with the low affinity peak of vascular activator
as determined on fibrin plates. However when this peak
was run on protamine-Sepharose no binding of radioactivity
was observed. When the labelled activator was run on
Sephadex G-200 in a tris buffer containing 1.5M NaCl,
the radioactivity eluted at V . However when run on
o
Sepharose 6B in a tris buffer containing 1M lysine, the
radioactivity eluted at V .
s
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Kabi plasmm was reacted with H-DFP with and without
cold DFP (to a final concentration of lOmM) for either one
hour at 37°C or overnight at RT and then the binding of
radioactivity to lysine-Sepharose was tested. In each
case approximately 99.9% of the radioactivity did not
bind, and a very small peak of about 200cpm was eluted
from lysine-Sepharose with an exponential lysine gradient,
generally in the position occupied by unlabelled plasmin.
C DISCUSSION
The attempts to radiolabel the activator were not very
successful. The most successful method of iodination
was chloramine T; with this method 30% of the radio¬
activity did bind to lysine-Sepharose, when applied in a
crude perfusate, and eluted in the same position as the
low affinity peak of activator activity. This low per¬
centage binding to lysine-Sepharose could be due to
damage of the lysine binding sites on iodination. A
similar proportion of labelled plasminogen was also seen
to bind to lysine-Sepharose, although again the chloramine
T method gave the best results. When the lactoperoxidase/
^2^2 me"th0<3 was use<3 to label Kabi plasminogen no radio¬
activity was adsorbed when applied to lysine-Sepharose,
and when the double enzyme method was used to label Kabi
plasmin 5 of the radioactivity bound, but demonstrated
a lower affinity than unlabelled Kabi plasmin for lysine-
Sepharose. Damaged or modified lysine binding sites could
also explain the lowered affinity, or lack of affinity of
labelled Kabi plasminogen and plasmin for lysine-Sepharose.
When the radioactivity that eluted from lysine-Sepharose
(with the low affinity activator peak) was further purified
on protamine-Sepharose, 75% of the radioactivity did bind
but eluted earlier in the NaCl gradient than the vascular
activator activity. An arginine binding site has been
implicated in the in vivo interaction of plasminogen with
fibrin (Holleman et al, 1975), and may be involved in the
binding of the activator to fibrin. Alternatively
protamine-binding may correlate with benzamidine-binding
which was thought possibly to bind via the active site
(this xvork). Whichever is the case, damage of these
sites could be the cause of the lower affinity of the
activator after labelling. Alternatively the labelled
material may have been an impurity in the original sample
used for iodination.
When activator, labelled by the succinimide ester method,
was run on Sephadex G-200 in a buffer containing 1.5M
NaCl, four peaks of radioactivity ivere obtained at Vq ,
and two with K, values of 0.42 and 0.58. The V peakd o ^
was the largest comprising 86% of the total radioactivity.
This could be due to aggregation or possibly an interaction
of the labelled activator with soluble fibrin polymers,
although the 1.5M NaCl in the buffer should have broken
this association, unless the labelled activator has a
higher affinity for fibrin than the native enzyme. The
Vg peak (10% of the total radioactivity) may be due to
'free' activator interacting with the gel matrix. One of
the two peaks with values of 0.42 and 0.58 could represent
labelled activator with the other being a labelled impurity
or both could be activator, with one species being degraded.
However each peak only represents approximately 2% of the
total radioactivity and would not be very useful for further
experiments. Another activator sample labelled by the
succinimide ester method showed no binding to protamine-
Sepharose. The final method of labelling employed, the
double enzyme method, abolished binding to lysine-Sepharose
and benzamidine-Sepharose.
Other reasons for the lack of success in iodinating the
activator include the low amounts of the activator
present in the samples used and possibly also the absence
of aromatic residues in the activator.
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Only one sample of activator labelled with H-DFP showed
any binding to lysine-Sepharose, when applied in a crude
perfusate, and again as with the iodinated material, it
was associated with the low affinity peak of vascular
activator activity. However, when this radioactivity
was run on protamine-Sepharose no binding was observed.
But, if protamine-binding is via the active site it
would be expected that DFP would abolish this binding.
When a DFP-labelled sample of activator was run on
Sephadex G-200 in a buffer containing 1.5M NaCl, the
radioactivity eluted at V . Again any interaction between
soluble fibrin polymers and the activator should be
abolished by 1.5M NaCl, unless the DFP-labelled activator
has an increased affinity for soluble fibrin. In contrast,
when samples were run on Sepharose 6B in a buffer containing
1M lysine, the radioactivity eluted at V . The 1M lysine
may overcome any association of the labelled activator
with soluble fibrin polymers, but not with the gel matrix.
If it is assumed that interaction with DFP does not interfer
248
with the lysine binding sites then the poor binding of
radioactivity to lysine-Sepharose of DFP-labelled plasmin,
when O.Smg of pure Kabi plasmin is used, makes the chances
of success with the vascular activator very small indeed.
However, the activity of the activator sample can be seen
to be inhibited by the DFP and thus some radioactivity
must be incorporated into the active site. It is, of
course, quite possible that binding of DFP to the active
site does in some way interfere with binding to lysine-
Sepharose.
Fluorescent dansyl fluoride was also used in an attempt
to label the active site of the vascular activator, but
no binding of fluorescent activator to lysine- or fibrin-
Sepharose was observed. The reasons for lack of success
with dansyl fluoride would be the same as with the
iodinations and DFP labelling.
CHAPTER 4
INTERACTIONS OP HUMAN VASCULAR PLASMINOGEN
ACTIVATOR WITH FIBRIN; AND ITS COMPARISON WITH
ACTIVATORS FROM DIFFERENT SOURCES







2 INTERACTION OF VARIOUS ACTIVATORS WITH FIBRIN
A AFFINITY OF VARIOUS ACTIVATORS FOR SOLUBLE
FIBRIN POLYMERS
B AFFINITY OF VARIOUS ACTIVATORS FOR FIBRIN
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i PRODUCTION AND PROPERTIES OF SOLUBLE FIBRIN POLYMERS
A THEORY
The action of thrombin on fibrinogen produces fibrin
monomer by removal of fibrinopeptides A and B (see Fig 33)
Fibrin monomer has two polymerization sites , and under
the action of factor XIII (gift from Dr J Holbrook) in
the presence of calcium ions, will form insoluble fibrin.
However, when fibrinogen is digested by plasmin it
produces the characteristic fragments X, Y, D and E.
Fragments Y and D are both polymer chain terminators as
they only possess one polymerization site.
By varying the digestion time of fibrinogen by plasmin,
it is possible to vary the ratio of Y and D fragments to
unchanged fibrinogen and X fragment. If the ratio of
fibrinogen and fragment X to fragments Y and D (F:Y) is
1:1 then on average a polymer consisting of 4 fragments
(Y-F-F-Y) will be produced on addition of thrombin. If
the ratio is 2:1 then Y-F-F-F-F-Y will be produced, and
so on. Thus the length of polymer produced is related
to the digestion time employed.
The desired digestion time can be determined either by a
clottability trial or by monitoring the change in optical
density at 320nm of the digestion mixture. The clottabili
trial was carried out by setting up the digestion mixture











D'SOLUBLE FIBRIN POLYMER (SFP)
FIG33THEORYOFPRODUCTIONS LUBLEFIBRINPOLYMERS
plasminogen associated with the fibrinogen). 0.1ml
samples of this were removed at half minute intervals,
which were added to a mixture of thrombin, EACA and
Trasylol at final concentrations of 5u/ml, lOmM and
1000 kiu/ml respectively. The desired digestion time was
the one that rendered the fibrinogen just non-clottable.
Alternatively, a sample of the digestion mixture can be
transferred to a cuvette, in a thermostatted cell (37°C),
and the optical density change at 320nm recorded at half
minute intervals. As the fibrinogen is degraded, the
light scattering effect of the high molecular weight
molecule diminishes, which is accompanied by a decrease
in optical density at 320nm. This decrease flattens off
to a plateau when the fibrinogen molecule is completely
broken down, thus the desired digestion time can be taken
from a point just prior to the plateau portion of the
graph.
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Radioactive fibrinogen labelled with iodine may be
included in the digestion mixture, or alternatively may
be added at the end of the digestion, prior to addition
of thrombin and cross-linking.
B METHODOLOGY
The soluble fibrin polymers (SFPs) are produced according
to the scheme below:
Digestion 45ml 1% (w/ ) FibrinogenV'
5ml Urokinase (lOO Ploug u/ml)














Incubate at 37 C
for 30 minutes
The mixture, after 30 minutes at 37 C, is then centrifuged
to remove any insoluble fibrin that may have formed, and
can then be applied to a Sepharose 6B or 4B column to
separate the high molecular weight polymers from degradat¬
ion products.
C CHROMATOGRAPHIC BEHAVIOUR
The mixture obtained at the end of the polymerization
incubation was centrifuged, glucose added as a Vg marker,
and the sample applied to Sepharose 6B (5 x 80cm). This
was eluted at 4°C with 25mM tris, ImM EDTA, 3. 8mM borate,
O.lsM NaCl, pH8.8 containing Trasylol at lOkiu/ml (see
Fig 34). 30ml fractions were collected at 125ml/hour.
The molecular weight of the SFP's can also be determined
on Sepharose 4B. Fig 35 shows the results when a sample
of the Vq peak, obtained on Sepharose 6B, is applied to
Sepharose 4B (2.5 x 100cm) and eluted at 4°C with 25mM
tris, ImM EDTA, 3.8mM borate, 0.15M NaCl pH8.8 containing
Trasylol at lOkiu/ml. 8ml fractions were collected at
35ml/hour.
Samples of SFP's obtained as Vq peaks from Sepharose 6B
were applied to hydroxyapatite and lysine-Sepharose
chromatography columns, to determine their behaviour
on chromatographic systems used in the purification of
the vascular activator. The elution of an SFP sample
from a hydroxyapatite column (2.5 x 10cm) is shown in
Fig 36. The SFP's were eluted with an exponential
phosphate. (Na2HP0^) gradient from 5-500inM at pH7. 8ml
fractions were collected at 80ml/hour. The SFP's eluted
in one peak at 200mM phosphate.










Sepharose (2.5 x 15cm) with an exponential gradient of
0-1M lysine in 0.025M tris (pH7.5) at 4°C. 7ml fractions
were collected at 30ml/hour. One peak of SFP's did not
bind while the other eluted at 0.1M lysine.
A Staphylococcus aureus clumping test (see Methods Section)
for fibrin(ogen) related molecules was carried out on
the peak obtained on hydroxyapatite chromatography and the
two peaks obtained on lysine-Sepharose chromatography,
and all gave positive reactions.
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D ELECTROPHORETIC BEHAVIOUR
Unreduced and reduced (with {3-mercaptoethanol) samples
of SFP's from the peaks of Sepharose 6B and 4B were
run on SDS-polyacrylamide gel electrophoresis. The
unreduced samples were run on 5% polyacrylamide gels
along with a sample of X, Y, D and E fragments, produced
by plasmin digestion of fibrinogen. The reduced samples
were run on 7% polyacrylamide gels along with a reduced
sample of Kabi fibrinogen.
The high molecular weight material was mostly of molecular
weight greater than fragment X and fibrinogen, and there
was a trace of fragments Y and D present. The chain
data from the reduced samples suggested X and Y like
material cross-linked mainly by ^ chains to form ^ dimers,
as there was barely any oc-polymers in the high molecular
weight region of the gel. Thus it appears that the
polymers were largely devoid of intact oc chains and
were ^ chain cross-linked X fragments, terminated by
incorporation of Y and D fragments into the polymer.
E DISCUSSION
The production of SFP's was quite a short and simple
process and reproducible if all the conditions were kept
constant. One problem encountered was the lability of
stock solutions of urokinase, even when stored at -40°C;
this was overcome by storing the urokinase in liquid
nitrogen at -196°C.
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As mentioned earlier, I-fibrinogen can be incorporated
into the SFP's. If the radiolabelled fibrinogen is added
at the start of the digestion with plasmin, the radio¬
activity follows the protein profile when run on Sepharose
6B. However if the radiolabelled fibrinogen is added
at, or near, the end of the digestion, the majority of
the radioactivity is incorporated into the Vq peak on
Sepharose 6B (see Fig 34).
A good yield of high molecular weight SFP's is generally
obtained from a digest, but all subsequent operations
after polymerization and cross-linking must be carried
out in Trasylol at lOkiu/ml. If this is not done the
polymers are prone to degradation.
All the SFP's bound to the hydroxyapatite column, and
eluted in one peak at 200mM phosphate. This is within
the range reported for the elution of the vascular
activator from hydroxyapatite, and suggests that the
binding of the activator to hydroxyapatite is through
soluble fibrin.
The SFP's were divided into a non-binding and a bound
peak on lysine-Sepharose, although this could merely be
due to overloading of sample on the column. Again the
bound peak eluted at a value (0.1M lysine) close to the
value reported for the elution of the low affinity peak
of the activator from lysine-Sepharose, and supports the
hypothesis that the low affinity peak of vascular activator
on lysine-Sepharose is indeed a soluble fibrin-activator
complex.
As already stated both peaks obtained on lysine-Sepharose
gave a positive Staphylococcus aureus clumping test, and
both peaks when re-run on Sepharose 6B eluted at Vq, and
as will be seen in the next Section, the vascular activator
has an equally high affinity for both of them. The
identical behaviour of the two peaks in all but lysine
binding suggests that overloading did produce the non-
binding peak.
2 INTERACTION OF VARIOUS ACTIVATORS WITH FIBRIN
A AFFINITY OF VARIOUS ACTIVATORS FOR SOLUBLE FIBRIN
POLYMERS
Binding studies were carried out to judge the relative
affinities of the vascular activator, urokinase and the
melanoma activator, for SFP's.
The top half of Fig 38 shows a fairly typical separation
of a resuspended PEG precipitate on Sepharose 6B in 25mM
tris, lmM EDTA, 3.8mM borate, O.ISM NaCl pH8.8. However,
if the activator eluting between fractions 20 and 30 is
pooled, and a sample of this mixed with a sample of
SFP's taken from a Vq peak on Sepharose 6B, when this
mixture is re-run on the same column under identical
conditions, the vascular activator activity now elutes at
V as shown in the bottom half of Fig 38. This same
o 3
high affinity of vascular activator for SFP's has been
demonstrated for both peaks obtained when SFP's are
applied to lysine-Sepharose (see last Section).
The same procedure was adopted for the melanoma activator.
When run alone on Sepharose 6B the melanoma activator
eluted with a of 0.76. When re-run with SFP's approx¬
imately 8% of the total activity eluted at V , while the
remainder eluted with an unaltered K,. Urokinase was
d
similarly tested; when run alone the activity eluted





eluted with an unaltered K^, with no activity at V . The
column, buffer and conditions used for both the melanoma
and urokinase affinity studies were identical to those
used for the vascular activator studies above.
B AFFINITY OF VARIOUS ACTIVATORS FOR FIBRIN CLOTS
The affinity of the vascular activator, urokinase and
the melanoma activator for fibrin formed in situ was
tested. The vascular activator sample used was a
resuspended PEG precipitate (160 Ploug u/ml), urokinase
(Leo) was used at 250 Ploug u/ml and the melanoma activator
had a value of 150 Ploug u/ml.
To 50ml samples of each activator was added lOmls of 1%
fibrinogen and 0.2ml thrombin (50u/ml); this was allowed
to clot for half an hour at RT before being centrifuged.
The activity of the supernatent (1) was determined on a
fibrin plate. To the clot was added 50ml of a solution
of 1M NaBr and 1M lysine; this was magnetically stirred
for half an hour at RT. The solution was then centrifuged
and again the activity present in the supernatent (2)
determined on a fibrin plate.
The activity in supernatent 1 represents the unbound
activity, while the activity in supernatent 2 represents
the activity that has bound to the fibrin, and been eluted
from the clot by the 1M lysine. The results of the
binding studies are given in Table 13. As can be seen the
vascular activator has a very high affinity for fibrin
giving 75% binding. Urokinase only gave 17% binding,








TABLE 13 PERCENTAGE OF VARIOUS ACTIVATORS BINDING
TO FIBRIN FORMED IN SITU
C DISCUSSION
The results clearly show that the vascular activator has
a far greater affinity for both SFP's and insoluble fibrin
than urokinase or the melanoma activator.
The vascular activator sample used in both cases was a
resuspended PEG precipitate, thus the activator would
already have been in a complex with soluble fibrin. The
sample used for the SFP-binding experiments on Sepharose
6B eluted after Vq (fractions 20-30), but was obviously of
higher molecular weight than uncomplexed vascular activator.
Thus the vascular activator shows a preference for the
higher range molecular weight SFP's over the lower
molecular weight soluble fibrin it was already bound to.
Similarly the activator shows a higher affinity for
insoluble fibrin (or perhaps the affinity is for the
soluble phase present during the formation of insoluble
fibrin), than the soluble fibrin with which it was already
complexed. The higher affinity could be due to the presence
of a more complete binding site in the larger polymers
or insoluble fibrin, or that the binding site only attains
the desired configuration when certain bonds are present
and intact. Alternatively, the polymer (whether soluble
or insoluble) may provide a series of binding sites in
the correct orientation, which become less attractive to
the activator as the polymer is broken down.
The elution of the vascular activator from the formed
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fibrin clot in the affinity experiments, was put to further
practical use. It was possible to retrieve activator,
that would have otherwise been lost, from fibrin clots
forming spontaneously during purification procedures,
usually at the concentration steps. A useful purification
can also be effected by forming a fibrin clot in a crude
perfusate or resuspended PEG precipitate, removing it
by centrifugation, and then breaking up the clot and
stirring it in a buffer containing 1M NaBr (to help break
up the fibrin clot) and 1M lysine (to elute the activator
from the fibrin).
3 A SYNTHETIC CARRIER?
A EFFECT OF POLY-LYSINE ON THE RATE OF ACTIVATION OF
PLASMINOGEN
The effect of poly-D-lysine on the rate of production of
plasmin from plasminogen, using various activators, was
investigated.
Fig 39 shows the effect of poly-D-lysine (M Wt 144,000)
used at O.lmg/ml (final concentration = 0.046pM) on a
mixture of purified vascular activator, plasminogen and
S-2251. The S-2251 measures the plasmin formed. As can
be seen from Fig 39, in the presence of O.lmg/ml poly-D-
lysine the amount of plasmin produced is increased
approximately 4-fold. However this increase is seen to
be more when the effect of poly-D-lysine on plasmin is
studied. The cleavage of S-2251 by plasmin (lcu/ml) is
inhibited 50% by poly-D-lysine at a final concentration of
0.046;aM. Thus the true increase in the amount of plasmin
produced, by activation of plasminogen by the vascular
activator, in the presence of 0.046_pM poly-D-lysine (M Wt
144,000) is in the region of an 8-fold increase.
Thus a range of concentrations of poly-D-lysine was used
with the vascular activator and plasminogen to determine
the optimum range of concentrations. Fig 40 shows the
effect of the range from 0.02mg/ml to O.lmg/ml (0.0092-
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to lQmg/ml (0.092-4.6pM) . The range O.Ol^g/ml to O.Olmg/ml
was also tested (not shown), but the effects of these
concentrations fell between 0.02mg/ml and no poly-D-lysine
(Fig 40), as would be expected.
The range of concentrations that give an overall increase
is 0.06-4mg/ml ( 0.028-1.84pM). However the range would
be wider if an allowance was made for the plasmin inhibit¬
ion by poly-D-lysine. The biggest increases occur in
the range 0.08-0.8mg/ml (0.037-0. 37jjM) , and O.lmg/ml
(0.046juM) is the most effective. Overall inhibition is
seen with concentrations up to 0.04mg/ml (0.018pM) and
over 6mg/ml (2.76,pM).
The effect of poly-D-lysine at a final concentration of
0.046jiM was then investigated on a range of activators.
The melanoma activator showed a 13% increase in plasmin
production after 5 minutes in the presence of poly-D-
lysine. This effect would be masked somewhat by the
inhibitory effect of poly-D-lysine on plasmin. When
streptokinase was tested, an initial small increase in the
rate of production of plasmin, was overtaken by the plasmin
inhibitory effect later, and after 5 minutes the amount
of plasmin produced with or without poly-D-lysine was
approximately the same. When urokinase was tested an
overall inhibition was seen that could be accounted for
by plasmin inhibition, and thus no enhancing effect was
present *
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An 11 to 12-fold increase in the amount of plasmin produced
was obtained with human uterine tissue activator (gift
from Dr D Rijken) in the presence of poly-D-lysine (see
Fig 42) used at O.lmg/ml. The effects of poly-L-lysines
(used at O.lmg/ml) of various molecular weights, were
also investigated, on human uterine tissue activator. As
can be seen by reference to Fig 42, the response to poly-
L-lysine appeared to be related to its molecular weight.
The higher the molecular weight, the greater the amount
of plasmin produced.
Finally a resuspended PEG precipitate was tested with and
without poly-D-lysine (O.lmg/ml). The poly-D-lysine
showed approximately 33% inhibition. This means that there
was a slight enhancement, but that this was swamped by the
inhibitory effect on plasmin.
10-
Humanuterinetissueactivator Plasminogen(2-5cu/ml) 50mMtris-38mMNaClpH8 Poly-lysine(various)(01mg/ml) S-2251(3mM)
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B DISCUSSION
Poly-D-lysine appears to have a far greater effect on the
purified vascular activator and human uterine tissue
activator than the other activators tested. Bearing in
mind that poly-D-lysine inhibits plasmin (Kabi, lcu/ml)
approximately 50%, the enhancement with the vascular
activator is in the region of 8-fold, and with the
uterine tissue activator 22 to 24-fold. The melanoma
activator shows a slight overall enhancement, streptokinase
no overall effect and urokinase is inhibited by an amount
that can be accounted for by plasmin inhibition.
The greater enhancement associated with the vascular
activator over the other activators tested reflects
the affinities found of these activators for SFP's and
fibrin. The human uterine tissue activator also has a
high affinity for fibrin (Dr D Rijken - personal communicat¬
ion). It appears that the poly-lysine may be acting as
a synthetic carrier, partly mimicing the binding sites
present on SFP's and fibrin. Thus if the vascular activator
and uterine tissue activator, with their high affinity
for fibrin also bind to poly-lysine they may undergo a
conformational transition giving a more active enzyme.
The other activators not having this high affinity for
fibrin, would not benefit from the presence of poly-lysine.
If this is the case then it may go some way to explaining
why an overall inhibition of 33% was seen when the
activator sample was a resuspended PEG precipitate. SFP's
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vrould be present in this sample and presumably the vascular
activator would show a preference for SFP's over poly-D-
lysine, and thus very little effect would be seen, except
for the inhibitory effect of poly-D-lysine on plasmin. It
is unlikely that plasminogen possesses the affinity for
poly-lysine that is seen for fibrin. Plasminogen appears
to require a 6-carbon chain terminated in a COOH group for
binding. These requirements are fulfilled by EACA and
lysine but not by poly-lysine. In poly-lysine the COOH
group is lost during polymerization and thus the ability
to bind plasminogen would not be expected.
We have, on several occasions, attempted to demonstrate
an enhancing effect with SFP's. In some cases an increase
in the rate of production of plasmin does occur in the
presence of SFP's, using the same system as with poly-
lysine. Hoivever, often they shoxv an inhibitory effect.
One explanation could be that the natural substrate of
the formed plasmin is fibrin, and thus with SFP's present
a substrate is introduced to compete with S-2251; whereas
when poly-D-lysine is used, the enhancement remains the
same but there is no competition with S-2251. Bovine
plasmin is known to degrade poly-L-lysine (Rigbi, 1957)
but not poly-D-lysine.
A range of poly-L-lysines of molecular weights 2,700 to
91,200 were investigated, with a different sample of
vascular activator, and no enhancement was found. However,
with this particular sample no effect was found with
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poly-D-lysine either, possibly due to contamination with
SFP's. More work is required here.
However, enhancement was demonstrated with poly-L-lysines
(used at 0.. lmg/ml) of different molecular weights when
used with human uterine tissue activator. The enhancement
of plasmin produced appeared to be related to the molecular
weight of the poly-I—lysine, the poly-L-lysine of highest
molecular weight (91,200) having the greatest effect.
It is difficult to compare the effects of poly-L and
poly-D-lysines as preparations of the same molecular weight
were not available. Poly-D-lysine induced a greater
response, but this may have been due to the molecular
weight of 144,000 as opposed to the 91,200 of the poly-L-
lysine; alternatively it could be due to the fact that
the plasmin formed may degrade the poly-L-lysine but not
affect the poly-D-ly'sine. Bovine plasmin is known to
degrade poly-L-lysine (Rigbi, 1957) but not poly-D-lysine.
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1 ASSAY METHODS
A PLASMINOGEN ACTIVATOR
This is assayed on a fibrin plate prepared from the
following reagents:
1 6ml 1% (W/ ) human fibrinogen (Kabi Pharmaceuticals,
v Grade L)
2 24ml 0.05M tris , 0.15M NaCl pH7.5
3 0.6ml Thrombin (Parke Davis) 10 Iu/ml
The fibrinogen is mixed with the buffer, then the thrombin
is added, the mixture thoroughly mixed and immediately
25ml transferred into a 10 x 10cm square plastic petri
dish on a levelled table. This is left at room temperature
for 30 minutes. The petri dish can be marked off into
16 (or 25, depending on the level of activity expected)
equal sections, and'30pl of each sample applied to the
centre of each section using a micro-syringe. The plates
are calibrated with urokinase (Leo Pharmaceuticals) from
l-lOO Ploug u/ml. The plates are then incubated on a
levelled table at 37°C overnight.
The lysis areas are visualised by adding a few drops of
0.1% bromothymol blue in 50% ethanol, 0.25M NaOH, Two
perpendicular diameters of the lysis areas are measured
and the average of these for the urokinase standards
are plotted against the log of the urokinase concentrations
(in Ploug u/ml). The unknown plasminogen activator activities
can then be read from the graph using the average diameter
of the lysis areas of the test samples.
The activator converts the plasminogen (associated with
the fibrinogen) to plasmin, and the subsequent lysis is
measured. Thus it must be noted that the assay is not
specific for activator; plasmin applied to the plate or
contaminating the activator sample will also cause lysis.
However if samples suspected of being contaminated with
plasmin are screened in parallel on normal fibrin plates
and plasminogen-free fibrin plates, prepared using plasminogen-
free fibrinogen (see Section 3D), then the latter will
detect lysis due to non-specific or direct proteolysis (eg
plasmin) and deduction of this value from the value obtained
on normal fibrin plates will give a value for the plasminogen
activator activity.
B PLASMIN
Plasmin was detected in two ways. Firstly on plasminogen-
free fibrin plates (3Qul samples), prepared as normal
fibrin plates, except that the fibrinogen used had been
passed through a lysine-Sepharose column (to remove
plasminogen).
Alternatively the synthetic substrate S-2251 was used to
screen column eluate fractions containing only plasmin.
0.1ml of the sample was added to a tube containing 50^1
S-2251 (3mM). This was incubated at 37°C until a yellow
colour became visible; this could be measured at 405nm.
C PLASMINOGEN
Two assays were used in this work for the detection of
plasminogen in column eluate fractions. In both assays
the samples (0.1ml) were added to 0.1ml streptokinase
(Lederle) and incubated for half an hour at 37°C. Then
either 30j.il of each was screened on plasminogen-free
fibrin plates, or 0.1ml of each was added to 50pl S-2251
(3mM) and incubated at 37°C until a yellow colour developed,
which was measured at 405nm.
The Laurell electroimmunoassay was used for the determinat¬
ion of plasminogen antigen. 1% agarose was prepared in
25mM tris, ImM EDTA, 3.8mM borate pH8.8. 0.1ml Behringwerke
anti-plasminogen was added to 12.5ml of 1% agarose, which
was poured onto an 8 x 8cm glass plate on a level surface
and allowed to set. 5pl samples were applied to wells
cut along one edge of the gel and the plate was run over¬
night at 120 volts. The tank buffer was the same as the
gel buffer. Serial dilutions of normal plasma were run as
standards.
After electrophoresis the gel was dried under weighted
filter paper and stained in 0.1% Coomassie brilliant
blue R250 (Sigma) in 40% methanol, 10% acetic acid, 50%
H^O, destained in the solvent and the 'rocket' heights
measured.
D PROTEIN
The folin assay was used for protein estimations. The
reagents used were as follows:
Reagent A
(Stable for 24 hrs)
Copper Citrate lml
2% Na^CO^ (anhyd) in 0.1M NaOH 49ml
Reacent B Folin reagent (diluted 1:1 with
distilled H20)
To 0.5ml sample or standard was added 2.5ml reagent A.
This was mixed and left 10 minutes at room temperature
then 0.25ml reagent B was added. This was mixed and left
30 minutes at room temperature before being read at 750nm.
The range of the assay is 5-200pg, and human serum albumin
was the standard used.
E SOLUBLE FIBRIN POLYMERS
(STAPHYLOCOCCUS AUREUS CLUMPING TEST)
Staphylococcus aureus (Strain Newman D^C) xvas made up at
lOmg/ml. It was mixed vigorously (Vortex mixer) for at
least one minute, before being allowed to stand for 5
minutes. The suspension was freshly prepared for each
assay and must be used within 30 minutes of being made.
50jj1 of test sample and 50pl cell suspension were spread
on a glass plate and then rotated for two minutes before
being viewed over a black background. Clumping was
scored from - (no visible clumping) to ++++ (maximum
clumping). Controls of the cell suspension against
distilled water and against 1% fibrinogen were set up.
All the reagents must be at room temperature and have no
visible signs of bacterial growth to be sure that no
false positives occur.
The Staphylococcus aureus clumping test was used to
assay column eluates when investigating the chromatographic
behaviour of soluble fibrin polymers. The higher molecular
weight polymers tend to give a stronger clumping reaction.
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GEL FILTRATION CHROMATOGRAPHY
A PREPARATION OF THE GEL FILTRATION COLUMN
Sepharose 6B and 4B were obtained as preswollen aqueous
suspensions. Sephadex G-25 and G-200 were obtained as
dry powders and swollen in approximately five times their
water-regain weight of appropriate buffer at room temper¬
ature for three days. Fines consisting of fractured and
undersized gel beads that tend to reduce the flow rate
and affect separation, were removed by allowing the gel
beads to sediment freely in a two litre measuring cylinder.
As the beads settle, the supernatent containing the fines
was pumped off. This process was repeated until the
majority of fines were removed (usually ten times) .
A glass column open at one end and with a Teflon stopcock
at the other was filled with appropriate buffer and
clamped in a vertical position. A spherical glass bead
was dropped to the bottom of the column to prevent sand
entering the stopcock and outlet tubing. Sufficient
acid washed sand to cover the rounded portion of the
column was added, such that after sedimentation the sand
level would just reach the parallel portion of the column.
A two litre Imhoff sedimentation cone was connected to the
top of the column through a rubber bung and firmly clamped.
The gel slurry was poured into the cone and a variable
speed peristaltic pump (LKB 12000 Varioperpex) was connected
to the bottom of the column, the stopcock opened and
pumping started. The flow rate was immediately measured
and adjusted, to the correct value for the gel type in use.
Pumping was continued for 12 hours which was sufficient
for the gel to sediment and form a packed gel bed. Excess
solution remaining in the cone was removed and the top 2cm
of the gel bed stirred and allowed to sediment, thus form¬
ing a perfectly flat bed surface. A reservoir containing
the desired eluant was connected to the top of the column
and pumping continued until at least one column volume of
buffer had been eluted, at which point the apparatus was
ready for use. Two types of fraction collectors were
used depending on the size of the column employed. The
Gilson microcol TDC 80 was able to collect 80 fractions of
10ml, whereas the LKB 7000 Ultrorac fraction collector
was used with the larger columns; this xvas capable of
collecting 200 fractions of 30ml.
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B CALIBRATION OF SEPHADEX G-200 IN TERMS OF STOKES RADIUS
AND THE INVERSE ERROR FUNCTION OF THE DISTRIBUTION
COEFFICIENT









and is a measure of the hydrodynamic radius of the molecule
in solution. It has been shown that the Stokes radius
of a molecule in solution can be related to its behaviour
in gel filtration through the inverse error function of
the distribution coefficient (K^) by the relationship:
T = a + b erfc-1 (1-K.) (Ackers, 1967)
s o o y d' x ' '
where aQ and bQ are constants relating to the particular
column in use. erfc is the inverse error function from
"Tables of the Error Function and its Derivatives" (1954).
A plot of rg against erfc ^ (1-K^) for molecules of unknown
Stokes radius will allow the latter to be determined if the









Since T and D are readily interconverted through the
s
Stokes-Einstein equation, D values can be calculated from
measured r values and used in the Svedberg equation for
the calibration of molecular weights.
K_j is calculated from the equation:
Kd
(V -V )x e o'
(V -V )v
s o'
where Vg = Elution volume of the compound.
V = Void volume, which is the elution volume of a
o '
compound sufficiently large to be completely excluded from
the gel matrix. This is equal to the volume of liquid
exterior to the gel beads.
V = Solvent volume; this is the total volume of
s '
liquid both outside and inside the gel beads and is the
elution volume of a compound sufficiently small to be
totally free to enter the gel matrix.
Compounds of intermediate size between those eluting at
Vq and Vs are partially excluded from the gel matrix and
consequently elute at intermediate volumes (V ) depending
on their size. values range from O to 1; values greater
than 1 are not possible for simple gel filtration but do
occur when adsorption of the solute onto the gel matrix
occurs. Vq is generally measured by determining the
elution volume of Dextran Blue 2000, a dyed macromolecular
dextran of molecular weight 2 x 10^. V is measured by
s
determining the elution volume of glucose, detected ivith
Clinistix (Ames).
3 AFFINITY CHROMATOGRAPHY
A COUPLING OF LIGANDS VIA THE CNBr LINKAGE
The general method for coupling a ligand to CNBr-activated
Sepharose is given below. The quantities given are for
coupling lOOg ligand to 1 litre of gel.
200g cyanogen bromide (Koch-Light) were dissolved in
approximately I20ml N-methylpyrrolidone and added slowly,
with stirring, to 1 litre of gel in a large beaker
surrounded by an ice-water-salt mixture. The 1 litre of
gel was suspended in 1 litre of 5M K^HPO^ pH12. When all
the CNBr was added the reaction mixture was retained at
4°C with stirring for 45 minutes.
The gel was then washed with 5 litres cold distilled
water, slurried in 1 litre 0.1M NaHCO^_O.SM NaCl pH9 and
lOOg of solid ligand added. The pH was re-adjusted to 9
(if necessary) and this was left at room temperature
overnight with gentle stirring.
Then ethanolanine was added to a final concentration of
1 molar and left for four hours at 20°C. The gel was
then filtered off on a Buchner funnel, washed with distilled
water and put through the washing cycle three times, using '
0.1M sodium acetate - 1M NaCl pH4
distilled water
0.1M boric acid - 1M NaCl pH8
distilled water.
B COUPLING LIGANDS VIA THE ADIPIC ACID DIHYDRAZIDE (ADH)
LINKAGE
Sepharose activated with CNBr (as above) xvas treated with
an equal volume of 0.5M ADH in 0.2M NaHCO^ at pH9. The
suspension was gently shaken for 15 hours at 4°C and an
additional 4-6 hours at room temperature. The hydrazido-
Sepharose was washed with 10 volumes of 1M NaCl over a
coarse sintered glass funnel and incubated with 1M
glycine at pH9 for 4 hours at room temperature. The
substituted Sepharose was extensively washed with 1M
NaCl until ADH was no longer detected in the washings.
The hydrazido-Sepharose derivative is stable for months
if stored at 4°C in the presence of 0.02% NaN^.
To couple ligands to hydrazido-Sepharose, lOmls (for
example) was taken and suspended in 8ml distilled water
and 2ml 1M HCl. The suspension was cooled in an ice-bath
for 30 minutes and while stirring, 2ml of an ice-cold
solution of 1M NaNO^ was added dropwise over a 1 minute
period. The suspension was stirred for an additional
2-3 minutes, then rapidly (1-2 minutes) filtered with
suction on a previously cooled (4°C) coarse sintered glass
funnel and xvashed with 20-30ml 5mM HCl at 4°C. The ligand
to be coupled (Ig), in 0.2M NaHCO^ pH8, was added while
being stirred with a glass rod. The suspension was trans¬
ferred to a polyethylene vial and shaken gently for 15
hours at 4°C. The substituted Sepharose was washed
extensively with 1M NaCl, and finally transferred to the
appropriate buffer before use.
C PREPARATION OF THE IgG FRACTION OF ANTISERA
5ml of antiserum was applied to a protein A-Sepharose
column (1 x 20cm) in 0.025M tris pH7.5 and the column was
then well washed in the same buffer. Then 2ml O.ISM
glycine HC1 pH2.1 in neutral red indicator dye was applied
to the column and washed through with 0.025M tris pH7.5.
lml fractions were collected. As the fractions containing
the red dye (also contains IgG) were collected enough 1M
tris pH9.5 was added to turn the indicator dye to brown-
orange (pH7). Collection of lml fractions was continued
until all the dye had been washed through the column.
The coloured fractions were pooled and concentrated
(dilution and re-concentration removed the dye) in an
Amicon ultrafiltration system to give the IgG fraction.
D PREPARATION OF PLASMINOGEN-FREE FIBRINOGEN
lg of human fibrinogen (Kabi Pharmaceuticals) was made up
in 100ml of a buffer of final concentration 0.3M NaCl -
0.4% sodium citrate pH7.5 (the freeze-dried Kabi material
already contained lg NaCl and O.lg sodium citrate). This
was applied to a lysine-Sepharose column (2.5 x 20cm) in
0.3M NaCl - 0.4% sodium citrate pH7.5 and 8ml fractions
collected at 35ml/hour. The fractions were screened for
protein at 280nm, and the fractions containing plasminogen-
free fibrinogen were pooled and could be concentrated
(if necessary) to lOOml to give the same concentration of
fibrinogen (1%) as is used to prepare a fibrin plate.
The lysine-Sepharose column has to be regenerated after
use with a wash in a buffer containing 1M lysine to
remove the bound plasminogen.
The plasminogen-free plate is made in the same way as
the normal fibrin plate except that plasminogen-free fibrin
ogen is used. The plate was always tested for absence of
plasminogen when used by applying 30pl urokinase (100
Ploug u/ml). This gave no lysis. To check that the
sensitivity in normal and plasminogen-free fibrin plates
was the same when set up in parallel a 30pl sample of
plasmin (5cu/ml) was applied to both types of plate and
the lysis areas compared.
4 DETERMINATION OF SEDIMENTATION COEFFICIENTS BY SUCROSE
DENSITY GRADIENT ULTRACENTRIFUGATION
The behaviour of a solute in a gravitational field can be
described in the following way. In the condition where a
density difference between the solute and solvent occurs
the effective mass can be expressed as:
meff m ~ msolvent displaced
= m - m ,,/dp
= m - mvp
= m (1-vp)
where m = mass of the protein molecule
d = density of the protein molecule
p = solvent density
v = partial specific volume of the protein
(ie the reciprocal of its density).
Since f = ma
where f = force
m = mass
a = acceleration
then in a centrifuge rotor rotating with an angular
velocity of w radians/second a solute molecule will
experience a centrifugal force 0 per molecule such that
at distance x a point is reached when:
2 _
0 = mw x (1 -vp) .
The centrifugal force exerted on the protein molecule in
the gravitational field is counterbalanced by the resisting
force of the solvent due to its viscous resistance which
is given by:
resisting force = f^/dt
where f = frictional coefficient.
Thus the sedimenting molecule reaches constant velocity.
kT
Since f = /D
ivhere k = Boltzmann's constant
T = Absolute temperature
D = Translational diffusion coefficient
then when resisting and gravitatonal forces are equal
^/D * dx/dt = m(l-vp)
Multiplying through by Avogadros number (N) and rearranging
gives the equation originally derived by Svedberg:
M = RT/D(1-V) . dx/dt
w X
where M = molecular weight
R = Gas constant.
The quantity is determined in the ultracentrifuge
w x
and is termed the sedimentation coefficient s. The unit
of s is usually expressed as one Svedberg (S) thus
s = 1 x 10'13 Sec-1 = IS.
The Svedberg equation is usually written in the form
M = RTs/D(l-vp).
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The centrifuge used was an MSE superspeed 65 preparative
ultracentrifuge with a titanium 3 x 6.5ml swing-out rotor
(MSE type 59587) capable of producing 420,000g at its
maximum radius at a speed of 60,000rpm. 6ml thin walled
polycarbonate centrifuge tubes (MSE type 59203) were used
to contain the gradients which were produced by over-
w . rrf
layering 0.4ml of 30% / sucrose with 1.4ml each of 24%,
18%, 12% and 6% sucrose solutions in 25mM tris, ImM EDTA,
3.8mM borate, 1.5M NaCl pH8.8. The gradients were left
for four hours at room temperature to diffuse. The protein
to be investigated as well as standards were over-layered
on the gradient and centrifuged for 20 hours.
The gradients were fractionated with a peristaltic pump
connected at one end to a pasteur pipette which was care¬
fully lowered to the bottom of the gradient. Pumping was
then begun and 30 equal fractions collected for each
gradient. The fractions were analysed for protein,
radioactivity and/or biological activity and graphs
constructed of the latter versus the number of fractions
moved (sedimentation distance) from the meniscus (Figs 22-
24). A standard curve was then constructed (Fig 25) of the
number of fractions moved versus S°0(_. (sedimentation20, w
coefficient corrected for density and viscosity to water
at 20°C), from which the unknown S°_~ could be read
2u,w
using the determined sedimentation distance. The standard
curve was linear which was slightly surprising due to the
non-linear viscosity characteristics of the sucrose gradient.
This was explained by inspection of a graph of viscosity
versus concentration for sucrose solutions . In the range
of concentrations used the viscosity increases in an
almost linear manner and this is counterbalanced by the
increase in 'g' with radius. Only at higher concentrations
does the viscosity increase become significantly non-linear.
As already stated the determination of the sedimentation
coefficient at 4°C by comparison with standards of known
S° also run at 4°C gives S° „ directly. A further20,w 20,w
advantage is that temperature variation with time during
the run and also temperature differences within the gradient
have no effect on the results obtained since internal
standards were used.
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5 CALCULATION OF THE FRICTIONAL RATIO
_ is defined as the ratio of the frictional coefficient
fo
of the hydrated solute, f, to that of the anhydrous
spherical molecule, fo.
Using the Stokes equation
f = 6-rrnr
where "H = coefficient of viscosity
T = radius of the solute
.. f, 6-TT-nr,then /, = A _fo 6tta r0
The molecular volume of an anhydrous spherical solute
can be expressed as
v = -trr 3
m
3 o













The quantity r is the Stokes radius of the hydrated molecule
and can be found from the diffusion coefficient using the
Stokes-Einstein equation or can be measured by gel filtration.
^/fQ is always greater than unity and is a measure of
hydration and asymmetry. values range from 1.1 to
over 2. Globular proteins have values ranging up to about
1.3. Ratios in excess of 1.3 cannot be accounted for
solely by hydration and indicate asymmetry of the molecule
and/or an expanded non-compact structure.
6 PREPARATION OF ANTISERA
The antisera were raised in 3-5kg New Zealand white
rabbits. 0.5ml of the vascular plasminogen activator and
0.5ml Freunds complete adjuvant was injected sub cutan-
eously at four sites (two above the scapula and two on the
inside of the thigh). Six weeks later a boost injection
of 0.5ml activator and 0.5ml Freunds incomplete adjuvant
was administered at the same sites. Ten days later the
rabbit was bled from the lateral ear vein. 50mls of
blood was collected. This was left at 4°C (to retract the
clot) for 24 hours before the serum (20mls) was decanted.
7 OUCHTERLGNY IMMUNODIFFUSION
A molten solution of 1.5% agarose in 25mM tris , ImM EDTA,
3.8mM borate, 0.15M NaCl pH8.8 was prepared by heating in
a boiling water bath for 20 minutes. 12.5ml of this
solution was poured onto an 8 x 8cm glass plate placed on
a level surface and left to set for one hour.
A central well was cut and six peripheral wells at a
distance of 5mm. The antiserum (20pl) was placed in the
central well and a range of antigens (20pl) in the
surrounding wells. The plate was left to diffuse at room
temperature for 48 hours.
The gel was then dried under weighted filter paper, washed
overnight in a large volume of saline, dried as before and
then washed in distilled water. The gel was then dried,
under a piece of filter paper, at approximately 50°C for
1-2 hours before being stained in 0.5% amido black 10B in
45% ethanol, 10% acetic acid (15 minutes) and destained in
the solvent.
8 CONCENTRATION OF PROTEIN SOLUTIONS
Concentration of protein solutions was carried out by gas
pressure ultrafiltration. The apparatus was manufactured
by the Amicon Corporation. Various membrane porosities
are available. In this work FM10, PM30 and XM5O xvere
generally used; they retain molecules of molecular weight
greater than 10,000, 30,000 and 50,000 respectively. The
PM10 and PM30 membranes were operated at 50psi, while the
XM50 was used at 25psi. The XM50 membrane was used for
solutions of the activator known to be in a high molecular
weight complex with soluble fibrin.
The solution could be stirred magnetically while the system
was pressurised thus eliminating the possibility of the
formation of a thin layer of highly concentrated protein
above the membrane. The apparatus is available in various
capacities of which 5ml, 50ml, 400ml and 2 litre versions
were used.
The system was used at 4°C as well as room temperature,
although the flow rate was reduced at the lower temperature.
Occasionally fibrin precipitation was a problem; this slows




A P OLYACRYL AM IDE GEL ELECTROPHORESIS
P-lyacrylanide gel gradient slabs of 4-30% acrylamide were
ecuilibrated before use in the electrophoresis tank at
400V/50mA. This was to replace the gel buffer with tank
buffer. The tank buffer used was generally O.SM tris,
C.02M EDTA, 0.075M borate pH8.8. However a ^/5th dilution
of this was also employed.
Ts 25j-il of the concentrated sample was added 10pl of a
bromophenoi blue/sucrose mixture before being applied to
the gel. The gels were normally run at lOO volts (although
50 volts and 75 volts were also used). The buffer was
circulated through a cooling tank at 4°C.
After electrophoresis the gels were placed in distilled
'water for half an hour to remove the buffer salts before
either being stained in 0.04% Coomassie blue G-250 in 3%
HC10 overlayered with fibrin or screened for radioactivity
(s ee Text).
B SODIUM DODECYL SULPHATE - POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS-PAGE)
The method used was that described by Weber and Osborn
(1969). The samples to be run in the SDS-PAGE system
(see Text) were incubated at 37°C for two hours in O.OlM
sodium phosphate buffer pH7. containing 1% SDS and 1%
j3-mercaptoethanol.
After incubation, the samples with added bromophenol blue
and a drop of glycerol were applied to 7% polyacrylamide
gels in 10cm glass tubes of 6mm internal diameter. The
buffer employed was 0.05M NaH2P04-0.14M Na2HP04-0.2% SDS.
The gels were run at a constant current of 8mA/tube before
being stained in Coomassie brilliant blue R250 in 40% v/
v
methanol, 10% v/ acetic acid, 50% v/ distilled water'
v ' v
and destained in the same solvent.
C CELLULOSE ACETATE ELECTROPHORESIS
Cellulose acetate strips (Cellogel, Reeve Angel) were
immersed in the electrophoresis buffer for ten minutes,
then carefully blotted to remove excess liquid before the
samples were applied with a Pasteur pipette drawn out to
a fine diameter. The strips were 2.5 x 17cm and the
samples (5pl) with added bromophenol blue were applied
across the strip about 6cm from the cathodic end.
The tank buffer used was 0.5M tris, 0.02M EDTA, O.O75M
borate pH8.8. This was also used at a "^/5th dilution.
The samples were run at 50-100 volts and ImA/strip for
2-3 hours. A plasma standard was generally run as a
reference of the mobility of the various classes of
proteins. Once run the strip was either stained for
protein with 1% napthalene black, 50% methanol, 5% acetic
acid (and destained in 50% methanol, 5% acetic acid),
assayed for activator activity by fibrin overlay or cut
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into 1mm slices and counted for iodine.
D AGAROSE GEL ELECTROPHORESIS
Electrophoresis of the activator was carried out in 1%
agarose gels. Samples (15pl) and standards were applied,
with bromophenol blue, onto pieces of filter paper which
were placed into slit wells 1cm long in the agarose.
These slits were situated nearer the cathodic end of the
plate.
The gel Was run in 0.5M tris, 0.02M EDTA, 0.075M borate
pH8.8 at 200V and 25mA for four hours. Staining was
accomplished with 1% napthalene black in 50% methanol, 5%
acetic acid and was destained in the same solvent.
10 IODINATION METHODS
A CHLORAMINE T
The vascular activator solution to be labelled was con¬
centrated in a Minicon A25 concentrator (Amicon) to lOpl
( ideally this should contain about 5pg of protein) . To
1 2 S
this xvas added 5pl carrier-free Na I (lOOmCi/ml,
Arnersham) and lOpl chloramine T (5mg/ml). This was
shaken and after 1 minute 20Qul Na£S205 (0.6mg/ml) and
0.1ml KI (lOmg/ml) was added and mixed. The mixture was
chromatographed on Sephadex G-25 to separate the labelled
protein from other components of the mixture.
The column was eluted in 0.05M Na^HPO^ pH7.5 containing
2% horse serum. This is to overcome any interactions
between the labelled protein and the gel matrix.
B SUCCINIMIDE ESTER (N-SUCCINIMIDYL 3-(4-HYDROXYPHENYL)
PROPIONATE) - SHPP
Iodinated succinimide ester was obtained in benzene from
Amersham. The benzene was evaporated in a stream of
nitrogen gas. To the dried ester was added lOpl of the
activator sample in 0.1M borate buffer pH8.5 and this was
placed in an ice-bath for 30 minutes. To obviate sub¬
sequent conjugation to carrier proteins, unchanged ester
was reacted with 0.5ml of 0.2M glycine-O.lM borate buffer
pHS.5 for 5 minutes at room temperature.
The mixture was then run on Sephadex G-25 eluted with
25m>l tris, lmM EDTA, 3.8mM borate, 0.15M NaCl, 0.3% W/v
gelatin pH8.8. The gelatin was to avoid adsorption to
the gel and co-elution of adsorbed hydroxy-phenyl propionic
acid.
C LACT0PER0XIDASE/H202
To lQpl of the vascular activator solution (120u/ml) was
added 3Qul 0.5M Na2HP04 pH7.5, 3Cpl solid phase lactoper-
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oxidase (Worthington) and lOjul Na I (lOOmCi/ml, Amersham) .
To this was added 5pl H209 (made by diluting lOpl of "lOO
volumes" H2^2 wi"th distilled water) and the
mixture kept at room temperature for 30 minutes with
occasional shaking. The reaction xvas stopped by dilution,
by addition of 20Qul 0.1M Na2HP04 pH7.5.
The mixture was then run on Sephadex G-25 in O.O5M Na2HP04
pH7.5.
D LACTOPEROXIDASE/GLUCOSE OXIDASE
The procedure for this method is identical to the latter
except that the H2°2 ^"S rePlace<^ by 30jal solid phase


























High Molecular Weight Kininogen
p-Aminomethylbenzoic Acid
Polyethylene Glycol











PEPPER D S, ALLEN R A In Progress in Chemical
Fibrinolysis and Thrombolysis, Vol 3; Editors Davidson J
Rowan R M, Samama M M, Desnoyers P C; Raven Press,
New York, 1978, 91-98. Isolation and Characterization
of Human Cadaver Vascular Endothelial Activator.




ABLONDI F B, HAGAN J J Proc Soc Exptl Biol Med, 95,
1957, 195-200. Comparison of Certain Properties of Human
Plasminogen and Proactivator.
ACKERS G K J Biol Chem, 242, 1967, 3237-3238. A New
Calibration Procedure for Gel Filtration Columns.
AHLQUIST R P Amer J Physiol, 153, 1948, 586-600. The
Study of Adrenotropic Receptors.
ALAGILLE D, SOULIER J P Sem Hop Par, 32, 1956, 355-359.
Action des Enzymes Proteolytiques sur le Sang Total 'In
Vitro'. Modifications des Facteurs de Coagulation et du
Complement.
ALBRECHTSEN 0 K, THAYSEN J H Acta Physiol Scand, 35.,
1955, 138-145. Fibrinolytic Activity in Human Saliva.
AL3RECHTSEN 0 K Brit J Haematol, 3, 1957, 284-291.
The Fibrinolytic Activity of Human Tissues.
ALBRECHTSEN O K, STORM O, CLAASSEN M Scand J Clin Lab
Invest, 10, 1958, 310-318. Fibrinolytic Activity in
Some Human Body Fluids.
ALI S Y, EVANS L Biochem J, 107, 1968, 293-303.
Purification of Rabbit Kidney Cytokinase and a Comparison
of its Properties \vith Human Urokinase.
ALKJAERSIG N, FLETCHER A P, SHERRY S J Clin Invest, 38,
1959, 1086-1095. The Mechanism of Clot Dissolution by
Plasmin.
AMBRUS C M, MARKUS G Amer J Physiol, 199, I960, 491-494.
Plasmin-Antiplasmin Complex as a Reservoir of Fibrinolytic
Enzyme .
AMBRUS C M, AMBRUS J L, LASSMAN H B, MINK I B Res Commun
Chem Pathol Pharmacol, 1., 1970, 67-85. On the Heterogeneity
of Activity by Various Types of Plasmins and the Spectra
of Inhibition of Some Plasmin Inhibitors.
AOKI N, VON KAULLA K N Thrombos Diathes Haemorrh, 22.,
1969a, 251-262. Inactivation of Human Serum Plasminogen
Antiactivator by Synthetic Fibrinolysis Inducers.
AOKI N, VON KAULLA K N Proc Soc Exptl Biol Med, 130,
1969b, 101-106. p^C-Globulin and Synthetic Fibrinolytic
Agents.
AOKI N, VON KAULLA K N Amer J Clin Pathol, 55, 1971a,
171-179. The Extraction of Vascular Plasminogen Activator
from Human Cadavers and a Description of Some of its Properties.
AOKI N, VON KAULLA K N J Lab Clin Med, 78(3), 1971b,
354-362. Dissimilarity of Human Vascular Plasminogen
Activator and Human Urokinase.
AOKI N, VON KAULLA K N Amer J Physiol, 220(4), 1971c,
1137-1145. Human Serum Plasminogen Antiactivator: Its
Distinction from Antiplasmin.
AOKI N J Biochem, 75., 1974, 731-741. Preparation of
Plasminogen Activator from Vascular Trees of Human Cadavers
Its Comparison with Urokinase.
ASTEDT B, SVANBERG L, NILSSQN I M Brit Med J, 4, 1971,
453-459. Fibrin Degradation Products and Ovarian Tumours
ASTEDT B J Obstet Gynaecol Br Commonw, 79_, 1972, 205-206
Significance of Placenta in Depression of Fibrinolytic
Activity During Pregnancy.
ASTEDT B Thrombos Diathes Haemorrh, 34_(1), 1975, 339.
Release of Plasminogen Activators from Isolated Human
Glomeruli.
ASTEDT B, HOLMBERG L Nature, 261, 1976, 595-597.
Immunological Identity of Urokinase and Ovarian Carcinoma
Plasminogen Activator Released in Tissue Culture.
ASTEDT B, BARLOW G, HOLMBERG L Thromb Res, 11, 1977,
149-153. Time-Related Release of Various Molecular Forms
of Urokinase in Tissue Culture.
ASTEDT B, HOLMBERG L In Progress in Chemical Fibrinolysi
and Thrombolysis, Vol 3j Editors J F Davidson, R M Rowan,
M M Samama, P C Desnoyers; Raven Press, New York, 1978,
555-558. Comparison Betxveen Fibrinolytic Activators
from Normal and Malignant Tissues.
A3TRUP T, PERMIN P M Nature, 159, 1947, 681-682.
Fibrinolysis in the Animal Organism.
ASTRUP T, MULLERTZ S Arch Biochem Biophys, 40, 1952,
346-351. The Fibrin Plate Method for Estimating
Fibrinolytic Activity.
ASTRUP T, STAGE A Nature, 170, 1952, 929. Isolation
of a Soluble Fibrinolytic Activator from Animal Tissue.
ASTRUP T, STERNDORFF I Proc Soc Expt1 Biol Med, 84.
1953, 605-608. A Fibrinolytic System in Human Milk.
ASTRUP T Blood, 11, 1956, 781-806. Fibrinolysis in
the Organism.
ASTRUP T, STERNDORFF I Acta Physiol Scand, 36 . 1956,
250-255. Plasminogen Activator in Animal Tissue.
318
ASTRUP T, ROSA A T Thromb Res, 4, 1974, 609-613.
A Plasminogen Proactivator-Activator System in Human Blood
Effective in Absence of Hageman Factor.
ASTRUP T 23rd Ann Symp on Blood-Fibrinolytic System,
Physiologic and Molecular Aspects, Detroit, 1975.
Abstract: Cellular and Humoral Fibrinolysis.
ASTRUP T, FEDDERSCN F Thromb Res, 7, 1975, 501-504.
Deomonstration of a Tissue Factor Causing the Conversion
of Native Plasminogen to a More Reactive Form.
BACHMANN F, FLETCHER A P, ALKJAERSIG N, SHERRY S
Biochem, .3(10), 1964, 1578-1585. Partial Purification
and Properties of the Plasminogen Activator from Pig Heart..
BACK N, AMBRUS J L, MINK I B Circul Res, 9, 1961,
1208-1216. Distribution and Fate of I -Labelled
Components of the Fibrinolysin System.
BACK N, GUTH P, MUNSON A Ann NY Acad Sci, 104, 1963,
53-68. On the Relationship Between Plasmin and Kinin.
BALL A P, SILVER D, DAY E D Thrombos Diathes Haemorrh,
25, 1971, 114-128. Plasminogen-Fibrinogen Complex
Formation as a Prelude to Fibrinogenolysis. A Density-
Gradient Ultracentrifugation Study of Radioiodinated
Systems Involving Urokinase, Plasminogen and Fibrinogen.
BARG W F, BOGGIANO E, DE RENZO EC J Biol Chem, 240,
1965, 2944-2950. Interaction of Streptokinase and
Human Plasminogen. II Starch Gel Electrophoretic
Demonstration of a Reaction Product with Activator Activity.
BARKER J L, CRAYTON'J W, NICOL R A Sci, 171. 1972,
208-209. Supraoptic Neurosecretory Cells: Adrenergic
and Cholinergic Sensitivity.
BARLOW G H, LAZER L Thromb Res, 1, 1972, 201-208.
Characterization of the Plasminogen Activator Isolated
from Human Embryo Kidney Cells: Comparison with Urokinase.
BARNHART M I, RIDDLE J M Blood, 21, 1963, 306-321.
Cellular Localization of Profibrinolysin (Plasminogen).
BARRETT A J, STARKEY P M Biochem J, 133, 1973, 709-724.
The Interaction of oc -Macroglobulin with Proteinases.
Characteristics and Specificity of the Reaction, and a
Hypothesis Concerning its Molecular Mechanism.
BARRETT A J, STARKEY P M, MUNN E A In Proteinase
Inhibitors; Editors Fritz H, Tschesche H, Greene L J,
Truscheit E; Springer-Verlag, New York, 1974, 72-77.
The Unique Nature of the Interaction of oc^-Macroglobulin
with Proteinases.
319
BAUMGARTEN W, PRIESTER L I, STILLER D W, DUNCAN A E W
Thrombos Diathes Haemorrh, 24, 1970, 495-506. Mechanism
of Action of Synthetic Fibrinolytic Compounds.
BAUMGARTEN W Haematol Rev, 3, 1972, 231-295, Synthetic
Antifibrinolytic Agents.
BEATTIE A G, OGSTON D. BENNETT B, DOUGLAS AS Brit J
Haematol, 3_2_, 1976, 135-142. Inhibitors of Plasminogen
Activation in Human Blood.
BECKER C G, HARPEL PC J Exptl Med, 144, 1976, 1-9.
cc0-Macroglobulin on Human Vascular Endothelium.
BSNETATO G, DUMITRESCU-PAPAHAGI E Stud Cercet Fiziol,
9, 1964, 39-45. The Effect of Ultra-Short Wave Stimulation
of the Hypothalamic Region Upon the Fibrinolytic Activity
of the Blood In Relation to Age.
BERNIK M B, KWAAN H C J Lab Clin Med, 70, 1967, 650-661.
Origin of Fibrinolytic Activity in Cultures of the Human
Kidney.
BERNIK M B, KWAAN H C J Clin Invest, 48, 1969, 1740-1753.
Plasminogen Activator Activity in Cultures from Human
Tissues. An Immunological and Histochemical Study.
BERNIK MB J Clin Invest, 52_, 1973, 823-834. Increased
Plasminogen Activator (Urokinase) in Tissue Culture After
Fibrin Deposition.
BSRTHILLIER G, GOT R, BERTAGNOLIO G Biochim Biophys Acta,
17Q, 1968, 140-151. Biochimie de L'Alpha 1-Macroglobuline
de Lapin. IV Effect sur L'Activite Esterasique de la
Trypsine et de la Ch'ymotrypsine.
BIGGS R, MACFARLANE R G, PILLING J Lancet, 1, 1947,
402-405. Observations on Fibrinolysis. Experimental
Activity Produced by Exercise or Adrenaline.
BLIX S Acta Med Scand, 172, 1962, Suppl
Effectiveness of Activators in Clot Lysis,
Reference to Fibrinolytic Therapy.
BLOMBACK B, BLCMBACK M, EDMAN P, HESSEL B
BLophys Acta, 115, 1966, 371-396. Human
Isolation, Characterization and Structure.
BLOMBACK B, BLQMBACK M, HENSCHEN A, HESSEL
WOODS K R Nature, 218, 1968, 130-134.
Disulphide Knot of Human Fibrinogen.
BLOMBACK B Brit J Haematol, 17, 1969, 145-157. The
N-Terminal Disulphide Knot of Human Fibrinogen.
BLQMBACK B, BLQMBACK M Ann NY Acad Sci, 202, 1972,








BONNAR J, McNICOL G P, DOUGLAS A S Brit Med J, 3, 1969,
387-389. Fibrinolytic Enzyme System and Pregnancy.
BOUMA H, COTTRELL B A, FRIEZNER S J, TAKAGI T, DOOLITTLE R F
Thromb Haem, 3j3, 1977, 99. Amino Acid Sequence Studies
on the $-Chain of Human Fibrinogen.
BRAKMAN P, ASTRUP T Scand J Clin Lab Invest, T5, 1963,
603-609. Selective Inhibition in Human Pregnancy
Blood of Urokinase-Induced Fibrinolysis.
BRAKMAN P, MOHLER E R, ASTRUP T Scand J Haematol, 3,
1966, 389-398. A Group of Patients with Impaired Plasma
Fibrinolytic System and Selective Inhibition of Tissue
Activator-Induced Fibrinolysis.
BROCKWAY W J, CASTELLINO F J Biochem, 13, 1974,
2063-2070. A Characterization of Native Streptokinase
and Altered Streptokinase Isolated from a Human Plasminogen
Activator Complex.
BUCKELL M, ELLIOTT F A Lancet, 1, 1959, 660-662.
Diurnal Fluctuation of Plasma Fibrinolytic Activity in
Normal Males.
CAMIOLO S M, THORSEN S, ASTRUP T Proc Soc Exptl Biol
Med, 138, 1971, 277-280. Fibrinogenolysis and Fibrinolysis
with Tissue Plasminogen Activator, Urokinase, Streptokinase-
Activated Human Globulin, and Plasmin.
CASH J D In Thrombosis : Risk Factors and Diagnostic
Approaches; Editor Brinkhous K; Schattauer Verlag, New York,
1972, 93-104. Platelets, Fibrinolysis and Stress.
CASH J D In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 3; Editors Davidson J F, Rowan R M,
Samama M M, Desnoyers P C; Raven Press, New York, 1978,
65-75. Control Mechanism of Activator Release.
CASPARY E A, KEKWICK R A Biochem J, 67, 1957, 41-48.
Some Physicochemical Properties of Human Fibrinogen.
CASTELLINO F J, SODETZ J M, BROCKWAY W J, SIEFRING G E
In Methods in Enzymology, Vol XLV, Proteolytic Enzymes
Part B; Editors in Chief Colowick S P, Kaplan N O; Edited
by Lorand L; Academic Press, 1976, 244-257. Streptokinase.
CASTELLINO F J, VIOLAND B N Thromb Haem, 38, 1977, 60.
The Mechanism of Activation of Human Plasminogen by
Urokinase.
CEDERHOLM-WILLIAMS S A Thromb Res, 11, 1977a, 421-423.
The Binding of Plasminogen (Molecular Weight 84,000) and
Plasmin to Fibrin.
CEDERHOLM-WILLIAMS S A Biochem Soc Trans, 5, 1977b,
1441-1443. The Binding of Plasminogen, Plasmin and
Streptokinase-Plasminogen Activator to Fibrin.
321
CELANDER D R, LANGLINAIS R P, GUEST M M Arch Biochem
Biophys, 55, 1955, 286-287. The Application of Foam
Technique to the Partial Purification of a Urine Activator
of Plasma Profibrinolysin.
CHATTOPADHYAY D P, CLIFFTON E E Amer J Physiol, 208.
1965, 190-197. Activation of Rabbit Plasminogen by
Streptokinase.
CHRISTENSEN L R J Gen Physiol, 28, 1945, 363-383.
Streptoccal Fibrinolysis: A Proteolytic Reaction Due to a
Serum Enzyme Activated by Streptococcal Fibrinolysin.
CHRISTENSEN L R, MACLEOD C M J Gen Physiol, 28, 1945,
559-583. A Proteolytic Enzyme of Serum: Characterization,
Activation, and Reaction with Inhibitors.
CHRISTENSEN L R, SMITH D H Proc Soc Exptl Biol Med, 74,
1950, 840-844. Plasminogen Purification by Acid Extraction.
CHRISTENSEN U, MULLERTZ S Biochim Biophys Acta, 334,
1974, 187-198. Mechanism of Reaction of Human Plasmin
with oc-N-Benzoyl-L-Arginine-p-Nitroanilide.
CHRISTMAN J K, ACS G Biochim Biophys Acta, 34Q, 1974,
339-347. Purification and Characterization of a Cellular
Fibrinolytic Factor Associated with Oncogenic Transformation:
The Plasminogen Activator from SV-40-Transformed Hamster
Cells.
CHRISTMAN J K, SILAGI S, NEWCOMB E W, SILVERSTEIN S, ACS G
Proc Nat Acad Sci, 72_, 1975a, 47-50. Correlated
Suppression by 5-Bromodeoxyuridine of Tumorigenicity and
Plasminogen Activator in Mouse Melanoma Cells.
CHRISTMAN J K, ACS G, SILAGI S, SILVERSTEIN S C In
Proteases and Biological Control; Cold Spring Harbour,
New York, 1975b, 827-839. Plasminogen Activator:
Biochemical Characterization and Correlation with
Tumorigenicity.
CLAEYS H, MOLLA A, VERSTRAETE M Thromb Res, 3, 1973,
515-523. Conversion of NH^-Terminal Glutamic Acid to
NH^-Terminal Lysine Human Plasminogen by Plasmin.
CLAEYS H, VERMYLEN J Biochim Biophys Acta, 342, 1974,
351-359. Physico-Chemical and Proenzyme Properties of
NH?-Terminal Glutamic Acid and NH^-Terminal Lysine Human
Plasminogen.
CLAEYS H, SOTTRUP-JENSEN L, ZAJDEL M, PETERSEN T E,
MAGNUSSCN S Febs Lett, 61, 1976, 20-24. Multiple
Gene Duplication in the Evolution of Plasminogen. Five
Regions of Sequence Homology with the Two Internally
Homologous Structures in Prothrombin.
322
CLEMMENSEN I, CHRISTENSEN F Biochim Biophys Acta, 429,
1976, 591-599. Inhibition of Urokinase by Complex
Formation with Human oc,-Antitrypsin.
CLEMMENSEN I, THORSEN S, MULLERTZ S Haemostasis, 5,
1976, 218-230. Purification of a Plasminogen Activator
Inhibitor Indistinguishable from oc_.-Antitrypsin and a
Urokinase Inhibitor in Pregnancy Plasma.
CQCCHERI S, GENNARI P, LORETI A Clin Ter, 25, 1963,
3-46. L'Attivazione Delia Fibrinolisi Mediante Polisaccaridi
Acidi. Parte 1. Aspetti Biologici.
COLLEN D Doctorate Thesis, University of Leuven (Faculty
of Sciences), 1973. The Microheterogeneity of Human
Plasminogen.
COLLEN D, SEMERARO N, VERSTRAETE M Thromb Res, 4, 1974,
491-496. The Fibrinogenolytic Pathway of Fibrinogen
CsTabolism: A Reply.
COLLEN D, DE COCK F, VERSTRAETE M Thromb Res, 7, 1975a,
245-249. Immunochemical Distinction Between Antiplasmin
and cx^-Antitrypsin.
COLLEN D, ONG E B, JOHNSON A J Thromb Res, 7, 1975b,
515-529. Human Plasminogen: In Vitro and In Vivo
Evidence for the Biological Integrity of NH^-Terminal
Glutamic Acid Plasminogen.
COLLEN D Eur J Biochem, <59, 1976, 209-216. Identification
and Some Properties of a New Fast-Reacting Plasmin
Inhibitor in Human Plasma.
COLLEN D, BILLIAU A, EDY J, DE SQMER P Biochim Biophys
Acta, 499, 1977, 194-201. Identification of the Human
Plasma Protein Which Inhibits Fibrinolysis Associated
with Malignant Cells.
COLLEN D, NAUWELAERS F, WIMAN B In Progress in Chemical
Fibrinolysis and Thrombolysis, Vol 3; Edited by Davidson J F,
Rowan R M, Samama M M, Desnoyers P C; Raven Press, New York,
1978, 243-243. Isolation and Partial Characterization
of Antiplasmin, the Fast-Reacting Plasmin Inhibitor of
Human Plasma.
COMP P C Circulation, 54, Supplement II, 1976, 204.
Purification of Streptokinase Using Affinity Chromatography.
COX H T, POLLER L, THOMSON J M Lancet, 1, 1967, 1300-1302.
Gastric Fibrinolysis. A possible Aetiological Link with
Peptic Ulcer.
CRAWFORD G P M, OGSTON D Biochim Biophys Acta, 354, 1974,
107-113. The Influence of cc-l-Antitrypsin on Plasmin,
Urokinase and Hageman Factor Cofactor.
323
CRAWFORD G, OGSTON D Biochim Biophys Acta, 391, 1975,
139-192. The Action of Antithrombin III on Plasmin and
Activators of Plasminogen.
CRAWFORD G P M, OGSTON D, DOUGLAS AS Brit J Haematol,
30(1), 1975, 131. The Action of Antithrombin III on
Components of the Fibrinolytic Enzyme System.
DALAL P M, SHAH P M, ALLINGTON M J, SHARP A A Nature,
222, 1969, 988-990. Activator of Plasminogen in Saline
Extracts of Human Thrombi.
DASTRE A Arch Physiol Norm Path, 5, 1893, 661-663.
Fi'orinolyse dans le Sang.
DAVIES M C, ENGLERT ME, DE RENZO EC J Biol Chem, 239 ,
1964, 2651-2656. Interaction of Streptokinase and Human
Plasminogen. I Combining of Streptokinase and Plasminogen
Observed in the Ultracentrifuge Under a Variety of
Experimental Conditions.
DEMUTH F, VON RIESEN I Biochem Z, 203, 1928, 22-49.
Eiweisstoffwechel Normaler und Bosartiger Gewebe in Vitro.
DENIS P-S Fibrine du Sang Apres la Mort, Premiere
Partie "Essai sur L'Application de la Chimie a L'Etude
Physiologique du Sang de L1 Homme et a L'Etude Physiologico,
Pathelogique, Hygieneque et Therapeutique des Alterations
Morbides de Cette Humeur. Paris Bechet, 1838, 67.
DE RENZO E C, SIITERI P K, HUTCHINGS B L, BELL P H
J Biol Chem, 242, 1967, 533-542. Preparation and Certain
Properties of Highly Purified Streptokinase.
DEUTSCH D G, MERTZ E T Sci, 170, 1970, 1095-1096.
Plasminogen: Purification from Human Plasma by Affinity
Chromatography.
DOOLITTLE R F, CASSMAN K G, CHEN R, SHARP J J, WOODING G L
Ann NY Acad Sci, 202, 1972, 114-126. Correlation of
the Mode of Fibrin Polymerization with the Pattern of
Cross-Linkin g.
DOOLITTLE R F, GOLDBALM D, DOOLITTLE L R Thromb Haem,
38, 1977, 26. Amino Acid Sequence Studies on Human
Fibrinogen: Arrangement of Interchain Disulphide Bonds
Bounding the Regions of Three-Stranded Ropes.
EDY J, COLLEN D Biochim Biophys Acta, 484, 1977,
423-432. The Interaction in Human Plasma by Antiplasmin,
the Fast-Reacting Plasmin Inhibitor, with Plasmin, Thrombin,
Trypsin and Chymotrypsin.
EKULAND H, HEDNER U, NILSSON I M Acta Paediatr Scand,
59, 1970, 33-43. Fibrinolysis in Newborns.
324
ELMADJIAN F. HOPE J M, LAMSON E T J Clin Endocrinol
Metab, Y7_, 1957, 608-620. Excretion of Epinephrine
and Norepinephrine in Various Emotional States.
EXDE N, AUDITORE J Amer J Clin Pathol, 36_, 1961, 16-24.
Fibrinolytic Activity of Human Tissues and Dog Mast Cell
Tumors.
ENDRES G F, SCHERAGA H A Arch Biochem Biophys, 144,
1971, 519-528. Molecular Weight of Bovine Fibrinogen
by Sedimentation Equilibrium.
ERAS P, HARPEL P, WINAWER S J Gut, 11, 1970, 851-854.
Histological Localization of Plasminogen Activator and
Proteolytic Activity in the Human Stomach and Duodenum.
FANTL P, SIMON S E Aust J Exp Biol Med Sci, 26, 1948,
521-529. Fibrinolysis Following Electrically Induced
Convulsions.
FANTL P Sci, 135 , 1962, 787-788. Plasminogen Activity
of Plasma and Serum.
FEARNLEY G R, TWEED J M Clin Sci, 12, 1953, 81-89.
Evidence of Active Fibrinolytic Enzyme in Plasma of
Normal People with Observations on Inhibition Associated
with Presence of Calcium.
FEARNLEY G R, LACKNER H Brit J Haematol, 1, 1955,
189-198. Fibrinolytic Activity of Normal Blood.
FEARNLEY G R, BALMFORTH G, FEARNLEY E Clin Sci, 16,
1957, 645-650. Evidence of a Diurnal Fibrinolytic
Rhythm; with a Simple Method of Measuring Natural Fibrinolysis.
FINLAYSON J S, MOSESSON M W, BRONZERT T J, PISANO J J
J Biol Chem , 247, 1972, 5220-5222. Human Fibrinogen
Heterogeneities. II Cross-Linking Capacity of High
Solubility Catabolic Intermediates.
FISCHER A Arch Entwicklungsmech Org (Wilhelm Roux),
1Q4, 1925, 210-219. Beitrog zur Biologie der Gewebezellen.
Eine Vergleichend Biologische Studie der Normalen und
Malignen Gewebezellen In Vitro.
FISCHER A Nature, 157, 1946, 442. Mechanism of
Proteolytic Activity of Malignant Tissue Cells.
FITZGERALD J D Clin Pharmacol Ther, 10, 1969, 292-306.
Perspectives in Adrenergic Beta-Receptor Blockade.
FLEISHER M S, LOEB L J Biol Chem, 21, 1915, 477-501.
On Tissue Fibrinolysins.
FLUTE P T Proc 7th Cong Europ Soc Haematol (London)
Pt 2, I960, 894. Fibrinolytic Factors as Demonstrated
by Electrophoresis of Human Blood.
325
FRANKSSON C. GEMZELL C A, VON EULER US J Clin Endocrinol
Mstab, 14, 1954, 608-621. Cortical and Medullary
Adrenal Activity in Surgical and Allied Conditions.
FRETTO L J, FERGUSON E W, McKEE P A Thromb Haem, 38,
19 ~ 7, 192. Localization of Cross-Link Sites in cc-Chain
ox Hunan Fibrin.
FURLAN M, BECK E A Biochim Biophys Acta, 263, 1972,
6 31-644. Plasmic Degradation of Human Fibrinogen.
I Structural Characterization of Degradation Products.
FURLAN M, KEMP G, BECK E A Biochim Biophys Acta, 400,
1975a, 95-111. Plasmic Degradation of Human Fibrinogen.
Ill Molecular Model of the Plasmin-Resistant Disulphide
Knot in Mononeric Fragment D.
FURLAN M, SEELICH T, BECK E A Biochim Biophys Acta,
4CO, 1975b, 112-120. Plasmic Degradation of Human
Fibrinogen. IV Identification of Subunit Chain Remnants
in Fragment Y.
GADER A M A, CLARKSON A R, CASH J D Thromb Res, 2,
19~3a, 9-16. The Plasminogen Activator and Coagulation
Factor VIII Responses to Adrenaline, Noradrenaline,
Isoprenaline and Salbutamol in Man.
GADER A M A, DA COSTA J, CASH J D Lancet, 2, 1973b,
1417-1418. A New Vasopressin Analogue and Fibrinolysis.
G.ADER A M A, DA COSTA J, CASH J D Thromb Res, 4, 1974,
25-33. The Effect of Propranolol, Alprenolol and
Practolol on the Fibrinolytic and Factor VIII Response
to Adrenaline and Salbutamol in Man.
GAFFNEY P J Thromb Res, 2, 1973, 201-218. Subunit
Relationships 3etween Fibrinogen and Fibrin Degradation
Products.
GAFFNEY P J, BRASHER M Biochim Biophys Acta, 295, 1973,
303-313. Subunit Structure of the Plasmin-Induced
Degradation Products of Cross-Linked Fibrin.
GAFFNEY P J, BRASHER M Nature, 251, 1974, 53-54.
Mode of Action of Ancrod as a Defibrinating Agent.
GAFFNEY P J In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 3; Editors Davidson J F, Rowan R M,
Samama M M, Desnoyers P C; Raven Press, New York, 1978,
349-372. Fibrinolysis by Plasmin and Brinase: In Vitro
and In Vivo Observations.
GALLIMORE M J Brit J Haematol, 31, 1975, 217-231.
Serum Inhibitors of Fibrinolysis.
GALLIMORE M J, HEDNER U Thromb Res, 11, 1977, 267-273.
Brief Communication. Further Evidence for the Presence of
Two Plasma Inhibitors of Fibrinolysis distinct from
ccQ -Macroglobulin.
326
GALLIMORE M J Thromb Res, 12, 1978, 687-692.
Inter-oc-Antiplasmin : Its Distinction from Antiactivator .
GANROT P 0 Clin Chim Acta, 16, 1967, 328-330.
Inhibition of Plasmin Activity by oc0-Macroglobulin .
GANROT P O, NILEHN J-E Clin Chim Acta, 17, 1967,
511-513. Competition Between Plasmin and Thrombin for
oc9 -Macroglobulin.
CANS H, MORI K, QUINLAN R, RICHTER D, TAN B H Proc Soc
Exptl Biol Med, 136, 1971, 627-629. The Intestine as
Source of Plasminogen Activator Activity.
GEIGER W B J Immunol, 69, 1952, 597-604. Involvement
of Complement-Like Factor in Activation of Blood Protease.
GERATZ J D, CHENG M C-F Thrombos Diathes Haemorrh, 33,
1975, 230-243. The Inhibition of Urokinase by Aromatic
Diamidines.
GLEY E, LE BAS G Arch Physiol Norm Path, 9, 1897,
848-863. De L'Immunite Contre L'Action Anticoaguante
des Injections Intraveineuses de Propeptone.
GOLDSMITH G H, SAITO H, RATNOFF 0 D J Clin Invest, 62,
1978, 54-60. The Activation of Plasminogen by Hageman
Factor (Factor XII) and Hageman Factor Fragments.
GORDON Y B, MARTIN M J, McNEILE A T, CHARD T Lancet,
2_, 1973, 1168-1170. Specific and Sensitive Determination
of Fibrinogen-Degradation Products by Radioimmunoassay.
GOTTLOB R, BLUMEL G Thrombos Diathes Haemorrh, 19, 1968,
94-98. Studies on Thrombolysis with Streptokinase.
I On the Penetration of Streptokinase into Thrombi.
GRANELLI-PIPERNO A, VASSALLI J-D, REICH E J Exptl Med,
146, 1977, 1693-1706. Secretion of Plasminogen Activator
by Human Polymorphonuclear Leukocytes.
GREEN J R J Physiol, 8_, 1887, 372-377. Note on the
Action of Sodium Chloride in Dissolving Fibrin.
GROSKOPF W R, HSIEH B, SUMMARIA L, ROBBINS K C Biochim
Biophys Acta, 168, 1968, 376-379. The Specificity of
Human Plasmin on the B-Chain of Oxidized Bovine Insulin.
GROSKOPF W R, SUMMARIA L, ROBBINS K C J Biol Chem, 244,
1969, 3590-3597. Studies on the Active Centre of
Human Plasmin. Partial Amino Acid Sequence of a Peptide
Containing the Active Centre Serine Residue.
GUREWICH V, NOWAK A, LIPINSKA I, LIPINSKI B Thrombos
Diathes Haemorrh, 32, 1974a, 582-591. The Resistance of
Soluble Derivatives of Fibrinogen and the Sensitivity of
its Insoluble Forms to Fibrinolytic Degradation in Blood.
327
GUREWICH V, LIPINSKA I, LIPINSKI B Thromb Res, 5,
1974b, 647-656. Exercise-Induced Fibrinolytic Activity
and its Effect on the Degradation of Fibrinogen, Fibrin
and Fibrin-Like Precipitates.
GUREWICH V, HYDE E, LIPINSKI B Blood, 46(4), 1975,
555-565. The Resistance of Fibrinogen and Soluble
Fibrin Monomer in Blood to Degradation by a Potent
Plasminogen Activator Derived from Cadaver Limbs.
HARPEL P C, MOSESSON M W J Clin Invest, 52, 1973,
2175-2184. Degradation of Human Fibrinogen by Plasma
oc0-Macroglobulin-Enzyme Complexes .
HBDNER U, NILSSON I M, JACOBSEN C D Scand J Clin Lab
Invest, 25^, 1970, 329-336. Demonstration of Low Content
of Fibrinolytic Inhibitors in Individuals with High
Fibrinolytic Capacity.
HEDNER U, NILSSON I M Acta Med Scand, 189, 1971,
185-189. Urokinase Inhibitors in Serum in a Clinical
Series.
HEDNER U Thrombos Diathes Haemorrh, _30, 1973, 414-424.
Studies on an Inhibitor of Plasminogen Activation in
Human Serum.
HEDNER U Thrombos Diathes Haemorrh Suppl (Thrombosis,
Pathogenesis and Clinical Trials), 59, 1974, 287-294.
Fibrinolytic Inhibitors.
HEDNER U, COLLEN D Thromb Res, 8, 1976, 875-879.
Immunochemical Distinction Between the Inhibitors of
Plasminogen Activation and Antiplasmin in Human Plasma.
HEDNER U, GALLIMORE M J Thromb Haem, 38, 1977, 145.
Two Human Immunochemically Distinct Low Molecular Fibrinolytic
Inhibitors.
HEDNER U XVII Congress of the International Society of
Haematology, Paris, 1978, 302. Inhibition of Hageman
Factor (Factor Xlla) by an Inhibitor of the Plasminogen
Activation.
HEDNER U, GALLIMORE M J, MARTINSSON G, COLLEN D In
Progress in Chemical Fibrinolysis and Thrombolysis, Vol 3;
Editors Davidson J F, Rowan R M, Samama M M, Desnoyers P C;
Raven Press, New York, 1978, 249-255. Studies on
Fibrinolytic Inhibitors.
HENSCHEN A, LOTTSPEICH F, TOPFER-PETERSEN E, WARBINEK R
Thromb Haem, 38_, 1977, 25. On the Primary Structure of
Human Fibrinogen.
HIGHSMITH R F, KLINE D L Sci, 174, 1971, 141-142.
Kidney - Primary Source of Plasminogen After Acute Depletion
in the Cat.
HIGHSMITH R F, ROSENBERG R D J Biol Chem, 249(14).
1974, 4335-4338. The Inhibition of Human Plasmin by-
Human Antithrombin-Heparin Cofactor.
HOLLEMAN W H, ANDRES W W, WEISS L J Thromb Res, 7,
1975, 683-693. The Relationship Between the Lysine and
the p-Aminobenzamidine Binding Sites on Human Plasminogen.
HOLMBERG L, BLADH B, ASTEDT B Biochim Biophys Acta,
445, 1976, 215-222. Purification of Urokinase by
Affinity Chromatography.
HUNTER J A Treatise on Blood, Inflammation and Gunshot
Wounds; Nicoll G, London, 1794.
IATRIDIS S G, FERGUSON J II Thrombos Diathes Haemorrh,
6, 1961, 411-423. Effect of Surface and Hageman Factor
on the Endogenous or Spontaneous Activation of the
Fibrinolytic System.
ISACSON S, NILSSON I M Thrombos Diathes Haemorrh, 22,
1969, 211-215. The Kidneys and the Fibrinolytic Activity
in the Blood.
IWAMOTO M Thrombos Diathes Haemorrh, 3_3, 1975, 573-585.
Plasminogen-Plasmin System. IX Specific Binding of
Tranexamic Acid to Plasmin.
JANUSZKO T, FURMAN M, BULUK K Thrombos Diathes Haemorrh,
15, 1966, 554-560. The Kidneys and the Liver as the
Organs Regulating the Fibrinolytic System of the Circulating
Blood.
JOHNSON A J, McCARTY W R J Clin Invest, 38, 1959,
1627-1643. The Lysis of Artificially Induced Intra¬
vascular Clots in Man by Intravenous Infusion of Streptokinas
JOIST J H Thromb Haem, 38, 1977, 955-962. Platelets
and Fibrinolysis.
KAPLAN A P, AUSTEN K F J Exptl Med, 136, 1972, 1378-1393.
The Fibrinolytic Pathway of Human Plasma. Isolation and
Characterization of the Plasminogen Proactivator.
KAPLAN A P, MEIER H L, MANDLE R Semin Thromb Haem, 1,
1976, 1—26. The Hageman Factor Dependent Pathways of
Coagulation, Fibrinolysis, and Kinin Generation.
VON KAULLA. K N Thrombos Diathes Haemorrh, lO, 1963,
151-163. Inactivation of Antiplasmin and Complement C
in Human Plasma Rendered Fibrinolytic by Synthetic
Organic Compounds.
KAWAI S, HANAFUSA H Virology, 46, 1971, 470-479. The
effects of Reciprocal Changes in Temperature on the
Transformed State of Cells Infected with a Rous Sarcoma
Virus Mutant.
329
KAWANO T, UEMURA Y Thrombos Diathes Haemorrh, 25, 1971,
129-133. Inhibition of Tissue Activator by Urokinase
Inhibitor.
KLINE D L J Biol Chem, 204, 1953, 949-955. The
Purification and Crystallization of Plasminogen
(Profibrinolysin).
KLINE D L, FISHMAN J B Ann NY Acad Sci, 68, 1957,
25-37. Plasmin : The Humoral Protease.
KLINE D L Proc Soc Exptl Biol Med, 121, 1966, 184-186.
Plasminogen and Proactivator Concentration in Human Plasma.
KLINE D L, BOWLDS C A Fed Proc, 30, 1971, 368 (Abs),
Abs No 984. Possible Isolation of an Active Derivative
of Streptokinase.
KLINE D L, TS'AO C-H Amer J Physiol, 220, 1971,
440-443. Activation of Human Plasminogen by Streptokinase
in Absence of Plasmin-SK Activator.
KLUFT C Haemostasis, 5, 1976, 136-146. Occurrence of
CI Inactivator and Other Proteinase Inhibitors in Euglobulin
Fractions and Their Influence on Fibrinolytic Activity.
KLUFT C Thromb Res, 13, 1978, 135-151. Cl-Inactivator-
Resistant Fibrinolytic Activity in Plasma Euglobulin
Fractions: Its Relation to Vascular Activator in Blood
and its Role in Euglobulin Fibrinolysis.
KOK P, ASTRUP T Biochem, .8(1), 1969, 79-86. Isolation
and Purification of a Tissue Plasminogen Activator and
its Comparison with Urokinase.
KOK P, ASTRUP T Thrombos Diathes Haemorrh, 2_7(1) , 1972,
77-87. Differentiation Betxveen Plasminogen Activators
by Means of Epsilon-Aminocaproic Acid.
KONTTINEN Y P, LALLA M L T, TURUNEN O Thrombos Diathes
Haemorrh, 30, 1973, 403-413. Preferential Degradation
of Soluble Fibrin Monomers in Streptokinase-Activated
Plasma.
KOPITAR M, STEGNAR M, ACCETTO B, LEBEZ D Thrombos
Diathes Haemorrh, 31, 1974, 72-85. Isolation and
Characterization of Plasminogen from Pig Leucocytes.
KOWALSKI E, KOPEC M, LATALLO Z, ROSZOWSKI S, SENDYS N
Blood, 8, 1958, 436-446. On the Occurrence of a
Plasminogen-Like Substance in Human Tissues.
KUCINSKI C S, FLETCHER A P, SHERRY S J Clin Invest, 47,
1968, 1238-1253. Effect of Urokinase Antiserum on
Plasminogen Activators: Demonstration of Immunologic
Dissimilarity Between Plasma Plasminogen Activator and
Urokinase.
330
LAAKE K, VENNEROD A M Thromb Res, 4, 1974, 285-302.
Factor Xll-Induced Fibrinolysis: Studies on the Separation
of Prekallikrein, Plasminogen Proactivator and Factor XI
in Human Plasma.
LACK C H, ALI S Y Nature, 201, 1964, 1030-1031.
Tissue Activator of Plasminogen.
LANDMANN H Thrombos Diathes Haemorrh, 29, 1973,
253-275. Studies on the Mechanism of Action of Synthetic
Antifibrinolytics . A Comparison with the Action of
Derivatives of Benzamidine on the Fibrinolytic Process.
LASSEN M Acta Chem Scand, 12, 1958, 1825-1829.
Adsorption of Plasminogen Activator to Fibrin.
LESUK A, TERMINIELLO L, TRAVER J H Sci, 147, 1965,
880-882. Crystalline Human Urokinase: Some Properties.
LESUK A, TERMINIELLO L, TRAVER J H, GROFF J L Thrombos
Diathes Haemorrh, JL8, 1967, 293-294. Biochemical and
Biophysical Studies of Human Urokinase.
LEWIS J H, HOWE A G, FERGUSON J H J Clin Invest, 28,
1949, 1507-1510. Thrombin Formation. II The Effects of
Lysin (Fibrinolysin, Plasmin) on Prothrombin, Ac-Globulin
and Tissue Thromboplastin.
LING C M, SUMMARIA L, ROBBINS K C J Biol Chem, 240,
1965, 4213-4218. Mechanism of Formation of Bovine
Plasminogen Activator from Human Plasmin.
LORAND L, JACOBSEN A J Biol Chem, 230, 1958, 421-434.
Studies of the Polymerization of Fibrin. The Role of the
Globulin: Fibrin Stabilizing Factor.
LORAND L, CONDIT E V Biochem, 4, 1965, 265-270.
Ester Hydrolysis by Urokinase.
LORMEAU J C, GOULAY J, VAIREL E G, CHOAY J Thromb Haem,
38, 1977, 257. The Action of Urokinases on Plasminogens.
LUKASIEWICZ H, NIEWIAROWSKI S, WOROWSKI K, LIPINSKI B
Biochim Biophys Acta, 159, 1968, 503-508. The Plasmin
Inhibition by Synthetic Antifibrinolytic Agents in Relation
to the Type of Substrate.
McCLINTOCK D K, BELL P H Biochem Biophys Res Comm, 43,
1971, 694-702. The Mechanism of Activation of Human
Plasminogen by Streptokinase.
McCLINTOCK D K, ENGLERT M E, DZIOBKOWSKI C, SNEDEKER E H,
BELL P H Biochem, 13, 1974, 5334-5344. Two Distinct
Pathways of the Streptokinase-Mediated Activation of Highly
Purified Human Plasminogen.
331
MacFARLANE R G Lancet, i_, 1937, 10-12. Fibrinolysis
Following Operation.
MacFARLANE R G, BIGGS R Lancet, 2, 1946, 862-864.
Observations on Fibrinolysis : Spontaneous Activity
Associated with Surgical Operations, Trauma, Etc.
MacFARLANE R G, PILLING J Nature, 159, 1947, 779.
Fibrinolytic Activity of Normal Urine.
McKEE P A, ROGERS L A, MARLER E, HILL R L Arch Biochem
Biophys, 116, 1966, 271-279. The Subunit Polypeptides
of Human Fibrinogen.
McKEE P A, MATTOCK P, HILL R L Proc Nat Acad Sci, 66,
1970, 738-744. Subunit Structure of Human Fibrinogen,
Soluble Fibrin and Cross-Linked Insoluble Fibrin.
Mc KILLOP C, EDGAR W, FORBES C D, PRENTICE CRM Thromb
Res, 7, 1975, 361-372. In Vivo Production of Soluble
Complexes Containing Fibrinogen-Fibrin Related Antigen
During Ancrod Therapy.
MAGNUSSON S In The Enzymes, Vol 3 (3rd Edit); Editor
Boyer R D; Acad Press, New York, 1971, 277-321. Thrombin
and Prothrombin.
MAGNUSSON S, SOTTRUP-JENSEN L, PETERSEN T E, DUDEKWOJCIECHOWSKA
G, CLAEYS H In Proteolysis and Physiological Regulation,
Eighth Miami Winter Symposia; Editors Brew K, Ribbons D W;
Acad Press, New York, 1976, 203-238. Homologous "Kringle"
Structures Common to Plasminogen and Prothrombin. Substrate
Specificity of Enzymes Activating Prothrombin and Plasminogen.
MANN K G, HELDEBRANT C M, FASS D N J Biol Chem, 246,
1971, 5994-6001. Multiple Active Forms of Thrombin.
1 Partial resolution, Differential Activities, and Sequential
Format ion.
MANN K G, YIP R, HELDEBRANT C M, FASS D N J Biol Chem,
248, 1973, 1868-1875. Multiple Active Forms of Thrombin.
Ill Polypeptide Chain Location of Active Site Serine and
Carbohydrate.
MANNUCCI P, BARBI G L Abstract in Vllth Ann Meeting
Europ Soc Clin Invest, Rotterdam, 1973, 144.
MANNUCCI P M, ABERG M, NILSSON I M, ROBERTSON B Brit J
Haematol, 30, 1975, 81-93. Mechanism of Plasminogen
Activator and Factor VIII Increase After Vasoactive Drugs.
MARDER V J, SHULMAN N R, CARROLL W R J Biol Chem, 244,
1969, 2111-2119. High Molecular Weight Derivatives
of Human Fibrinogen Produced by Plasmin. 1 Physicochemical
and Immunological Characterization.
332
HARDER V J, BUDZYNSKI A Z, JAMES H L J Biol Chem, 247,
1972, 4775-4781. High Molecular Weight Derivatives of
Human Fibrinogen Produced by Plasmin.
HARDER V J, DCNAHOE J F, BELL W R, CRANLEY J J, KWAAN H C,
SASAHARA A A, BARLOW G H Thromb Haem, 38, 1977, 195.
Comparison of In Vivo Biochemical Effects of Human Urokinase
Prepared from Urinary and Tissue Culture Sources .
MARKUS G, WERKHEISER W C J Biol Chem, 239, 1964, 2637-
2643. The Interaction of Streptokinase with Plasminogen.
I Functional Properties of the Activated Enzyme.
MARSH N A Thrombos Diathes Haemorrh, 24, 1970, 26-32.
The Kidney and Fibrinolysis. A Study of Aminonucleoside
Nephrotic Rats.
MARTIN M In Synthetic, Fibrinolytic and Thrombolytic
Agents; Editors von Kaulla K N, Davidson J F; Thomas C C,
Springfield, 111, 1975, 276-283. The Fibrinolytic
Effect of Euglobulin Fraction from Human Plasma Before
and After Addition of an Acid Polysaccharide (SP54).
MENON I S, MUSCAT-BARON'J, DEWAR HA J Atheroscler Res,
8, 1968, 547-554. Comparison of Fibrinolytic Activity
in Hepatic and Systemic Venous Blood.
MENON I S, WEIGHTMAN D, DEWAR H A Clin Sci, 36, 1969,
427-433. The Role of the Lung in Blood Fibrinolysis.
MENON I S, MUSCAT-BARON J, WEIGHTMAN D, DEWAR H A Clin
Sci, 38, 1970, 85-91. The Brain as Contributor of
Plasminogen Activator to the Blood.
MERSKEY C, LALEZARI P, JOHNSON A J Proc Soc Exptl Biol
Med, 131, 1969, 871-875. A Rapid, Simple, Sensitive
Method for Measuring Fibrinolytic Split Products in Human
Serum.
MEYERS W M, BURDON K L Amer J Physiol, 190, 1957,
303-309. Proteolytic Activity of Guinea Pig Serum
Activated by Streptokinase-Human Plasminogen Preparations.
MILLER L L, BALE W F J Exptl Med, 99, 1954, 125-132.
Synthesis of All Plasma Protein Fractions Except Gamma
Globulins by the Liver; Use of Zone Electrophoresis and
Lysine-e-C to Define the Plasma Proteins Synthesized by
the Isolated Perfused Liver.
MILSTQNE H J Immunol, 42, 1941, 109-116. A Factor
in Normal Human Blood xvhich Participates in Streptococcal
Fibrinolysis.
MIRSKY I A, PERISUTTI G, DAVIS N C J Clin Invest, 38,
1959, 14-20. Destruction of Glucagon, Adrenocorticotrophin
and Somatotropin by Human Blood Plasma.
MOODY G H PhD Thesis, Edinburgh, 1976. Investigations
.into the Fibrinolytic System of Human Mixed Native Saliva.
MOORE S, PEPPER D S, CASH J D Biochim Biophys Acta,
379, 1975, 360-369. The Isolation and Characterisation
of a Platelet-Specific B-Globulin (B-Thromboglobulin) and
the Detection of Anti-Urokinase and Antiplasmin Released
from Thrombin-Aggregated Washed Human Platelets.
MORGAGNI J B The Seats and Causes of Diseases Investigated
by Anatomy; Millar A, Cadell T, London, 1769.
MOROI M, AOKI N J Biol Chem, 251, 1976, 5956-5965.
Isolation and Characterization of oc^-Plasmin Inhibitor from
Human Plasma. A Novel Proteinase Inhibitor which Inhibits
Activator-Induced Clot Lysis.
MOROI M, AOKI N Thromb Res, 10, 1977a, 851-856.
Brief Communication. Inhibition of Plasminogen Binding to
Fibrin by OC2~Plasmin Inhibitor.
MOROI M, AOKI N Biochim Biophys Acta, 482, 1977b, 412-
420. On the Interaction of oc^-Plasmin Inhibitor and
Proteases. Evidence for the Formation of a Covalent
Cross linkage and Non-Covalent Weak Bonds Between the
Inhibitor and Proteases.
MOSESSON M W Thromb Res, 2, 1973, 185-200. The
Fibrinogenolytic Pathway of Fibrinogen Catabolism.
MULLERTZ S Acta Physiol Scand, 28, 1953a, 29-40.
The Action of Plasmin on Fibrin and Fibrinogen in Blood.
MULLERTZ S Proc Soc Exptl Biol Med, 82, 1953b, 291-295.
A Plasminogen Activator in Spontaneously Active Human Blood.
MULLERTZ S, LASSEN M Proc Soc Exptl Biol Med, 82,
1953, 264-268. An Activator System in Blood Indispensable
for Formation of Plasmin by Streptokinase.
MULLERTZ S Biochem J, 61, 1955, 424-434. Formation
and Properties of the Activator of Plasminogen and of Human
and Bovine Plasmin.
MULLERTZ S Biochem J, 143, 1974, 273-283. Different
Molecular Forms of Plasminogen and Plasmin Produced by
Urokinase in Human Plasma and Their Relation to Protease
Inhibitors and Lysis of Fibrinogen and Fibrin.
MULLERTZ S, CLEMMENSEN I Biochem J, 159, 1976, 545-553.
The Primary Inhibitor of Plasmin in Human Plasma.
MULLERTZ S In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 3; Editors Davidson J F, Rowan R M,
Samama M M, Desnoyers P C; Raven Press, New York, 1978,
213-237. Natural inhibitors of Fibrinolysis.
NIEUWENHUIZEN W, WIJNGAARDS G, GROENEVELD E Thromb Res,
11, 1977, 87-89. Synthetic Substrates and the
Discrimination Between Urokinase and Tissue Plasminogen
Activator Activity.
NIEWIAROWSKI S, PROU-WARTELLE O Thrombos Diathes
Haemorrh, 3, 1959, 593-603. Role du Facteur Contact
(Facteur Hageman) dans la Fibrinolyse.
NILEHN J E, GANROT P 0 Scand J Clin Lab Invest, 20,
1967, 113-121. Plasmin, Plasmin Inhibitors and
Degradation Products of Fibrinogen in Human Serum During
and After Intravenous Infusion of Streptokinase.
NILSSON I M, KROOK H, STERNBY N H, SODERBERG E, SODERSTRQM N
Acta Med Scand, 169, 1961, 323-337. Severe Thrombotic
Disease in a Young Man ivith Bone Marrow and Skeletal
Changes and with a High Content of an Inhibitor in the
Fibrinolytic System.
NITTA H, SUGIE I, M0RIM0T0 S, SATO S Nagoya Med J, 13,
1967, 151-164. Studies on Physiochemical Properties
of the Fibrinolytic Substances in Human Saliva.
NOLAN C, HALL L S, BARLOW G H, TRIBBY I I E Biochim
Biophys Acta, 496, 1977, 384-400. Plasminogen Activator
from Human Embryonic Kidney Cell Cultures. Evidence for a
Proactivator.
NOLF P Arch Internat De Physiol, 3^, 1904, 242-260.
Da la Nature de L'Hypoleucocytosi Propeptonique.
NOLF P Arch Internat De Physiol, 3, 1905, 1-43. Des
Modifications de la Coagulation du Sang chez le Chien
Apres L*Extirpation du Foie.
N00RDH0EK HEGT V Thromb Haem, 38, 1977, 407-419.
Relations Between Activation and Inhibition of Fibrinolysis
in the Walls of Human Arteries and Veins.
NORMAN PS J Exptl Med, 106, 1957, 423-437. Studies
of the Plasmin System: I Measurement of Human and Animal
Plasminogen. Measurement of an Activator in Human Serum.
NOSSEL H L, CANFIELD R E, BUTLER V P JR Proc IV
Internat Cong Thromb Haem, 1973, 237. Plasma Fibrinopeptide.
A Concentration as an Index of Intravascular Coagulation.
OGAWA N. YAMAMOTO H, KATAMINE T, TAJIMA H Thrombos
Diathes Haemorrh, 34, 1975, 194-209. Purification and
Some Properties of Urokinase
OGSTON D, 0GSTON C, RATNOFF 0, FORBES CD J Clin Invest,
48, 1969, 1786-1801. Studies on a Complex Mechanism
for the Activation of Plasminogen by Kaolin and by
Chloroform: the Participation of Hageman Factor and
Additional Cofactors.
0G5T0N D, MURRAY J, DOUGLAS A S Brit J Haematol, 24,
1973, 665-666. Studies of an Inhibitor of Plasminogen
Activation in Platelets.
OGSTON D, BENNETT B, MACKIE M Thromb Res, 8, 1976,
275-284. Properties of a Partially Purified Preparation
of a Circulating Plasminogen Activator.
OKAMOTO S, OSHI BA S, MIHARA H, OKAMOTO U Ann NY Acad
Sci, 146, 1968, 414-429. Synthetic Inhibitors of
Fibrinolysis: In Vitro and In Vivo Mode of Action.
OKAMOTO U, NAGAMATSU Y, MATSUMOTO M, YAMAMOTO J Acta
Haem Jap, 37_, 1974, 121-131. Studies on a Plasminogen
Activating System in Human Milk. I Isolation of Plasminogen
Activator and Proactivator from Human Milk, and Estimation
of Their Molecular Weights.
ONG E B, JOHNSON A J, SCHOELLMANN G Biochim Biophys Acta
429, 1976, 252-257. Identification of an Active Site
Histidine in Urokinase.
ONG E B, SOBERANO M E, JOHNSON A J, SCHOELLMANN G Thromb
Haem, 3<3, 1977, 801-808. Studies on the Biochemistry
of Urokinase.
05HIBA S, ARIGA T, SAWAI H, IMAI H Thromb Haem, 38,
1977, 273. Some Aspects of Biliary Fibrinolysis in Man.
OSSOWSKI L, UNKELESS J C, TOBIA A, QUIGLEY J P, RIFKIN D B,
REICH E J Exptl Med, 137, 1973, 112-126. An
Enzymatic Function Associated with Transformation of
Fibroblasts by Oncogenic Viruses. II Mammalian Fibroblast
Cultures Transformed by DNA and RNA Tumor Viruses.
PAINTER R H, CHARLES A F Amer J Physiol, 202, 1962,
1125-1130, Characterization of a Soluble Plasminogen
Activator from Kidney Cell Cultures.
PANDOLFI M, NILSSON I M, ROBERTSON B, ISACSON S Lancet,
2_, 1967, 127-128. Fibrinolytic Activity of Human Veins.
PANDOLFI M, ROBERTSON B, ISACSON S, NILSSON I M Thrombos
Diathes Haemorrh, 20, 1968, 247-256. Fibrinolytic
Activity of Human Veins in Arms and Legs.
PANDOLFI M, ISACSON S, NILSSON I M Acta Med Scand, 186,
1969, 1-5. Low Fibrinolytic Activity in the Walls of
Veins in Patients with Thrombosis.
PANDOLFI M Thrombos Diathes Haemorrh, 24, 1970, 43-47.
Persistence of Fibrinolytic Activity in Fragments of Human
Veins Cultured In Vitro.
PANDOLFI M, HEDNER U, NILSSON I M Ann Opthalmol, 2, 1970
481-484. Bilateral Occlusion of the Retinal Veins in a
Patient with Abnormally Large Content of Inhibitors of
Fibrinolysis in the Blood.
336
PA03I N F, CASTELLINO F J Biochem Biophys Res Comm,
65. 1975, 757-^64. Isolation of a Low Molecular Weight
Form of Plasminogen.
PERMIN P M Nature, 160, 1947, 571-572. Properties
of the Fibrinokinase-Fibrinolysin System.
PILLEMER L, RATNOFF 0 D, BLUM L, LEPOW I H J Exptl Med,
9~, 1952, 573-539. The Inactivation of Complement and
its Components by Plasmin.
PIZZO S V, SCHWARTZ M L, HILL R L, McKEE PA J Biol
Cham, 243, 19~3a, 4574-4583. The Effect of Plasmin on
the Subunit Structure of Human Fibrin.
PIZZO S V, TAYLOR L M, SCHWARTZ M L, HILL R L, McKEE P A
J 3iol Chem, 243, 1973b, 4584-4590. Subunit Structure
of Fragment D from Fibrinogen and Cross-Linked Fibrin.
PLOSZ P Archiv Gesamte Physiol, 7, 1873, 371-390.
Leber die Eiweissartigen Substanzen der Leberzelle.
PLOUG J, KJELDGAARD N 0 Biochim Biophys Acta, 2_4, 1957,
278-282. Urokinase. An Activator of Plasminogen from
Human Urine.
RADCLIFFE R, HEINZE T Arch Biochem Biophys, 189, 1978,
185-194. Isolation of Plasminogen Activator from Human
Plasma by Chromatography on Lysine-Sepharose.
RAKOCZI I, WIMAN B, COLLEN D Biochim Biophys Acta, 540,
1978, 295-300. On the Biological Significance of the
Specific Interaction Between Fibrin, Plasminogen and
Antiplasmin.
RATNOFF O D J Clin Invest, 32, 1953, 473-479. Studies
on a Proteolytic Enzyme in Human Plasma. IX Fibrinogen
and Fibrin as Substrates for the Proteolytic Enzyme of
Plasma.
REDDY K N N, MARKUS G J Biol Chem, 247, 1972, 1683-1691.
Mechanism of Activation of Human Plasminogen by Streptokinase.
Presence of Active Centre in Streptokinase-Plasminogen
Complex.
REDDY K N N, KLINE D L Thromb Res, 6, 1975, 481-488.
Requirement of Human Plasmin for Streptokinase Activation
of Bovine Plasminogen.
RICKLI E E, OTAVSKY W I Biochim Biophys Acta, 295, 1973,
381-384. Release of an N-Terminal Peptide from Human
Plasminogen During Activation with Urokinase.
RICKLI E E Thrombos Diathes Haemorrh, _34, 1975, 386-395.
The Activation Mechanism of Human Plasminogen.
337
RICKLI E E, CCAV3KY W I Eur J 3iochem, £59, 1975,
4-1-447. A ?»ew Method of Isolation and Some Properties
of the Heavy Chain of Human Plasmin.
RICKLI E E, LEP.GIER W, GILLESSEN D Biochim Biophys
Acta, 439, 19~6, 47-50. Investigations on the Primary
Structure of Hunan Plasminogen. Further Evidence for
Sequence Homology.
P. IF KIN D B, LOEB J N, MOORE G, REICH E J Exptl Med,
139, 1974, 1317-1328. Properties of Plasminogen
Activators Formed by Neoplastic Human Cell Cultures.
EIFKIN D B, BEAL E P, REICH E In Proteases and Biological
Control; Cold Spring Harbour, New York, 1975, 841-847.
Macromolecular Determinants of Plasminogen Activator
Synthesis.
PIG3I M PhD Thesis, Hebrew Univ, Jerusalem, 1957.
RIMON A, SHAMASH Y, SHAPIRO B J Biol Chem, 241 , 1966,
5102-5107. The Plasmin Inhibitor of Human Plasma.
IV Its Action on Plasmin, Trypsin, Chymotrypsin and Thrombin.
R03BINS K C Amer J Physiol, 142, 1944, 581-588.
A Study on the Conversion of Fibrinogen to Fibrin.
BOBBINS K C, SUMMARIA L J Biol Chem, 238 , 1963, 952-962.
Purification of Human Plasminogen and Plasmin by Gel
Filtration on Sephadex and Chromatography on
Diethylaminoethyl-Sephadex.
BOBBINS K C, SUMMARIA L, ELWYN D, BARLOW G H J Biol
Chen, 24Q, 1965, 541-550. Further Studies on the Purif¬
ication and Characterization of Human Plasminogen and
Plasmin.
BOBBINS K C, SUMMARIA L, HSIEH B, SHAH R J J Biol Chem,
242, 1967, 2333-2342. The Peptide Chains of Human
Plasmin. Mechanism of Activation of Human Plasminogen
to Plasmin.
BOBBINS K C, BBRNABE P, ARZADON L, SUMMARIA L J Biol
Chem, 248, 1973, 7242-7246. NH^-Terminal Sequences of
Mammalian Plasminogens and Plasmin S-Carboxymethy1 Heavy
(A) and Light (3) Chain Derivatives. A Re-Evaluation
of the Mechanism of Activation of Plasminogen.
BOBBINS K C, BOREISHA I G, ARZADON L, SUMMARIA L, BARLOW G H
J Biol Chem, 250, 1975, 4044-4047. Physical and Chemical
Properties of the NHQ-Terminal Glutamic Acid and Lysine
Forms of Human Plasminogen and Their Derived Plasmins
with an NH0-Terminal Lysine Heavy (A) Chain.
R03BINS K C, SUMMARIA L, WOHL R C Thromb Haem, 38, 1977,
169. The Functional Activities of the Human Plasmin-
Derived Light (B) Chain.
ROSING D R, BRAXMAN P, REDWOOD D R, GOLDSTEIN R E,
BEISER G D Circul Res, 27, 1970, 171-184. Blood
Fibrinolytic Activity in Man. Diurnal Variation and the
Response to Varying Intensities of Exercise.
SAHLI W Arch Gesamte Physiol, 36, 1885, 209-229.
liber das Vorkormen von Pepsin und Trypsin im Normalen
Menschlichen Harn.
SCHNECK S A, VON KAULLA K N Neurology, 11., 1961,
959-969. Fibrinolysis and the Nervous System.
SCHWARTZ M L, PIZZO S V, HILL R L, McKEE PA J Biol Chem
248, 1973, 1395-1407. Human Factor XIII from Plasma
and Platelets. Molecular Weights, Subunit Structures,
Proteolytic Activation, and Cross-Linking of Fibrinogen
and Fibrin.
SCHWICK H G, HEIMBURGBR N, HAUPT H Thrombos Diathes
Haemorrh, 18, 1967, 302. Purification and Chemical-
Physical Properties of Some Proteinase Inhibitors of Plasma
SGOURIS J T, STOREY R W, McCALL K B, ANDERSON H D Vox
Sang, 7_, 1962, 739-749. The Purification, Assay,
Sterilization, and Removal of Pyrogenicity of Human
Urokinase.
SHAINOFF J R, DARDIK B N Thromb Haem, 38, 1977, 191.
Fibrinopeptide B and Aggregation of Fibrinogen.
SHARP A A In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 1; Editors Davidson J F, Samama M M,
Desnoyers P C; Raven Press, New York, 1975, 19-21.
Mechanism of Fibrinolysis.
SHEN L L, HERMANS J, McDONAGH J, McDQNAGH R P Amer J
Physiol, 232(6), 1977, H629-H633. Role of Fibrinopeptide
B Release: Comparison of Fibrins Produced by Thrombin and
Ancrod.
SHERRY S J Clin Invest, 33, 1954, 1054-1063.
Fibrinolytic Activity of Streptokinase Activated Human
Plasmin.
SHERRY S Gastroenterol, JVL, 1966, 901-912. Fibrinolyt
Mechanisms in Tissue Injury.
SHERRY S, ALKJAERSIG N, FLETCHER A P Thrombos Diathes
Haeraorrh, 16_, 1966, 18-31. Activity of Plasmin and
Streptokinase-Activator on Substituted Arginine and
Lysine Esters.
SIEFRING G E, CASTELLINO F J J Biol Chem, 249 , 1974,
1434-1438. Metabolic Turnover Studies on the Two Major
Forms of Rat and Rabbit Plasminogen.
339
SJOHOLM I, WIMAN B, WALLEN P Eur J Biochem, 39, 1973,.
471-479. Studies on the Conformational Changes of
Plasminogen Induced During Activation to Plasmin and by
o-Aminohexanoic Acid.
SKOZA L, TSE A 0, SEMAR M, JOHNSON A J Ann NY Acad Sci,
146, 1963, 659-672. Comparative Activities of Amino
Acid, and Polypeptide Inhibitors on Natural and Synthetic
Substrates.
SLOTTA K H, MICHL H, SANTOS B G Biochim Biophys Acta,
58. 1962, 459-466. Comparitive Studies on Native and
Acid Treated Plasminogens.
SOBEL G W, MOHLER S R, JONES N W, DOWDY ABC, GUEST M M
Amer J Physiol, 171, 1952, 768-769. Urokinase: An
Activator of Plasma Profibrinolysin Extracted from Urine.
SODETZ J M, BROCKWAY W J, MANN K G, CASTELLINO F J
Biochem Biophys Res Comm, C>0(2), 1974, 729-736. The
Mechanism of Activation of Rabbit Plasminogen by Urokinase.
Lack of a Preactivation Peptide.
SODETZ J M, CASTELLINO F J J Biol Chem, 250, 1975,
3041-3049. The Mechanism of Activation of Rabbit
Plasminogen by Urokinase.
SOTTRUP-JENSEN L, ZAJDEL M, CLAEYS H, PETERSEN T E,
MAGNUSSON S Proc Nat Acad Sci, 72, 1975, 2577-2581.
Amino Acid Sequence of Activation Cleavage Site in
Plasminogen Homology with "Pro" Part of Prothrombin.
SOTTRUP-JENSEN L, PETERSEN T E, MAGNUSSON S Thromb Haem,
38, 1977, 134. Primary Structure of Plasminogen.
Separation of Two Lysine-Binding Domains and One
Neoplasminogen (Molecular Weight = 38,000).
STEINBUCH M In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 1; Editors Davidson J F, Samama M M,
Desnoyers P C; Raven Press, New York, 1975, 16.1-172.
Molecular Properties of Plasminogen and Plasmin Activation
and Inhibition Mechanism.
STORM O Scand J Clin Lab Invest, 7, 1955, 55-58.
Fibrinolytic Activity in Human Tears.
STRACHAN C J L, SCULLY M F, KAKKAR V V Thromb Res, 4,
1974, 303-318. The Behaviour of Isotope Labelled Blood
Proteins in Thrombosis.
SUMMARIA L, HSIEH B, ROBBINS K C J Biol Chem, 242, 1967,
4279-4283. The Specific Mechanism of Activation of
Human Plasminogen to Plasmin.
SUMMARIA L, LING C M, GROSKOPF W R, ROBBINS K C J Biol
Chem, 243, 1968, 144-150. The Active Site of Bovine
Plasminogen Activator. Interaction of Streptokinase with
Human Plasminogen and Plasmin.
SUMMARIA L, HSIEH B, GROSKOPF W R, ROBBINS K C Proc Soc
Exptl Biol Med, 130, 1969, 737-743. Direct Activation
of Human Plasminogen by Streptokinase.
SUMMARIA L, ROBBINS K C, BARLOW G H J Biol Chem, 246,
1971, 2143-2146. Isolation and Characterization of the
S-Carboxymethyl Heavy Chain Derivative of Human Plasmin.
SUMMARIA L, ARZADON L, BERNABE P, ROBBINS K C J Biol
Chem, 247, 1972, 4691-4702. Studies on the Isolation
of the Multiple Molecular Forms of Human Plasminogen and
Plasmin by Isoelectric Focusing Methods.
SUMMARIA L, ARZADON L, BERNABE P, ROBBINS K C J Biol
Chem, 249, 1974, 4760-4769. The Interaction of
Streptokinase xvith Human Cat, Dog and Rabbit Plasminogens.
The Fragmentation of Streptokinase in the Equimolar
Plasminogen-Streptokinase Complexes.
SUMMARIA L, ARZADON L, BERNABE P, ROBBINS K C J Biol
Chem, 250, 1975, 3988-3995. The Activation of Plasminogen
to Plasmin by Urokinase in the Presence of the Plasmin
Inhibitor Trasylol. The Preparation of Plasmin with the
Same NH^-Terminal Heavy (A) Chain Sequence as the Parent
Zymogen.
SUMMARIA L, SPITZ F, ARZADON L, BOREISHA I G, ROBBINS K C
J Biol Chem, 251, 1976, 3693-3699. Isolation and
Characterization of the Affinity Chromatography Forms of
Human Glu- and Lys-Plasminogens and Plasmins .
SUYAMA T, NISHIDA M, IGA Y, NAITO R Thromb Haem, 38.
1977, 48. Difference in Thrombolytic Effect Between
Higher and Lower Molecular Weight Forms of Urokinase.
SVANBERG L, ASTEDT B Cancer, 35, 1975, 1382-1387.
Coagulative and Fibrinolytic Properties of Ascitic Fluid
Associated with Ovarian Tumours.
SVANBERG L, LINELL F, PANDOLFI M, ASTEDT B Acta Path
Microbiol Scand Sect A, 83, 1975, 193-198. Plasminogen
Activators in Ovarian Tumours.
TABLES OF THE ERROR FUNCTION AND ITS DERIVATIVES NBS,
Applied Mathematics Series 41, United States Printing
Office, Washington DC, 1954.
TAKADA Y, AMBRUS C M Fed Proc, 28, 1969, 746.
Isolation and Characterization of a Plasminogen Proactivator
in Human Plasma.
TADADA Y, TAKADA A, AMBRUS J L Thrombos Diathes Haemorrh,
21 , 1969, 594-603. Comparative Study of Proactivators
of the Fibrinolysin System in Three Mammalian Species
341
TAKADA A, TAKADA Y, AMBRUS J L J Biol Chem, 245, 1970,
5339-6396. Streptokinase-Activatable Proactivator of
Human and Bovine Plasminogen.
TAKADA A, TAKADA Y, AMBRUS J L Biochim Biophys Acta,
263 , 1972, 610-618. Further Studies of Plasminogen
Proactivator.
TAYLOR F B, BOTTS J Biochem, 7, 1968, 232-242.
Purification and Characterization of Streptokinase with
Studies of Streptokinase Activation of Plasminogen.
TAYLOR F B, BEISSWENGBR J G J Biol Chem, 248. 1973,
1127-1134. Identification of Modified Streptokinase
as the Activator of Bovine and Human Plasminogen.
TELESFORO P, SEMERARO N, VERSTRAETE M, COLLEN D Thromb
Res, 7, 1975, 669-676. The Inhibition of Plasmin by
Antithrombin. III-Heparin Complex In Vitro in Human Plasma
and During Streptokinase Therapy in Man.
THORSEN S, ASTRUP T Proc Soc Exptl Biol Med, 130,
1969, 811-813. Biphasic Inhibition of Urokinase-Induced
Fibrinolysis by e-Aminocaproic Acid; Distinction from
Tissue Plasminogen Activator.
THORSEN S, GLAS-GREENWALT P, ASTRUP T Thrombos Diathes
Haemorrh, 2_3, 1972, 65-74. Differences in the Binding
to Fibrin of Urokinase and Tissue Plasminogen Activator.
THORSEN S, ASTRUP T Thrombos Diathes Haemorrh, 32,
1974, 306-324. Substrate Composition and the Effect of
e-Aminocaproic Acid on Tissue Plasminogen Activator and
Urokinase-Induced Fibrinolysis.
THORSEN S, KOK P, ASTRUP T Thrombos Diathes Haemorrh,
32, 1974, 325-340. Reversible and Irreversible Alterations
of Human Plasminogen Indicated by Changes in Susceptibility
to Plasminogen Activators and in Response to e-Aminocaproic
Acid.
THORSEN S, MULLERTZ S Scand J Clin Lab Invest, 34, 1974,
167-176. Rate of Activation and Electrophoretic
Mobility of Unmodified and Partially Degraded Plasminogen.
Effects of 6-Aminohexanoic Acid and Related Compounds.
THORSEN S Biochim Biophys Acta, 393, 1975, 55-65.
Differences in the Binding to Fibrin of Native Plasminogen
and Plasminogen Modified by Proteolytic Degradation.
Influence of w-Aminocarboxylic Acids.
THORSEN S, ASTRUP T Haemostasis, £5, 1976, 295-305.
Differences in the Reactivities of Human Urokinase and the
Porcine Tissue Plasminogen Activator.
342
THORSEN S In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 3; Editors Da.vidson J F, Rowan R M,
Sanama M M, Desnoyers P C; Raven Press, New York, 1978,
269-283. Influence of Fibrin on the Effect of
6-Aminohexanoic Acid on Fibrinolysis Caused by Tissue
Plasminogen Activator or Urokinase.
TILLETT W S, GARNER R L J Exptl Med, 58, 1933, 485-502.
The Fibrinolytic Activity of Haemolytic Streptococci.
TODD AS J Pathol Bacteriol, 78, 1959, 281-283.
The Histological Localisation of Fibrinolysin Activator.
TODD A S Atheroscler, 15, 1972, 137-140. Endothelium
and Fibrinolysis.
TCMIKAWA M, ABIKO Y Thrombos Diathes Haemorrh, 29, 1973,
50-62. The Plasminogen-Plasmin System Part VIII. On
the Mechanism of Chemical Induction of Fibrinolysis.
Isolation of a Latent Plasminogen Activator from Human
Plasma.
TRUMPI-KALSHOVEN M M In Progress in Chemical Fibrinolysis
and Thrombolysis, Vol 3; Editors Davidson J F, Rowan R M,
Samama M M, Desnoyers P C; Raven Press, New York, 1978,
257-267. The Relevance of CI Inhibitor in the Inhibition
of the Fibrinolytic Activity of Plasmin.
UNGAR G, MIST S H J Exptl Med, 90, 1949, 39-51.
Observations on the Release of Serum Fibrinolysin by
Specific Antigen, Peptone and Certain Polysaccharides.
UNKELESS J C, TOBIA A, OSSOWSKI L, QUIGLEY J P, RIFKIN D B,
REICH E J Exptl Med, 137, 1973, 85-111. An Enzymatic
Function Associated xvith Transformation of Fibroblasts by
Oncogenic Viruses. I Chick Embryo Fibroblast Cultures
Transformed by Avian RNA Tumor Viruses.
UNKELESS J, DAN0 K, KELLERMAN G M, REICH E J Biol Chem,
249, 1974a, 4295-4305. Fibrinolysis Associated with
Oncogenic Transformation. Partial Purification and
Characterization of the Cell Factor, a Plasminogen Activator.
UNKELESS J C, GORDON S, REICH E J Exptl Med, 139,
1974b, 834-850. Secretion of Plasminogen Activator by
Stimulated Macrophages.
USZYNSKI M, ABILDGAARD U Thrombos Diathesis Haemorrh,
2_5, 1971, 580-589. Separation and Characterization
of Two Fibrinolytic Inhibitors from Human Placenta.
VIOLAND B N, SODETZ J M, CASTELLINO F J Arch Biochem
Biophys, 17Q, 1975, 300-305. The Effect of e-Amino
Caproic Acid on the Gross Conformation of Plasminogen and
Plasmin.
YIOLAND 3 N. CASTELLINO F J J Biol Chem, 251 , 1976,
3306-3912. Mechanism of the Urokinase-Catalyzed
Activation of Human Plasminogen.
WALLACE A G In Acute Myocardial Infarction; Editors
Julian D B, Oliver M F; Livingstone, Edinburgh, 1968,
237-242. Catecholamine Metabolism in Patients with
.Acute Myocardial Infarction.
FALLEN P, IWANAGA S Biochim Biophys Acta, 154, 1968,
414-417. Differences Between Plasmic and Tryptic
Digests of Human S-Sulfo-Fibrinogen.
FALLEN P Scand J Haematol Suppl, 1_3, 1971, 3-14.
Plasmic Degradation of Fibrinogen.
FALLEN P, FTMAN B Biochim Biophys Acta, 257, 1972,
122-134. Characterization of Human Plasminogen.
II Separation and Partial Characterization of Different
Molecular Forms of Human Plasminogen.
FALLEN P, WIMAN B Thrombos Diathesis Haemorrh, 34(2) ,
1975a, 609. Purification of Tissue Activator Using
Affinity Adsorption on Fibrin and Hydrophobic Interaction
Chromatography. Effect of Fibrin on the Enzymatic
Properties of the Activator.
FALLEN P, WIMAN B In Proteases and Biological Control;
Editors Reich E, Rifkin D B, Shaw E; Cold Spring Harbour,
New York, 1975b, 291-303. On the Generation of
Intermediate Plasminogen and its Significance for the
Activation.
FALLEN P In Thrombosis and Urokinase; Editors Paoletti
Sherry S; Acad Press, London, 1977, 91-102. Activation
of Plasminogen with Urokinase and Tissue Activator.
FALLEN P, RANBY M Thromb Haem, 38, 1977, 61.
Purification and Some Properties of Tissue Plasminogen
Activator.
FALLEN P In Progress in Chemical Fibrinolysis and
Thrombolysis, Vol 3; Editors Davidson J F, Rowan R M,
Samama M M, Desnoyers P C; Raven Press, New York, 1978,
167-181. Chemistry of Plasminogen and Plasminogen
Activation.
FALTHER P J, STEINMAN H M, HILL R L, McKEE PA J Biol
Chem, 249, 1974, 1173-1181. Activation of Human
Plasminogen by Urokinase,
FALTHER P J, HILL R L, McKEE PA J Biol Chem, 250,
1975, 5926-5933. The Importance of the Preactivation
Peptide in the Two Stage Mechanism of Human Plasminogen
Ac tivation.
WALTON P L Biochim Biophys Acta, 132, 1967, 104-114.
The Hydrolysis of oc-N-Acetylglycyl-L-Lysine Methyl Ester
by Ur okina s e.
WAP.REN B A, KHAN S, VALES 0 Thrombos Diathes Haemorrh
Suppl 56, 1973, 35-50. The Interaction of Platelets,
Endothelium and Fibrin with Reference to Fibrinolysis .
WEBER K, OSBORN M J Biol Chem, 244, 1969, 4406-4412^
The Reliability of Molecular Weight Determinations by
Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis.
WEINSTEIN M J, DOOLITTLE R F Biochim Biophys Acta, 258,
1972, 577-590. Differential Specificities of Thrombin,
Plasmin and Trypsin with Regard to Synthetic and Natural
Substrates and Inhibitors.
WERKHEISER W C, MARKUS G J Biol Chem, 239, 1964,
2644-2650. The Interaction of Streptokinase with
Plasminogen. II The kinetics of Activation.
WHITEHOUSE H B Lancet, 1, 1914, 877-885. The
Physiology and Pathology of Uterine Haemorrhage.
WiLLIAMS J R B Brit J Exptl Pathol, 32, 1951, 530-537.
The Fibrinolytic Activity of Urine,
WIMAN B Thromb Res, 1_, 1972, 89-94. On the Structure
of the N-Terminal Fragment of Human Plasminogen Obtained
After Cleavage with Cyanogen Bromide.
WIMAN B Eur J Biochem, _39, 1973, 1-9. Primary Structure
of Peptides Released During Activation of Human Plasminogen
by Urokinase.
WIMAN B, WALLEN P Eur J Biochem, 36_, 1973, 25-31.
Activation of Human Plasminogen by an Insoluble Derivative
of Urokinase. Structural Changes of Plasminogen in the
Course of Activation to Plasmin and Demonstration of a
Possible Intermediate Compound.
WIMAN B, WALLEN P Eur J Biochem, 50, 1975a, 489-494.
Structural Relationship Between "Glutamic Acid" and
"Lysine" Forms of Human Plasminogen and Their Interaction
with the NH -Terminal Activation Peptide as Studied by
Affinity Chromatography.
WIMAN B, WALLEN P Thromb Res, 7, 1975b, 239-243.
Brief Communication. Amino Acid Sequence Around the
Arginyl-Valy1 Bond in Plasminogen which is Cleaved During
the Second Step of the Activation Process.
WIMAN B, WALLEN P Eur J Biochem, J57, 19 75c, 387-394.
On the Primary Structure of Human Plasminogen and Plasmin.
Purification and Characterization of Cyanogen-Bromide
Fragments.
345
WIMAN B Eur J Biochem, 76, 1977, 129-137. Primary
Structure of the B-Chain of Human Plasmin.
WIMAN B, COLLEN D Eur J Biochem, 78, 1977, 19-26.
Purification and Characterization of Human Antiplasmin,
the Fast-Acting Plasmin Inhibitor in Plasma.
WIMAN B, WALLEN P Thromb Res, 10, 1977, 213-222.
The Specific Interaction Between Plasminogen and Fibrin.
A Physiological Role of the Lysine Binding Site in
Plasminogen.
WIMAN B, COLLEN D Eur J Biochem, 84, 1978a, 573-578.
On the Kinetics of the Reaction Between Human Antiplasmin
and Plasmin.
WIMAN B, COLLEN D Nature, 272, 1978b, 549-550.
Molecular Mechanism of Physiological Fibrinolysis.
WUM-C, YUNIS A A Fed Proc, 35(7), 1976, 1462. A
Plasminogen Activator Secreted by Human Pancreatic Carcinoma
Cells in Continuous Culture,
WUEPPER K D Clin Res, 21, 1973, 484 (Abs). Prekallikrein-
Hageman Factor Cofactor - Fletcher Factor: Are They Identical?
ZYLBER J, BLATT W F, JENSEN H Proc Soc Exptl Biol Med,
102, 1959, 755-761. Mechanism of Bovine Plasminogen
Activation by Human Plasmin and Streptokinase.
